Novel peptide complex

By using interaction technology of domains such as Titin-T chain or Obscurin-O chain in the preparation of bispecific antibodies, the problem of uncertainty in polypeptide chain combination is solved, the efficiency and purity of the antibody are improved, and the process development is simplified , enhances the stability and biological activity of the product.

CN114746440BActive Publication Date: 2024-11-15JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180006946.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-01-09
Filing Date
2021-01-08
Publication Date
2024-11-15
Estimated Expiration
2041-01-08

AI Technical Summary

Technical Problem

In the process of preparing bispecific antibodies, random combination of polypeptide chains leads to the production of a variety of by-products, including antibodies, haplotypes, heavy chain polymers, light chain and heavy chain mismatches, which provide downstream process development belts A challenge is coming.

Method used

A polypeptide complex is provided that comprises a first antigen binding moiety, including a heavy chain variable domain (VH1) and a light chain variable domain (VL1) from the N-terminus to the C-terminus, via the Titin-T chain or Obscurin Interactions of domains such as -O chains form dimers, ensuring correct combination and connection of polypeptide chains and reducing the generation of by-products.

Benefits of technology

It improves the preparation efficiency and purity of bispecific antibodies, reduces the generation of by-products, simplifies downstream process development, and enhances the stability and biological activity of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114746440B_ABST
    Figure CN114746440B_ABST
Patent Text Reader

Abstract

The present disclosure relates to novel polypeptide complexes. Specifically, the present disclosure relates to a domain-engineered antibody, wherein at least one constant region domain CH1 and / or CL of the antibody is replaced, and the domain CH1 / CL is replaced by titin T chain / obscurin-O chain or by titin T chain / obscurin-like-O chain.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to the Chinese patent application filed on January 9, 2020 (application number CN202010020878.7). Technical Field

[0002] The present disclosure relates to the field of antibody drugs, and specifically includes novel antibodies with substituted CH1 and CL structures and applications thereof. Background Art

[0003] The statements herein merely provide background information related to the present disclosure and do not necessarily constitute prior art.

[0004] With the continuous improvement of antibody humanization technology, monoclonal antibodies have developed rapidly in recent years. A variety of monoclonal antibodies have been used to treat major diseases such as malignant tumors and autoimmune diseases. However, tumor immune escape is often accompanied by a variety of different mechanisms, and a single monoclonal antibody can only bind to one specific target, which greatly reduces the therapeutic effect of monoclonal antibodies.

[0005] Bispecific antibodies (BsAb) are artificial antibodies formed by combining antibodies targeting two different antigens or two different antigen epitopes through genetic engineering. Unlike monoclonal antibodies, bispecific antibodies have the ability to target two different epitopes at the same time and can play special biological functions, such as immune cell recruitment, receptor co-stimulation or co-inhibition, multivalent virus neutralization, etc., and are expected to achieve better clinical treatment effects than single monoclonal antibodies or even antibody combinations.

[0006] A wide variety of recombinant bispecific antibody formats have been developed, such as tetravalent bispecific antibodies by fusing, for example, IgG antibody formats and single chain domains (see Coloma, MJ, et al., Nature Biotech. 15 (1997) 159-163; Morrison, SL, Nature Biotech. 25 (2007) 1233-1234). Other bispecific formats, such as DVD-Ig, CrossMab, BiTE, etc. (Spiess et al., Molecular Immunology, 67 (2), pp. 95-106 (2015)).

[0007] Various structural models of bispecific antibodies have also been published: for example, introducing mutations "knobs-into-holes" into the Fc region (Ridgway et al., Protein Engineering, 9(7), pp.617-21(1996)); introducing electrostatic design (Gunasekaran et al., Journal of Biological Chemistry, 285(25), pp 19637-19646(2010)), or negative state design (Kreudenstein et al., mAbs, 5(5), pp.646-654(2013); Leaver-Fay et al., Structure, 24(4), pp.641-651(2016)), exchanging CH1 and CL domains (CrossMab platform) (Schaefer et al., Proceedings of the National Academy of Sciences of the United States ofAmerica, 108(27), pp.11187-11192(2011)), fused with TCR constant region (WO2019057122A1), etc. Summary of the invention

[0008] However, in the process of preparing bispecific antibodies, different polypeptide chains randomly combine to produce a variety of different products, and only one product is desired. These byproducts include antibodies lacking a light chain, half antibodies, heavy chain polymers, light chain and heavy chain mismatches, etc., which poses a great challenge to downstream process development. To this end, the present disclosure provides a new domain-engineered polypeptide complex.

[0009] In some embodiments, the present disclosure provides a polypeptide complex comprising a first antigen binding moiety, the first antigen binding moiety comprising:

[0010] A) a first polypeptide comprising a first heavy chain variable domain (VH1) from N-terminus to C-terminus, wherein VH1 is operably linked to a first domain, wherein the first domain comprises a titin-T chain, and

[0011] a second polypeptide comprising a first light chain variable domain (VL1) from N-terminus to C-terminus, wherein VL1 is operably linked to a second domain, wherein the second domain comprises a domain capable of interacting with a titin-T chain;

[0012] or

[0013] B) a first polypeptide comprising VH1 from N-terminus to C-terminus, wherein VH1 is operably linked to a first domain comprising a domain capable of interacting with a titin-T chain, and

[0014] a second polypeptide comprising VL1 from N-terminus to C-terminus, wherein VL1 is operably linked to a second domain, wherein the second domain comprises a Titin-T chain;

[0015] or

[0016] C) a first polypeptide comprising VH1 from N-terminus to C-terminus, wherein VH1 is operably linked to a first domain, wherein the first domain comprises an Obscurin-O chain or an Obscurin-like-O chain, and

[0017] a second polypeptide comprising a VL1 from the N-terminus to the C-terminus, wherein the VL1 is operably linked to a second domain, wherein the second domain comprises a domain capable of interacting with an Obscurin-O chain or an Obscurin-like-O chain;

[0018] or

[0019] D) a first polypeptide comprising, from N-terminus to C-terminus, VH1 operably linked to a first domain comprising a domain capable of interacting with an Obscurin-O chain or an Obscurin-like-O chain, and

[0020] a second polypeptide comprising a VL1 from the N-terminus to the C-terminus, wherein the VL1 is operably linked to a second domain, wherein the second domain comprises an Obscurin-O chain or an Obscurin-like-O chain;

[0021] The first antigen binding portion specifically binds to the first antigen, and the first domain and the second domain can form a dimer.

[0022] In some embodiments, in the aforementioned polypeptide complex, the domain capable of interacting with Obscurin-O chain or Obscurin-like-O chain is Titin-T chain, and the domain capable of interacting with Titin-T chain is Obscurin-O chain or Obscurin-like-O chain.

[0023] In some embodiments, in the aforementioned polypeptide complex, VH1 and VL1 of the first antigen binding portion form a first antigen binding site that specifically binds to the first antigen.

[0024] In some embodiments, the C-terminus of the VH1 is operably linked to the N-terminus of the first domain.

[0025] In some embodiments, the C-terminus of VL1 is operably linked to the N-terminus of the second domain.

[0026] In some embodiments, in the aforementioned polypeptide complex, the first domain and the second domain form a dimer through a natural interchain bond and / or a non-natural interchain bond.

[0027] In some embodiments, the first domain and the second domain form a dimer through a natural interchain bond; in some embodiments, one or more residues selected from positions 7-15, 19-24, 26, 55, 59 and 60 on the titin-T chain are combined with one or more residues selected from positions 3-6, 9, 41, 73, 75 and 80-90 on the obscurin-O chain, or one or more residues selected from positions 1, 7-10, 13-16, 19-26, 59-60 and 96 on the titin-T chain are combined with one or more residues selected from positions 4-5, 10, 12-13, 74, 76, 78 and 82-91 on the obscurin-like-O chain; the midpoint of the titin-T chain residue position is the natural sequence numbering position relative to the sequence SEQ ID NO: 32; the midpoint of the obscurin-O chain residue position is the natural sequence numbering position relative to the sequence SEQ ID The natural sequence numbering position of NO:33; the Obscurin-like-O chain residue position is the natural sequence numbering position relative to the sequence SEQ ID NO:34.

[0028] In some embodiments, in any of the aforementioned polypeptide complexes, the first domain and the second domain form a dimer via at least one non-native interchain bond.

[0029] In some embodiments, the non-natural interchain bond is formed between a specific mutation residue in the first domain and a specific mutation residue in the second domain. In some embodiments, at least one of the specific mutation residue in the first domain and the specific mutation residue in the second domain is a cysteine ​​residue.

[0030] In some embodiments, the non-native interchain bonds are disulfide bonds; in some embodiments, wherein the dimer comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 non-native interchain bonds.

[0031] In some embodiments, in the aforementioned polypeptide complex, the specific mutated residue in the first domain and the specific mutated residue in the second domain are located at the contact interface between the first domain and the second domain.

[0032] In some embodiments, the specific mutated residues in the aforementioned first domain and the specific mutated residues in the second domain have mutations selected from the following: the titin-T chain has one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39, and / or the obscurin-O chain has one or more amino acid residue mutations selected from positions 3, 9, 25, 76 and 88; or the titin-T chain has one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39, and / or the obscurin-like-O chain has one or more amino acid residue mutations selected from positions 6, 26, 74, 77, 84 and 86. The titin-T chain mutation sites are sites with natural sequence numbering relative to the sequence SEQ ID NO: 32; the obscurin-O chain mutation sites are sites with natural sequence numbering relative to the sequence SEQ ID NO: 33; and the obscurin-like-O chain mutation sites are sites with natural sequence numbering relative to the sequence SEQ ID NO: 34.

[0033] In some specific embodiments, the aforementioned first mutated residue and the second mutated residue have mutations selected from the following: the Titin-T chain has one or more amino acid residue mutations selected from 8C, 20C, 22C, 25S, 26C and 39T, and / or the Obscurin-O chain has one or more amino acid residue mutations selected from 3C, 9C, 25S, 76S and 88C; or the Titin-T chain has one or more amino acid residue mutations selected from 8C, 20C, 22C, 25S, 26C and 39T, and / or the Obscurin-like-O chain has one or more amino acid residue mutations selected from 6E, 26S, 74C, 77S, 84C and 86C. In some embodiments, the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 88C mutations;

[0034] The Titin-T chain has 25S, 39T, and 20C mutations, and the Obscurin-O chain has a 3C mutation;

[0035] The Titin-T chain has 25S, 39T, and 26C mutations, and the Obscurin-O chain has a 9C mutation;

[0036] The Titin-T chain has 25S, 39T, and 8C mutations, and the Obscurin-O chain has 25S, 76S, and 88C mutations;

[0037] The Titin-T chain has 25S, 39T, and 20C mutations, and the Obscurin-O chain has 25S, 76S, and 3C mutations;

[0038] The Titin-T chain has 25S, 39T, and 26C mutations, and the Obscurin-O chain has 25S, 76S, and 9C mutations;

[0039] The Titin-T chain has 25S, 39T, and 8C mutations, and the Obscurin-like-O chain has 6E and 74C mutations;

[0040] The Titin-T chain has 25S, 39T, and 20C mutations, and the Obscurin-like-O chain has 6E and 84C mutations;

[0041] The Titin-T chain has 25S, 39T, and 22C mutations, and the Obscurin-like-O chain has 6E and 86C mutations;

[0042] The Titin-T chain has 25S, 39T, and 8C mutations, and the Obscurin-like-O chain has 6E, 26S, 77S, and 74C mutations;

[0043] The Titin-T chain has 25S, 39T and 20C mutations and the Obscurin-like-O chain has 6E, 26S, 77S and 84C mutations; or

[0044] The Titin-T chain has 25S, 39T, and 22C mutations, and the Obscurin-like-O chain has 6E, 26S, 77S, and 86C mutations;

[0045] The mutation sites of Titin-T chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO: 32; the mutation sites of Obscurin-O chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO: 33; and the mutation sites of Obscurin-like-O chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO: 34.

[0046] In some specific embodiments, the aforementioned first mutated residue and the second mutated residue have mutations selected from the following: the Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T, and / or the Obscurin-O chain has one or more amino acid residue mutations selected from A3C, R9C, C25S, C76S and A88C; or the Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T, and / or the Obscurin-like-O chain has one or more amino acid residue mutations selected from C6E, C26S, C77S, V74C, G84C and A86C. The titin-T chain mutation site is the natural sequence numbering site relative to the sequence SEQ ID NO: 32; the obscurin-O chain mutation site is the natural sequence numbering site relative to the sequence SEQ ID NO: 33; and the obscurin-like-O chain mutation site is the natural sequence numbering site relative to the sequence SEQ ID NO: 34.

[0047] In some embodiments, the aforementioned specific mutated residues in the first domain and the specific mutated residues in the second domain have mutations selected from the following: Titin-T chain has C25S, C39T and A8C mutations, and Obscurin-O chain has A88C mutation; Titin-T chain has C25S, C39T and V20C mutations, and Obscurin-O chain has A3C mutation; Titin-T chain has C25S, C39T and A26C mutations, and Obscurin -O chain has R9C mutation; Titin-T chain has C25S, C39T and A8C mutations, Obscurin-O chain has C25S, C76S and A88C mutations; Titin-T chain has C25S, C39T and V20C mutations, Obscurin-O chain has C25S, C76S and A3C mutations; Titin-T chain has C25S, C39T and A26C mutations, Obscurin-O chain has C25S, C76S and R9 C mutation; Titin-T chain has C25S, C39T and A8C mutations, Obscurin-like-O chain has C6E and V74C mutations; Titin-T chain has C25S, C39T and V20C mutations, Obscurin-like-O chain has C6E and G84C mutations; Titin-T chain has C25S, C39T and T22C mutations, Obscurin-like-O chain has C6E and A86C mutations; Titin-T chain has C25 S, C39T and A8C mutations, Obscurin-like-O chain has C6E, C26S, C77S and V74C mutations; Titin-T chain has C25S, C39T and V20C mutations, Obscurin-like-O chain has C6E, C26S, C77S and G84C mutations; Titin-T chain has C25S, C39T and T22C mutations, Obscurin-like-O chain has C6E, C26S, C77S and A86C mutations. The mutation sites of the Titin-T chain are sites corresponding to the natural sequence numbering relative to the sequence SEQ ID NO: 32; the mutation sites of the Obscurin-O chain are sites corresponding to the natural sequence numbering relative to the sequence SEQ ID NO: 33; and the mutation sites of the Obscurin-like-O chain are sites corresponding to the natural sequence numbering relative to the sequence SEQ ID NO: 34.

[0048] In some embodiments, the aforementioned first domain and second domain are selected from the following Titin-T chain / Obscurin-O chain, or Titin-T chain / Obscurin-like-O chain: the Titin-T chain is a polypeptide having one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39 based on the sequence of SEQ ID NO: 32, and / or the Obscurin-O chain is a polypeptide having one or more amino acid residue mutations selected from positions 3, 9, 25, 76 and 88 based on the sequence of SEQ ID NO: 33; or the Titin-T chain is a polypeptide having one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39 based on the sequence of SEQ ID NO: 32, and / or the Obscurin-like-O chain is a polypeptide having one or more amino acid residue mutations selected from positions 6, 26, 74, 77, 84 and 86 based on the sequence of SEQ ID NO: 34.

[0049] In some embodiments, the aforementioned first domain and second domain are selected from the following: Titin-T chain / Obscurin-O chain, or Titin-T chain / Obscurin-like-O chain. The Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T based on the sequence of SEQ ID NO: 32, and / or the Obscurin-O chain has one or more amino acid residue mutations selected from A3C, R9C, C25S, C76S and A88C based on the sequence of SEQ ID NO: 33; or the Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T based on the sequence of SEQ ID NO: 32, and / or the Obscurin-like-O chain has one or more amino acid residue mutations selected from C6E, C26S, C77S, V74C, G84C and A86C based on the sequence of SEQ ID NO: 34. The titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; and the obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 34.

[0050] In some embodiments, the aforementioned first domain and second domain are selected from the following: Titin-T chain / Obscurin-O chain, or Titin-T chain / Obscurin-like-O chain. The titin-T chain has C25S, C39T and A8C mutations based on the sequence of SEQ ID NO: 32, and the obscurin-O chain has A88C mutation based on the sequence of SEQ ID NO: 33; the titin-T chain has C25S, C39T and V20C mutations based on the sequence of SEQ ID NO: 32, and the obscurin-O chain has A3C mutation based on the sequence of SEQ ID NO: 33; the titin-T chain has C25S, C39T and A26C mutations based on the sequence of SEQ ID NO: 32, and the obscurin-O chain has R9C mutation based on the sequence of SEQ ID NO: 33; the titin-T chain has C25S, C39T and A8C mutations based on the sequence of SEQ ID NO: 32, and the obscurin-O chain has C25S, C76S and A88C mutations based on the sequence of SEQ ID NO: 33; ID NO: 32, the Obscurin-O chain has C25S, C39T and V20C mutations based on the sequence of SEQ ID NO: 32, the Obscurin-O chain has C25S, C76S and A3C mutations based on the sequence of SEQ ID NO: 33; the Titin-T chain has C25S, C39T and A26C mutations based on the sequence of SEQ ID NO: 32, the Obscurin-O chain has C25S, C76S and R9C mutations based on the sequence of SEQ ID NO: 33; the Titin-T chain has C25S, C39T and A8C mutations based on the sequence of SEQ ID NO: 32, the Obscurin-like-O chain has C6E and V74C mutations based on the sequence of SEQ ID NO: 34; the Titin-T chain has C25S, C39T and V20C mutations based on the sequence of SEQ ID NO: 32, the Obscurin-like-O chain has C6E and V74C mutations based on the sequence of SEQ ID NO: 34. NO: 34 has C6E and G84C mutations; the Titin-T chain has C25S, C39T and T22C mutations based on the SEQ ID NO: 32 sequence, and the Obscurin-like-O chain has C6E and A86C mutations based on the SEQ ID NO: 34 sequence;The Titin-T chain has C25S, C39T and A8C mutations based on the sequence of SEQ ID NO: 32, and the Obscurin-like-O chain has C6E, C26S, C77S and V74C mutations based on the sequence of SEQ ID NO: 34; the Titin-T chain has C25S, C39T and V20C mutations based on the sequence of SEQ ID NO: 32, and the Obscurin-like-O chain has C6E, C26S, C77S and G84C mutations based on the sequence of SEQ ID NO: 34; the Titin-T chain has C25S, C39T and T22C mutations based on the sequence of SEQ ID NO: 32, and the Obscurin-like-O chain has C6E, C26S, C77S and A86C mutations based on the sequence of SEQ ID NO: 34. The titin-T chain mutation site is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 32; the obscurin-O chain mutation site is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 33; the obscurin-like-O chain mutation site is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 34. ;

[0051] In some embodiments, in the aforementioned polypeptide complex, the Obscurin-O chain has one or more amino acid residue mutations selected from positions 7, 11, and 62. In some embodiments, the Obscurin-O chain has one or more amino acid residue mutations selected from 7R or 7K, 62K or 62H, and 11L; most preferably, the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 25S, 76S, 88C, 7K and 62K mutations; the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 25S, 76S, 88C, 7K and 62H mutations; the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 25S, 76S, 88C, 11L and 62K mutations; or the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 25S, 76S, 88C, 11L and 62H mutations; the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 25S, 76S, 88C, 11L and 62K mutations; The mutation site of Obscurin-O chain is the natural sequence numbering site relative to SEQ ID NO: 32; the mutation site of Obscurin-O chain is the natural sequence numbering site relative to SEQ ID NO: 33.

[0052] In some embodiments, the Obscurin-O chain has one or more amino acid residue mutations selected from L7K or L7R, K11L, T62K or T62H; in some embodiments, the Titin-T chain has C25S, C39T and A8C mutations, and the Obscurin-O chain has C25S, C76S, A88C, L7K and T62K mutations; the Titin-T chain has C25S, C39T and A8C mutations, and the Obscurin-O chain has C25S, C76S, A88C, L7K and T62K mutations. The curin-O chain has C25S, C76S, A88C, L7K and T62H mutations; the titin-T chain has C25S, C39T and A8C mutations, and the obscurin-O chain has C25S, C76S, A88C, K11L and T62K mutations; the titin-T chain has C25S, C39T and A8C mutations, and the obscurin-O chain has C25S, C76S, A88C, K11L and T62H. The mutation sites of the titin-T chain are sites corresponding to the natural sequence numbering relative to the sequence SEQ ID NO: 32; the mutation sites of the obscurin-O chain are sites corresponding to the natural sequence numbering relative to the sequence SEQ ID NO: 33.

[0053] In some embodiments, in the aforementioned polypeptide complex, the Obscurin-O chain is an Obscurin-O chain having one or more amino acid residue mutations selected from positions 7, 11, and 62 based on SEQ ID NO: 45; in some embodiments, the Obscurin-O chain has one or more amino acid residue mutations selected from positions L7K or L7R, K11L, and T62K or T62H based on SEQ ID NO: 45; in some embodiments, the Titin-T chain has C25S, C39T, and A8C mutations based on SEQ ID NO: 32, and the Obscurin-O chain has C25S, C76S, A88C, L7K, and T62K mutations based on SEQ ID NO: 45; the Titin-T chain has C25S, C39T, and A8C mutations based on SEQ ID NO: 32, and the Obscurin-O chain has C25S, C76S, A88C, L7K, and T62K mutations based on SEQ ID NO: NO: 45, with C25S, C76S, A88C, L7K and T62H mutations; Titin-T chain has C25S, C39T and A8C mutations on the basis of SEQ ID NO: 32, and Obscurin-O chain has C25S, C76S, A88C, K11L and T62K mutations on the basis of SEQ ID NO: 45; Titin-T chain has C25S, C39T and A8C mutations on the basis of SEQ ID NO: 32, and Obscurin-O chain has C25S, C76S, A88C, K11L and T62H mutations on the basis of SEQ ID NO: 45. The mutation site of the Titin-T chain is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 32; the mutation site of the Obscurin-O chain is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 33.

[0054] In some embodiments, in the aforementioned polypeptide complex, the first domain and the second domain have one or more amino acid residue mutations selected from the following: the titin-T chain has one or more amino acid mutations selected from positions 3, 11, 13, 22, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84, and / or the obscurin-O chain has one or more amino acid mutations selected from positions 2, 11, 12, 13, 14, 17, 20, 22, 30, 32, 34, 36, 41, 42, 44, 45, 53, 58, 62, 67, 69, 89, 92, 94 and 97. The titin-T chain mutation sites are sites with natural sequence numbering relative to the sequence of SEQ ID NO: 35; the obscurin-O chain mutation sites are sites with natural sequence numbering relative to the sequence of SEQ ID NO: 50.

[0055] In some embodiments, in the aforementioned polypeptide complex, the first domain and the second domain are Titin-T chain / Obscurin-O chain selected from the following: the Titin-T chain is a polypeptide having one or more amino acid mutations selected from the 3rd, 11th, 13th, 22nd, 40th, 42nd, 45th, 47th, 49th, 56th, 58th, 66th, 70th, 75th, 77th, 79th, 81st, 82nd, 83rd and 84th positions based on SEQ ID NO: 35; the Obscurin-O chain is a polypeptide having one or more amino acid mutations selected from the 2nd, 11th, 12th, 13th, 14th, 17th, 20th, 22nd, 30th, 32nd, 34th, 36th, 41st, 42nd, 44th, 45th, 53rd, 58th, 62nd, 67th, 69th, 89th, 92nd, 94th and 97th positions based on SEQ ID NO: 50. The titin-T chain mutation site is a site numbered in the natural sequence relative to the sequence SEQ ID NO: 35; the obscurin-O chain mutation site is a site numbered in the natural sequence relative to the sequence SEQ ID NO: 50.

[0056] In some embodiments, the aforementioned first domain and the second domain have one or more residue mutations selected from the following: the Titin-T chain has one or more amino acid mutations selected from 3W, 11I, 13L, 22M, 40S, 42K, 45S, 47E, 49G, 56S, 58E, 66S or 66K, 70R, 75V, 77S, 79T, 81R, 82M, 83D and 84L, and / or the Obscurin-O chain has one or more amino acid mutations selected from 2E, 11K, 12S, 13Y, 14T, 17E, 20L, 22M or 22S, 30D, 32P, 34E, 36T, 41K, 42L, 44I, 45T, 53L, 58V, 62E, 67Q or 67T, 69S, 89L, 92E, 94G and 97G.In some embodiments, the titin-T chain has 66S and 77S amino acid mutations, and / or the obscurin-O chain has 11K, 12S, 13Y, 14T, and 22S amino acid mutations; the titin-T chain has 66K, 70R, 79T, and 81R amino acid mutations, and / or the obscurin-O chain has 2E, 17E, 30D, 32P, 34E, 36T, 44I, 45T, 58V, 62E, 67Q, 69S, and 97G amino acid mutations; the titin-T chain has 3W, 11I, 13L, 22M and 82M amino acid mutations, and / or the obscurin-O chain has 20L, 22M and 53L amino acid mutations; the titin-T chain has 11I, 66K, 79T and 81R amino acid mutations, and / or the obscurin-O chain has 41K, 45T, 67Q, 69S and 89L amino acid mutations; the titin-T chain has 40S, 42K, 45S, 4 7E, 49G, 56S, 58E, 75V, 83D and 84L amino acid mutations, and / or the Obscurin-O chain has 42L, 45T, 67T, 69S, 92E and 94G amino acid mutations; the Titin-T chain has 47E, 49G, 56S, 58E and 75V amino acid mutations, and / or the Obscurin-O chain has 42L, 45T, 67T, 69S, 92E and 94G amino acid mutations; the Titin-T chain has 56S , 58E and 75V amino acid mutations, and / or the Obscurin-O chain has 42L, 45T, 67T, 69S, 92E and 94G amino acid mutations; or the Titin-T chain has 56S, 58E, 66S and 77S amino acid mutations, and / or the Obscurin-O chain has 12S, 13Y, 22S, 42L, 45T, 67Q, 69S, 92E and 94G amino acid mutations; the mutation sites of the Titin-T chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 35; the mutation sites of the Obscurin-O chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 50.

[0057] In some embodiments, the aforementioned first domain and the second domain have one or more residue mutations selected from the following: Titin-T chain has one or more amino acid mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L , and / or the Obscurin-O chain has one or more amino acid mutations selected from G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G. The mutation sites of the Titin-T chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 35; the mutation sites of the Obscurin-O chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 50.

[0058] In some embodiments, the aforementioned first domain and the second domain are selected from the following Titin-T chain / Obscurin-O chain: the Titin-T chain is based on the sequence of SEQ ID NO: 35 and has one or more amino acid mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L, and / or the Obscurin-O chain is based on the sequence of SEQ ID NO: NO:35, has one or more amino acid mutations selected from G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G. The titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO:35; the obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO:50.

[0059] In some embodiments, the aforementioned Titin-T chain has M66S and T77S amino acid mutations, and / or the Obscurin-O chain has L11K, A12S, F13Y, V14T and T22S amino acid mutations; the Titin-T chain has M66K, K70R, S79T and G81R amino acid mutations, and / or the Obscurin-O chain has G2E, V17E, N30D, T32P, Q34E, S36T, V44I, A45T, L58V, K62E, A67Q, G 69S and A97G amino acid mutations; the Titin-T chain has P3W, S11I, I13L, T22M and N82M amino acid mutations, and / or the Obscurin-O chain has D20L, T22M and A53L amino acid mutations; the Titin-T chain has S11I, M66K, S79T and G81R amino acid mutations, and / or the Obscurin-O chain has Q41K, A45T, A67Q, G69S and V89L amino acid mutations; the Titin-T chain has G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, L75V, E83D and F84L amino acid mutations, and / or the Obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations; the Titin-T chain has Q47E, Q49G, N56S, D58E and L75V amino acid mutations, and / or the Obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations. mutation; the titin-T chain has N56S, D58E and L75V amino acid mutations, and / or the obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations; or the titin-T chain has N56S, D58E, M66S and T77S amino acid mutations, and / or the obscurin-O chain has A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E and D94G amino acid mutations. The mutation sites of the titin-T chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 35; the mutation sites of the obscurin-O chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 50.

[0060] In some embodiments, the aforementioned first domain and the second domain are selected from the following titin-T chain / obscurin-O chain: the titin-T chain has M66S and T77S amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the obscurin-O chain has L11K, A12S, F13Y, V14T and T22S amino acid mutations based on the sequence of SEQ ID NO: 50; the titin-T chain has M66K, K70R, S79T and G81R amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the obscurin-O chain has G2E, V17E, N30D, T32P, Q34E, S36T, V44I, A45T, L58V, K62E, A67Q, G69S and A97G amino acid mutations based on the sequence of SEQ ID NO: 50; the titin-T chain has M66K, K70R, S79T and G81R amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the obscurin-O chain has G2E, V17E, N30D, T32P, Q34E, S36T, V44I, A45T, L58V, K62E, A67Q, G69S and A97G amino acid mutations based on the sequence of SEQ ID NO: NO: 35 sequence, and / or the Obscurin-O chain has P3W, S11I, I13L, T22M and N82M amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the Obscurin-O chain has D20L, T22M and A53L amino acid mutations based on the sequence of SEQ ID NO: 50; the Titin-T chain has S11I, M66K, S79T and G81R amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the Obscurin-O chain has Q41K, A45T, A67Q, G69S and V89L amino acid mutations based on the sequence of SEQ ID NO: 50; the Titin-T chain has G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, L75V, E83D and F84L amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the Obscurin-O chain has NO:50 has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations based on the sequence of SEQ ID NO:50; the Titin-T chain has Q47E, Q49G, N56S, D58E and L75V amino acid mutations based on the sequence of SEQ ID NO:35, and / or the Obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations based on the sequence of SEQ ID NO:50; the Titin-T chain has N56S, D58E and L75V amino acid mutations based on the sequence of SEQ ID NO:35, and / or the Obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations based on the sequence of SEQ ID NO:50;Or the titin-T chain has N56S, D58E, M66S and T77S amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the obscurin-O chain has A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E and D94G amino acid mutations based on the sequence of SEQ ID NO: 50. The mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence of SEQ ID NO: 35; the mutation sites of the obscurin-O chain are the natural sequence numbering sites of the sequence of SEQ ID NO: 50. ;

[0061] In some embodiments, in the aforementioned polypeptide complex, the VH1 is operably linked to the first domain via a first connecting domain, and the VL1 is operably linked to the second domain via a second connecting domain.

[0062] In some embodiments, the aforementioned first and / or second connecting domain is selected from: the N-terminal fragment of titin-T chain, the N-terminal fragment of obscurin-O chain or the N-terminal fragment of obscurin-like-O chain, and (G x S) y A linker, wherein X is selected from an integer of 1-5 (examples are 1, 2, 3, 4, 5), and Y is selected from an integer of 1-6 (examples are 1, 2, 3, 4, 5, 6).

[0063] In some embodiments, the aforementioned first and / or second connecting domain is selected from: "KAGIR", "DQPQF", (G 4 S) 1 and (G 4 S) 2 .

[0064] In some embodiments, in the aforementioned polypeptide complex, when the first domain is a Titin-T chain, the first connecting domain is a KAGIR polypeptide; when the second domain is an Obscurin-O chain, the second connecting domain is a DQPQF polypeptide. In other embodiments, when the second domain is a Titin-T chain, the second connecting domain is a KAGIR polypeptide, and when the first domain is an Obscurin-O chain, the first connecting domain is a DQPQF polypeptide.

[0065] In some embodiments of the polypeptide complex, wherein:

[0066] (A) The sequence of the titin-T chain is as shown in SEQ ID NO: 32 or further comprises one or more amino acid mutations selected from 8, 20, 22, 25, 26, 39, 3, 11, 13, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84 and / or a sequence with 5 amino acid residues KAGIR added to the N-terminus based on the sequence of SEQ ID NO: 32; preferably comprises a sequence selected from A8C, V20C, T22C, C25S, A26C, C39T, P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S or M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L, and / or a sequence with an additional KAGIR amino acid residue at the N-terminus; and / or

[0067] (B) The sequence of the Obscurin-O chain is as shown in SEQ ID NO: 33 or further comprises, based on the sequence of SEQ ID NO: 33, an amino acid mutation at one or more positions selected from 3, 9, 25, 76, 88, 7, 11, 62, 2, 12, 13, 14, 17, 20, 22, 30, 32, 34, 36, 41, 42, 44, 45, 53, 58, 67, 69, 89, 92, 94 and 97 and / or a sequence in which a KAGIR amino acid residue is added to the N-terminus; preferably, a sequence selected from A3C, R9C, C25S, C76S, A88C, L7K or L7R, T 62K or T62H, G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G, and / or a sequence in which the DQPQF amino acid residue is added to the N-terminus; or

[0068] The sequence of the Obscurin-like-O chain is as shown in SEQ ID NO: 34 or a sequence having one or more amino acid mutations selected from 6, 26, 74, 77, 84 and 86 based on the sequence of SEQ ID NO: 34; preferably a sequence having one or more amino acid mutations selected from C6E, C26S, C77S, V74C, G84C and A86C;

[0069] The above-mentioned Titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the Obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; and the Obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 34.

[0070] In some embodiments of the polypeptide complex, wherein: (A) the titin-T chain has one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39 based on the sequence of SEQ ID NO: 32, preferably one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; more preferably, the titin-T chain is the natural sequence numbering sites of the sequence SEQ ID NO: NO:35, has one or more amino acid mutations selected from positions 3, 11, 13, 22, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84, preferably has one or more amino acid mutations selected from positions P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L; the titin-T chain mutation sites are the natural sequence numbering sites of the sequence SEQ ID NO:35, and / or

[0071] (B) The Obscurin-O chain has one or more amino acid residue mutations selected from positions 3, 9, 25, 76 and 88 based on the sequence of SEQ ID NO: 33, preferably one or more amino acid residue mutations selected from A3C, R9C, C25S, C76S and A88C, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 33; preferably, the Obscurin-O chain has one or more amino acid residue mutations selected from positions 7, 11 and 62 based on the sequence of SEQ ID NO: 45, preferably one or more amino acid residue mutations selected from positions L7K or L7R, T62K or T62H, and K11L, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 45; more preferably, the Obscurin-O chain has one or more amino acid residue mutations selected from positions 7, 11 and 62 based on the sequence of SEQ ID NO: 45, preferably one or more amino acid residue mutations selected from positions L7K or L7R, T62K or T62H, and K11L, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 45. NO:50 has one or more amino acid mutations selected from the group consisting of the 2nd, 11th, 12th, 13th, 14th, 17th, 20th, 22nd, 30th, 32nd, 34th, 36th, 41st, 42nd, 44th, 45th, 53rd, 58th, 62nd, 67th, 69th, 89th, 92nd, 94th and 97th positions, preferably one or more amino acid mutations selected from the group consisting of G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G, wherein the Obscurin-O chain mutation site is the sequence of SEQ ID NO: natural sequence number locus 50; or

[0072] The Obscurin-like-O chain has one or more amino acid residue mutations selected from positions 6, 26, 74, 77, 84 and 86 based on the sequence of SEQ ID NO: 34, preferably one or more amino acid residue mutations selected from C6E, C26S, C77S, V74C, G84C and A86C, and the Obscurin-like-O chain mutation sites are the natural sequence numbering sites of the sequence SEQ ID NO: 34.

[0073] In some embodiments of the polypeptide complex, wherein: the Titin-T chain comprises a polypeptide having a sequence as shown in any one of SEQ ID NOs: 32, 35-41, 65-76 or having at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76, and / or the Obscurin-O chain comprises a polypeptide having a sequence as shown in any one of SEQ ID NOs: 33, 42-58, 77-86 or having at least 80% identity with any one of SEQ ID NOs: 33, 42-58, 77-86; or the Titin-T chain comprises a polypeptide having a sequence as shown in any one of SEQ ID NOs: 32, 35-41, 65-76 or having at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76, and / or the Obscurin-like-O chain comprises a polypeptide having a sequence as shown in any one of SEQ ID NOs: 34, 59-64 or having at least 80% identity with any one of SEQ ID NOs: NO: 34, 59-64 have at least 80% identical polypeptides. Wherein said having at least 80% identity is, for example, having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity.

[0074] In some embodiments, the aforementioned Titin-T chain comprises the polypeptide shown in SEQ ID NO:68, and the Obscurin-O chain comprises the polypeptide shown in SEQ ID NO:80.

[0075] In other embodiments, the Titin-T chain comprises the polypeptide set forth in SEQ ID NO:73, and the Obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:83.

[0076] In other embodiments, the Titin-T chain comprises the polypeptide set forth in SEQ ID NO:76, and the Obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:84.

[0077] In other embodiments, the Titin-T chain comprises the polypeptide set forth in SEQ ID NO:76, and the Obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:86.

[0078] In other embodiments, the Titin-T chain comprises the polypeptide set forth in SEQ ID NO:76, and the Obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:86.

[0079] In other embodiments, the Titin-T chain comprises the polypeptide set forth in SEQ ID NO:75, and the Obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:86.

[0080] In some embodiments, the Titin-T chain is a polypeptide as shown in SEQ ID NO: 68, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO: 80; the Titin-T chain is a polypeptide as shown in SEQ ID NO: 73, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO: 83; the Titin-T chain is a polypeptide as shown in SEQ ID NO: 76, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO: 84; the Titin-T chain is a polypeptide as shown in SEQ ID NO: 76, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO: 86; the Titin-T chain is a polypeptide as shown in SEQ ID NO: 76, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO: 86; or the Titin-T chain is a polypeptide as shown in SEQ ID NO: 75, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO: 86.

[0081] In some embodiments, in the aforementioned polypeptide complex, the first antigen is selected from: exogenous antigens, endogenous antigens, self-antigens, new antigens, viral antigens and tumor antigens.

[0082] In some embodiments, a multispecific polypeptide complex is disclosed, comprising:

[0083] A first polypeptide complex, which is any of the polypeptide complexes described above, which specifically binds to a first antigen, and

[0084] A second polypeptide complex, which comprises a second antigen binding portion, specifically binds to a second antigen.

[0085] In some embodiments, the first polypeptide complex and the second polypeptide complex bind two different antigens.

[0086] In some embodiments, the first polypeptide complex and the second polypeptide complex bind to two different epitopes on the same antigen.

[0087] In some embodiments, the multispecific polypeptide complex is a multispecific polypeptide complex, and more preferably, the multispecific polypeptide complex is a bispecific antibody.

[0088] In some embodiments, the second polypeptide complex of the multispecific polypeptide complex comprises a second heavy chain variable domain (VH2) and a second light chain variable domain (VL2). Mismatching is not likely to occur between the VH1 of the first polypeptide complex and the VL2 of the second polypeptide complex, and / or between the VH2 of the second polypeptide complex and the VL1 of the first polypeptide complex. In some embodiments, the VH2 and VL2 of the second antigen-binding moiety form a second antigen-binding site that specifically binds to a second antigen.

[0089] In some embodiments, in the aforementioned multi-specific polypeptide complex, the second antigen-binding portion of the second polypeptide complex comprises:

[0090] a third polypeptide comprising, from N-terminus to C-terminus, VH2 operably linked to a third domain comprising CH1, and

[0091] A fourth polypeptide, comprising VL2 from N-terminus to C-terminus, is operably linked to a fourth domain, wherein the fourth domain comprises CL.

[0092] In some embodiments, the C-terminus of the VH2 is bound to the N-terminus of CH1, and the C-terminus of the VL2 is bound to the N-terminus of CL.

[0093] In some embodiments, in the aforementioned multi-specific polypeptide complex, the first polypeptide complex further comprises a first dimerization domain that is operably connected, and the second polypeptide complex further comprises a second dimerization domain that is operably connected, and the first dimerization domain and the second dimerization domain are combined.

[0094] In some embodiments, the C-terminus of the first domain of the first polypeptide complex is operably linked to the N-terminus of the first dimerization domain, and the C-terminus of the third domain of the second polypeptide complex is operably linked to the N-terminus of the second dimerization domain.

[0095] In some embodiments, the aforementioned first dimerization domain and the second dimerization domain are combined to form a dimer through an antibody hinge region or a portion thereof, a linker, a disulfide bond, a hydrogen bond, an electrostatic interaction, a salt bridge, a hydrophobic-hydrophilic interaction, or a combination thereof.

[0096] In some embodiments, the aforementioned first dimerization domain and the second dimerization domain are combined to form a dimer through an antibody hinge region or a portion thereof, preferably a hinge region or a portion thereof of IgG1, IgG2 or IgG4 to form a dimer. In some embodiments, preferably a hinge region or a portion thereof of IgG1, IgG2, IgG3 or IgG4 is combined to form a dimer.

[0097] In some embodiments, in the aforementioned multi-specific polypeptide complex, the first dimerization domain and / or the second dimerization domain further comprises an antibody CH2 domain and / or an antibody CH3 domain.

[0098] In some embodiments, in the aforementioned multispecific polypeptide complex, the antibody CH2 domain and / or the antibody CH3 domain are derived from IgG1, IgG2 or IgG4. In some embodiments, the antibody CH2 domain and / or the antibody CH3 domain are derived from IgG1, IgG2, IgG3 or IgG4.

[0099] In some embodiments, in the aforementioned multi-specific polypeptide complex, the first polypeptide is sequentially arranged from N-terminus to C-terminus: VH1-L1-T chain-L2-CH2-CH3, the second polypeptide is sequentially arranged from N-terminus to C-terminus: VL1-L3-O chain or VL1-L4-OL chain, the third polypeptide is sequentially arranged from N-terminus to C-terminus: VH2-CH1-CH2-CH3, and the fourth polypeptide is sequentially arranged from N-terminus to C-terminus: VL1-CL; or, the first polypeptide is sequentially arranged from N-terminus to C-terminus: The sequence from the N-terminus to the C-terminus is: VH1-L2-O chain-L3-CH2-CH3, or VH1-L4-OL chain-L5-CH2-CH3; the sequence from the N-terminus to the C-terminus of the second polypeptide is: VL1-L1-T chain, the sequence from the N-terminus to the C-terminus of the third polypeptide is: VH2-CH1-CH2-CH3, and the sequence from the N-terminus to the C-terminus of the fourth polypeptide is: VL2-CL; the L1-L5 is a spacer (also called a connecting domain), and the spacer may be present or absent. Preferably, the spacer is selected from: the N-terminal fragment of the Titin-T chain, or the N-terminal fragment of the Obscurin-O chain, or the N-terminal fragment of the Obscurin-like-O chain, or a linker (for example (G x S) y Linker), wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6. Most preferably, the spacer is selected from: "KAGIR", "DQPQF", (G 4 S) 1 and (G 4 S) 2 .

[0100] In some embodiments, in the aforementioned multi-specific polypeptide complex, the first dimerization domain and the second dimerization domain are not identical and are bound in a manner that prevents homodimerization and / or favors heterodimerization.

[0101] In some embodiments, the aforementioned first dimerization domain and the second dimerization domain are combined to form a dimer by means of knob-into-hole, hydrophobic interaction, electrostatic interaction, hydrophilic interaction or increased flexibility.

[0102] In some embodiments, the first dimerization domain has amino acid residues 104 to 330 of the sequence as shown in SEQ ID NO: 2, and the second dimerization domain has amino acid residues 104 to 330 of the sequence as shown in SEQ ID NO: 3; or the first dimerization domain has amino acid residues 104 to 330 of the sequence as shown in SEQ ID NO: 3, and the second dimerization domain has amino acid residues 104 to 330 of the sequence as shown in SEQ ID NO: 2.

[0103] In some embodiments, the disclosure provides a domain engineered antibody, wherein at least one constant region domain CH1 and at least one constant region domain CL are replaced, wherein:

[0104] The CH1 domain is replaced by the titin-T chain, and the CL domain is replaced by a domain capable of protein-protein interaction with the titin-T chain;

[0105] The domain CL is replaced by the titin-T chain, and the domain CH1 is replaced by a domain capable of protein-protein interaction with the titin-T chain;

[0106] The CH1 domain is replaced by the Obscurin-O chain, and the CL domain is replaced by a domain capable of protein-protein interaction with the Obscurin-O chain;

[0107] The CL domain is replaced by the Obscurin-O chain, and the CH1 domain is replaced by a domain capable of protein-protein interaction with the Obscurin-O chain;

[0108] The CH1 domain is replaced by an Obscurin-like-O chain, and the CL domain is replaced by a domain capable of protein-protein interaction with an Obscurin-like-O chain; or

[0109] The domain CL is replaced by the Obscurin-like-O chain, and the domain CH1 is replaced by a domain capable of protein-protein interaction with the Obscurin-like-O chain.

[0110] In some embodiments, in the aforementioned domain-engineered antibody, the domain capable of interacting with Obscurin-O chain or Obscurin-like-O chain is Titin-T chain, and the domain capable of interacting with Titin-T chain is Obscurin-O chain or Obscurin-like-O chain;

[0111] In some embodiments, the antibody comprises a heavy chain variable region VH1 and a light chain variable region VL1, wherein VH1 and VL1 form a primary binding site that specifically binds to its antigen; the C-terminus of the VH1 is operably connected to the N-terminus of the Titin-T chain, and the C-terminus of the VL1 is operably connected to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain, or the C-terminus of the VL1 is operably connected to the N-terminus of the Titin-T chain, and the C-terminus of the VH1 is operably connected to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain.

[0112] In some embodiments, the present disclosure provides a Fab fragment of a domain-engineered antibody, wherein the constant region domain CH1 and the constant region domain CL are replaced, wherein,

[0113] The CH1 domain is replaced by the titin-T chain, and the CL domain is replaced by a domain capable of protein-protein interaction with the titin-T chain; or

[0114] The structural domain CL is replaced by the titin-T chain, and the structural domain CH1 is replaced by a structural domain capable of protein-protein interaction with the titin-T chain; or

[0115] The CH1 domain is replaced by the Obscurin-O chain, and the CL domain is replaced by a domain capable of protein-protein interaction with the Obscurin-O chain; or

[0116] The CL domain is replaced by the Obscurin-O chain, and the CH1 domain is replaced by a domain capable of protein-protein interaction with the Obscurin-O chain; or

[0117] The CH1 domain is replaced by an Obscurin-like-O chain, and the CL domain is replaced by a domain capable of protein-protein interaction with an Obscurin-like-O chain; or

[0118] The domain CL is replaced by the Obscurin-like-O chain, and the domain CH1 is replaced by a domain capable of protein-protein interaction with the Obscurin-like-O chain.

[0119] In some embodiments, in the aforementioned Fab fragment, the domain having protein-protein interaction with the titin-T chain is an obscurin-O chain or an obscurin-like-O chain; the domain having protein-protein interaction with the obscurin-O chain or an obscurin-like-O chain is a titin-T chain.

[0120] In some embodiments, the Fab comprises a heavy chain variable region VH1 and a light chain variable region VL1, wherein the VH1 and VL1 form an original binding site that specifically binds to its antigen; the C-terminus of the VH1 is operably connected to the N-terminus of the Titin-T chain, and the C-terminus of the VL1 is operably connected to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain, or the C-terminus of the VL1 is operably connected to the N-terminus of the Titin-T chain, and the C-terminus of the VH1 is operably connected to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain.

[0121] In some embodiments, the present disclosure provides a domain-engineered antibody comprising the aforementioned Fab fragment.

[0122] In some embodiments, the disclosure provides a bispecific antibody comprising a first heavy chain and a first light chain that specifically bind to a first antigen, and further comprising a second heavy chain and a second light chain that specifically bind to a second antigen, wherein:

[0123] The CH1 domain of the first heavy chain is replaced by the titin-T chain, and the CL domain of the first light chain is replaced by a domain capable of protein-protein interaction with the titin-T chain; or

[0124] The CL domain of the first light chain is replaced by a titin-T chain, and the CH1 domain of the first heavy chain is replaced by a domain capable of protein-protein interaction with a titin-T chain; or

[0125] The CH1 domain of the first heavy chain is replaced by the Obscurin-O chain, and the CL domain of the first light chain is replaced by a domain capable of protein-protein interaction with the Obscurin-O chain; or

[0126] The domain CL of the first light chain is replaced by the Obscurin-O chain, and the domain CH1 of the first heavy chain is replaced by a domain capable of protein-protein interaction with the Obscurin-O chain; or

[0127] The CH1 domain of the first heavy chain is replaced by an Obscurin-like-O chain, and the CL domain of the first light chain is replaced by a domain capable of protein-protein interaction with an Obscurin-like-O chain; or

[0128] The domain CL of the first light chain is replaced by the Obscurin-like-O chain, and the domain CH1 of the first heavy chain is replaced by a domain capable of protein-protein interaction with the Obscurin-like-O chain.

[0129] The first antigen and the second antigen bound by the bispecific antibody are different, or are two different epitopes on the same antigen.

[0130] In a specific embodiment, mispairing is not prone to occur between the first heavy chain and the second light chain, or between the first light chain and the second heavy chain.

[0131] In some embodiments, in the aforementioned bispecific antibody, the domain having protein-protein interaction with the titin-T chain is an obscurin-O chain or an obscurin-like-O chain; the domain having protein-protein interaction with the obscurin-O chain or an obscurin-like-O chain is a titin-T chain.

[0132] In some embodiments, the first heavy chain comprises a first heavy chain variable region (VH1), the first light chain comprises a first light chain variable region (VL1), the VH1 and VL1 form an antigen binding site that specifically binds to a first antigen, and the C-terminus of the VH1 is operably linked to the N-terminus of the Titin-T chain, the C-terminus of the VL1 is operably linked to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain, or the C-terminus of the VL1 is operably linked to the N-terminus of the Titin-T chain, and the C-terminus of the VH1 is operably linked to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain.

[0133] In some embodiments, the aforementioned bispecific antibody, wherein the second heavy chain comprises a second heavy chain variable region (VH2) from N-terminus to C-terminus, which is operably linked to CH1; the second light chain comprises a second light chain variable region (VL2) from N-terminus to C-terminus, which is operably linked to CL.

[0134] In some embodiments, in the aforementioned bispecific antibody, the VH2 and VL2 form an antigen binding site that specifically binds to a second antigen, and the C-terminus of the VH2 is operably linked to the N-terminus of the CH1; the C-terminus of the VL2 is operably linked to the N-terminus of the CL.

[0135] In some embodiments, the aforementioned bispecific antibody, wherein the bispecific antibody structural model is selected from F(ab) 2 , scFv-Fab, (scFv) 2-Fab, KiH, CrossMAb, Triomab quadroma, FcΔAdp, ART-Ig, BiMAb, Biclonics, BEAT, DuoBody, Azymetric, XmAb, 2:1 TCBs, 1Fab-IgG TDB, FynomAb, two-in-one / DAF, scFv-Fab-IgG, DART-Fc, LP-DART, CODY-Fab-TL, HLE-BiTE, F(ab) 2 -CrossMAb, IgG-(scFv) 2 , Bs4Ab, DVD-Ig, Tetravalent-DART-Fc, (scFv) 4 -Fc, CODV-Ig, mAb2, F(ab) 4 -CrossMAb, IgG and Fab-IgG, etc.

[0136] In some embodiments, in the aforementioned bispecific antibody, the C-termini of the first heavy chain and the second heavy chain comprise a CH2 and / or CH3 domain.

[0137] In some embodiments, the aforementioned CH1, CH2 and CH3 domains are derived from IgG1, IgG2 or IgG4. In some embodiments, the aforementioned CH1, CH2 and CH3 domains are derived from IgG1, IgG2, IgG3 or IgG4. In some embodiments, the aforementioned first heavy chain and the second heavy chain are combined to form a dimer by a combination of an antibody hinge region or a portion thereof, a linker, a disulfide bond, a hydrogen bond, an electrostatic interaction, a salt bridge, a hydrophobic-hydrophilic interaction or a combination thereof.

[0138] In some embodiments, in the aforementioned bispecific antibody, the first heavy chain is sequentially arranged from N-terminus to C-terminus: VH1-L1-T chain-L2-CH2-CH3, the first light chain is sequentially arranged from N-terminus to C-terminus: VL1-L3-O chain or VL1-L4-OL chain, the second heavy chain is sequentially arranged from N-terminus to C-terminus: VH2-CH1-CH2-CH3, and the second light chain is sequentially arranged from N-terminus to C-terminus: VL2-CL; or

[0139] The first light chain is VL1-L1-T chain from N-terminus to C-terminus, and the first heavy chain is VH1-L2-O chain-L3-CH2-CH3, or VH1-L4-OL chain-L5-CH2-CH3 from N-terminus to C-terminus; the second heavy chain is VH2-CH1-CH2-CH3 from N-terminus to C-terminus, and the second light chain is VL2-CL from N-terminus to C-terminus;

[0140] Wherein, the L1-L5 is a spacer region, which may be present or absent. Preferably, the spacer region is the N-terminal fragment of the titin-T chain, or the N-terminal fragment of the obscurin-O chain, or the N-terminal fragment of the obscurin-like-O chain, or a linker, for example (G x S) y Linker, wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6; preferably, the spacer is selected from: "KAGIR", "DQPQF", (G 4 S) 1 and (G 4 S) 2 .

[0141] In some embodiments, in the aforementioned bispecific antibody, CH2 and CH3 of the first heavy chain are different from CH2 and CH3 of the second heavy chain, and are bound in a manner that prevents homodimerization and / or favors heterodimerization.

[0142] In some embodiments, the aforementioned first heavy chain and the second heavy chain are combined to form a dimer by means of knob-into-hole, hydrophobic interaction, electrostatic interaction, hydrophilic interaction or increased flexibility.

[0143] In some embodiments, the first heavy chain and the second heavy chain are combined to form a dimer by knob-into-hole. In some embodiments, the first heavy chain CH2-CH3 domain has amino acid residues 104 to 330 of the sequence shown in SEQ ID NO: 2, and the second heavy chain CH2-CH3 domain has amino acid residues 104 to 330 of the sequence shown in SEQ ID NO: 3; or the first heavy chain CH2-CH3 domain has amino acid residues 104 to 330 of the sequence shown in SEQ ID NO: 3, and the second heavy chain CH2-CH3 domain has amino acid residues 104 to 330 of the sequence shown in SEQ ID NO: 2.

[0144] In some embodiments, in the aforementioned bispecific antibody, the first heavy chain is VH1-L1-T chain-L2-knob-Fc from N-terminus to C-terminus, the first light chain is VL1-L3-O chain or VL1-L4-OL chain from N-terminus to C-terminus, the second heavy chain is VH2-CH1-hole-Fc from N-terminus to C-terminus, and the second light chain is VL1-CL from N-terminus to C-terminus; or the first heavy chain is VH1-L1-T chain-L2-hole-Fc from N-terminus to C-terminus, the first light chain is VL1-L3-O chain or VL1-L4-OL chain from N-terminus to C-terminus, the second heavy chain is VH2-CH1-knob-Fc from N-terminus to C-terminus, and the second light chain is VL2-CL from N-terminus to C-terminus; or

[0145] The first light chain is VL1-L1-T chain from N-terminus to C-terminus, and the first heavy chain is VH1-L2-O chain-L3-knob-Fc, or VH1-L4-OL chain-L5-knob-Fc from N-terminus to C-terminus; the second heavy chain is VH2-CH1-hole-Fc from N-terminus to C-terminus, and the second light chain is VL2-CL from N-terminus to C-terminus; the first light chain is VL1-L1-T chain from N-terminus to C-terminus, and the first heavy chain is VH1-L2-O chain-L3-hole-Fc, or VH1-L4-OL chain-L5-hole-Fc from N-terminus to C-terminus; the second heavy chain is VH2-CH1-knob-Fc from N-terminus to C-terminus, and the second light chain is VL2-CL from N-terminus to C-terminus;

[0146] The L1-L5 is a spacer region, which may be present or absent. Preferably, the spacer region is the N-terminal fragment of the titin-T chain, or the N-terminal fragment of the obscurin-O chain, or the N-terminal fragment of the obscurin-like-O chain, or a linker, for example (G x S) y Linker, wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6; preferably, the spacer is selected from: "KAGIR", "DQPQF", (G 4 S) 1 and (G 4 S) 2 .

[0147] In some embodiments, the domain-modified antibody, or Fab fragment of the domain-modified antibody, or bispecific antibody described in any of the above items, wherein the domain that interacts with the titin-T chain is an obscurin-O chain or an obscurin-like-O chain; the domain that interacts with the obscurin-O chain or an obscurin-like-O chain is a titin-T chain. In the domain-modified antibody, or Fab fragment of the domain-modified antibody, or bispecific antibody described in any of the above items, the operably connected two polypeptide sequences are connected via a spacer or two polypeptides are directly connected.

[0148] In some embodiments, the aforementioned domain-engineered antibody, or bispecific antibody, or Fab fragment of the domain-engineered antibody, wherein the Titin-T chain and the Obscurin-O chain, or the Titin-T chain and the Obscurin-like-O chain are bound to form a dimer through natural interchain bonds and / or non-natural interchain bonds.

[0149] In some embodiments, the first domain and the second domain form a dimer through a natural interchain bond, and one or more residues selected from positions 7-15, 19-24, 26, 55, 59 and 60 on the Titin-T chain and one or more residues selected from positions 3-6, 9, 41, 73, 75 and 80-90 on the Obscurin-O chain are bound to each other, or

[0150] One or more residues selected from positions 1, 7-10, 13-16, 19-26, 59-60 and 96 on the titin-T chain and one or more residues selected from positions 4-5, 10, 12-13, 74, 76, 78 and 82-91 on the obscurin-like-O chain are combined with each other. The titin-T chain residue positions are positions with respect to the natural sequence numbering of the sequence SEQ ID NO: 32; the obscurin-O chain residue positions are positions with respect to the natural sequence numbering of the sequence SEQ ID NO: 33; and the obscurin-like-O chain residue positions are positions with respect to the natural sequence numbering of the sequence SEQ ID NO: 34.

[0151] In some embodiments, in the aforementioned domain-engineered antibody, bispecific antibody, or Fab fragment of a domain-engineered antibody, the titin-T chain and the obscurin-O chain or the titin-T chain and the obscurin-like-O chain form a dimer through at least one non-natural interchain bond. In some embodiments, the non-natural interchain bond is a disulfide bond; in some embodiments, the dimer comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 non-natural interchain bonds.

[0152] In some embodiments, the aforementioned domain-engineered antibody, bispecific antibody or Fab fragment of a domain-engineered antibody, wherein:

[0153] The Titin-T chain has one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39, and / or the Obscurin-O chain has one or more amino acid residue mutations selected from positions 3, 9, 25, 76 and 88; or

[0154] The Titin-T chain has one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39, and / or the Obscurin-like-O chain has one or more amino acid residue mutations selected from positions 6, 26, 74, 77, 84 and 86.

[0155] In some embodiments, the titin-T chain / obscurin-O chain, or titin-T chain / obscurin-like-O chain is:

[0156] The Titin-T chain is a polypeptide having one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39 based on the sequence of SEQ ID NO: 32, and / or the Obscurin-O chain is a polypeptide having one or more amino acid residue mutations selected from positions 3, 9, 25, 76 and 88 based on the sequence of SEQ ID NO: 33; or

[0157] The Titin-T chain is a polypeptide having one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39 based on the sequence of SEQ ID NO: 32, and / or the Obscurin-like-O chain is a polypeptide having one or more amino acid residue mutations selected from positions 6, 26, 74, 77, 84 and 86 based on the sequence of SEQ ID NO: 34.

[0158] In some embodiments, the aforementioned domain-engineered antibody, bispecific antibody or Fab fragment of a domain-engineered antibody, wherein:

[0159] The Titin-T chain has one or more amino acid residue mutations selected from 8C, 20C, 22C, 25S, 26C and 39T, and / or the Obscurin-O chain has one or more amino acid residue mutations selected from 3C, 9C, 25S, 76S and 88C; or

[0160] The Titin-T chain has one or more amino acid residue mutations selected from 8C, 20C, 22C, 25S, 26C and 39T, and / or the Obscurin-like-O chain has one or more amino acid residue mutations selected from 6E, 26S, 74C, 77S, 84C and 86C;

[0161] More preferably, the non-natural interchain bond is located at a mutation site selected from:

[0162] The Titin-T chain has 25S, 39T, and 8C mutations, and the Obscurin-O chain has an 88C mutation;

[0163] The Titin-T chain has 25S, 39T, and 20C mutations, and the Obscurin-O chain has a 3C mutation;

[0164] The Titin-T chain has 25S, 39T, and 26C mutations, and the Obscurin-O chain has a 9C mutation;

[0165] The Titin-T chain has 25S, 39T, and 8C mutations, and the Obscurin-O chain has 25S, 76S, and 88C mutations;

[0166] The Titin-T chain has 25S, 39T, and 20C mutations, and the Obscurin-O chain has 25S, 76S, and 3C mutations;

[0167] The Titin-T chain has 25S, 39T, and 26C mutations, and the Obscurin-O chain has 25S, 76S, and 9C mutations;

[0168] The Titin-T chain has 25S, 39T, and 8C mutations, and the Obscurin-like-O chain has 6E and 74C mutations;

[0169] The Titin-T chain has 25S, 39T, and 20C mutations, and the Obscurin-like-O chain has 6E and 84C mutations;

[0170] The Titin-T chain has 25S, 39T, and 22C mutations, and the Obscurin-like-O chain has 6E and 86C mutations;

[0171] The Titin-T chain has 25S, 39T, and 8C mutations, and the Obscurin-like-O chain has 6E, 26S, 77S, and 74C mutations;

[0172] The Titin-T chain has 25S, 39T and 20C mutations and the Obscurin-like-O chain has 6E, 26S, 77S and 84C mutations; or

[0173] The Titin-T chain has 25S, 39T, and 22C mutations, and the Obscurin-like-O chain has 6E, 26S, 77S, and 86C mutations;

[0174] The mutation sites of Titin-T chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO: 32; the mutation sites of Obscurin-O chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO: 33; and the mutation sites of Obscurin-like-O chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO: 34.

[0175] In some embodiments, the aforementioned domain-engineered antibody, bispecific antibody or Fab fragment of a domain-engineered antibody, wherein:

[0176] The Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T, and / or the Obscurin-O chain has one or more amino acid residue mutations selected from A3C, R9C, C25S, C76S and A88C; or

[0177] The Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T, and / or the Obscurin-like-O chain has one or more amino acid residue mutations selected from C6E, C26S, C77S, V74C, G84C and A86C; the mutation sites of the Titin-T chain are natural sequence sites relative to the sequence SEQ ID NO: 32; the mutation sites of the Obscurin-O chain are natural sequence sites relative to the sequence SEQ ID NO: 33; the mutation sites of the Obscurin-like-O chain are natural sequence sites relative to the sequence SEQ ID NO: 34.

[0178] In some embodiments, the aforementioned Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T based on the sequence of SEQ ID NO: 32, and / or the Obscurin-O chain has one or more amino acid residue mutations selected from A3C, R9C, C25S, C76S and A88C based on the sequence of SEQ ID NO: 33; or the Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T based on the sequence of SEQ ID NO: 32, and / or the Obscurin-like-O chain has one or more amino acid residue mutations selected from C6E, C26S, C77S, V74C, G84C and A86C based on the sequence of SEQ ID NO: 34. The titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; and the obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 34.

[0179] In some embodiments, the aforementioned domain-engineered antibody, bispecific antibody or Fab fragment of a domain-engineered antibody, wherein:

[0180] The Titin-T chain has C25S, C39T and A8C mutations, and the Obscurin-O chain has an A88C mutation;

[0181] Titin-T chain has C25S, C39T, and V20C mutations, and Obscurin-O chain has A3C mutation;

[0182] Titin-T chain has C25S, C39T, and A26C mutations, and Obscurin-O chain has R9C mutation;

[0183] Titin-T chain has C25S, C39T, and A8C mutations, and Obscurin-O chain has C25S, C76S, and A88C mutations;

[0184] Titin-T chain has C25S, C39T, and V20C mutations, and Obscurin-O chain has C25S, C76S, and A3C mutations;

[0185] Titin-T chain has C25S, C39T, and A26C mutations, and Obscurin-O chain has C25S, C76S, and R9C mutations;

[0186] Titin-T chain has C25S, C39T, and A8C mutations, and Obscurin-like-O chain has C6E and V74C mutations;

[0187] Titin-T chain has C25S, C39T, and V20C mutations, and Obscurin-like-O chain has C6E and G84C mutations;

[0188] Titin-T chain has C25S, C39T, and T22C mutations, and Obscurin-like-O chain has C6E and A86C mutations;

[0189] Titin-T chain has C25S, C39T, and A8C mutations, and Obscurin-like-O chain has C6E, C26S, C77S, and V74C mutations;

[0190] Titin-T chain has C25S, C39T, and V20C mutations, and Obscurin-like-O chain has C6E, C26S, C77S, and G84C mutations;

[0191] Titin-T chain has C25S, C39T, and T22C mutations, and Obscurin-like-O chain has C6E, C26S, C77S, and A86C mutations;

[0192] The titin-T chain mutation site is the natural sequence site relative to the sequence SEQ ID NO: 32; the obscurin-O chain mutation site is the natural sequence site relative to the sequence SEQ ID NO: 33; and the obscurin-like-O chain mutation site is the natural sequence site relative to the sequence SEQ ID NO: 34.

[0193] In some embodiments, in some embodiments, the aforementioned domain-engineered antibodies, bispecific antibodies or Fab fragments of domain-engineered antibodies: the Titin-T chain has C25S, C39T and A8C mutations based on the sequence of SEQ ID NO: 32, and the Obscurin-O chain has an A88C mutation based on the sequence of SEQ ID NO: 33; the Titin-T chain has C25S, C39T and V20C mutations based on the sequence of SEQ ID NO: 32, and the Obscurin-O chain has an A3C mutation based on the sequence of SEQ ID NO: 33; the Titin-T chain has C25S, C39T and A26C mutations based on the sequence of SEQ ID NO: 32, and the Obscurin-O chain has an R9C mutation based on the sequence of SEQ ID NO: 33; the Titin-T chain has C25S, C39T and A8C mutations based on the sequence of SEQ ID NO: 32, and the Obscurin-O chain has an A88C mutation based on the sequence of SEQ ID NO: 33. ID NO: 33, the Titin-T chain has C25S, C76S and A88C mutations based on the SEQ ID NO: 33 sequence; the Titin-T chain has C25S, C39T and V20C mutations based on the SEQ ID NO: 32 sequence, and the Obscurin-O chain has C25S, C76S and A3C mutations based on the SEQ ID NO: 33 sequence; the Titin-T chain has C25S, C39T and A26C mutations based on the SEQ ID NO: 32 sequence, and the Obscurin-O chain has C25S, C76S and R9C mutations based on the SEQ ID NO: 33 sequence; the Titin-T chain has C25S, C39T and A8C mutations based on the SEQ ID NO: 32 sequence, and the Obscurin-like-O chain has C6E and V74C mutations based on the SEQ ID NO: 34 sequence; the Titin-T chain has C25S, C39T and A26C mutations based on the SEQ ID NO: 32 sequence, and the Obscurin-like-O chain has C6E and V74C mutations based on the SEQ ID NO: 35 sequence; NO: 32 has C25S, C39T and V20C mutations, and the Obscurin-like-O chain has C6E and G84C mutations based on the sequence of SEQ ID NO: 34; the Titin-T chain has C25S, C39T and T22C mutations based on the sequence of SEQ ID NO: 32, and the Obscurin-like-O chain has C6E and A86C mutations based on the sequence of SEQ ID NO: 34; the Titin-T chain has C25S, C39T and A8C mutations based on the sequence of SEQ ID NO: 32, and the Obscurin-like-O chain has C6E, C26S, C77S and V74C mutations based on the sequence of SEQ ID NO: 34;The titin-T chain has C25S, C39T and V20C mutations based on the sequence of SEQ ID NO: 32, and the obscurin-like-O chain has C6E, C26S, C77S and G84C mutations based on the sequence of SEQ ID NO: 34; the titin-T chain has C25S, C39T and T22C mutations based on the sequence of SEQ ID NO: 32, and the obscurin-like-O chain has C6E, C26S, C77S and A86C mutations based on the sequence of SEQ ID NO: 34. The mutation site of the titin-T chain is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 32; the mutation site of the obscurin-O chain is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 33; and the mutation site of the obscurin-like-O chain is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 34. ;

[0194] In some embodiments, in the aforementioned domain-engineered antibody, bispecific antibody or Fab fragment of a domain-engineered antibody, the Obscurin-O chain further has one or more amino acid residue mutations selected from positions 7, 11, and 62. In some embodiments, the Obscurin-O chain has one or more amino acid residue mutations selected from 7R or 7K, 62K or 62H, and 11L; most preferably, the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 25S, 76S, 88C, 7K and 62K mutations; the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 25S, 76S, 88C, 7K and 62H mutations; the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 25S, 76S, 88C, 11L and 62K mutations; or the Titin-T chain has 25S, 39T and 8C mutations, and the Obscurin-O chain has 25S, 76S, 88C, 11L and 62H. In some embodiments, the Obscurin-O chain has one or more amino acid residue mutations selected from L7K or L7R, K11L, T62K or T62H; in some embodiments, the Titin-T chain has C25S, C39T and A8C mutations, the Obscurin-O chain has C25S, C76S, A88C, L7K and T62K mutations; the Titin-T chain has C25S, C39T and A8C mutations, the Obsc The titin-O chain has C25S, C76S, A88C, L7K and T62H mutations; the titin-T chain has C25S, C39T and A8C mutations, and the obscurin-O chain has C25S, C76S, A88C, K11L and T62K mutations; or the titin-T chain has C25S, C39T and A8C mutations, and the obscurin-O chain has C25S, C76S, A88C, K11L and T62H mutations. The mutation sites of the titin-T chain are natural sequence sites relative to the sequence SEQ ID NO: 32; the mutation sites of the obscurin-O chain are natural sequence sites relative to the sequence SEQ ID NO: 33.

[0195] In some embodiments, in the aforementioned domain-engineered antibody, bispecific antibody or Fab fragment of a domain-engineered antibody, the Obscurin-O chain is an Obscurin-O chain having one or more amino acid residue mutations selected from positions 7, 11, and 62 based on SEQ ID NO: 45; in some embodiments, the Obscurin-O chain has one or more amino acid residue mutations selected from positions L7K or L7R, K11L and T62K or T62H based on SEQ ID NO: 45; in some embodiments, the Titin-T chain has C25S, C39T and A8C mutations based on SEQ ID NO: 32, and the Obscurin-O chain has C25S, C76S, A88C, L7K and T62K mutations based on SEQ ID NO: 45; the Titin-T chain has C25S, C39T and A8C mutations based on SEQ ID NO: 32, and the Obscurin-O chain has C25S, C76S, A88C, L7K and T62K mutations based on SEQ ID NO: NO: 45, with C25S, C76S, A88C, L7K and T62H mutations; Titin-T chain has C25S, C39T and A8C mutations on the basis of SEQ ID NO: 32, and Obscurin-O chain has C25S, C76S, A88C, K11L and T62K mutations on the basis of SEQ ID NO: 45; Titin-T chain has C25S, C39T and A8C mutations on the basis of SEQ ID NO: 32, and Obscurin-O chain has C25S, C76S, A88C, K11L and T62H mutations on the basis of SEQ ID NO: 45. The mutation site of the Titin-T chain is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 32; the mutation site of the Obscurin-O chain is the site corresponding to the natural sequence number of the sequence SEQ ID NO: 33.

[0196] In some embodiments, the aforementioned domain-engineered antibodies, bispecific antibodies or Fab fragments of domain-engineered antibodies, the Titin-T chain has one or more amino acid mutations selected from positions 3, 11, 13, 22, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84, and / or the Obscurin-O chain has one or more amino acid mutations selected from positions 2, 11, 12, 13, 14, 17, 20, 22, 30, 32, 34, 36, 41, 42, 44, 45, 53, 58, 62, 67, 69, 89, 92, 94 and 97. In some embodiments, the Titin-T chain has one or more amino acid mutations selected from 3W, 11I, 13L, 22M, 40S, 42K, 45S, 47E, 49G, 56S, 58E, 66S or 66K, 70R, 75V, 77S, 79T, 81R, 82M, 83D and 84L, and / or the Obscurin-O chain has one or more amino acid mutations selected from 2E, 11K, 12S, 13Y, 14T, 17E, 20L, 22M or 22S, 30D, 32P, 34E, 36T, 41K, 42L, 44I, 45T, 53L, 58V, 62E, 67Q or 67T, 69S, 89L, 92E, 94G and 97G.More preferably, the titin-T chain has 66S and 77S amino acid mutations, and / or the obscurin-O chain has 11K, 12S, 13Y, 14T and 22S amino acid mutations; the titin-T chain has 66K, 70R, 79T and 81R amino acid mutations, and / or the obscurin-O chain has 2E, 17E, 30D, 32P, 34E, 36T, 44I, 45T, 58V, 62E, 67Q, 69S and 97G amino acid mutation; the titin-T chain has 3W, 11I, 13L, 22M and 82M amino acid mutations, and / or the obscurin-O chain has 20L, 22M and 53L amino acid mutations; the titin-T chain has 11I, 66K, 79T and 81R amino acid mutations, and / or the obscurin-O chain has 41K, 45T, 67Q, 69S and 89L amino acid mutations; the titin-T chain has 40S , 42K, 42K, 45S, 47E, 49G, 56S, 58E, 75V, 83D and 84L amino acid mutations, and / or the Obscurin-O chain has 42L, 45T, 67T, 69S, 92E and 94G amino acid mutations; the Titin-T chain has 47E, 49G, 56S, 58E and 75V amino acid mutations, and / or the Obscurin-O chain has 42L, 45T, 67T, 69S, 92E and 94G amino acid mutations The titin-T chain has 56S, 58E and 75V amino acid mutations, and / or the obscurin-O chain has 42L, 45T, 67T, 69S, 92E and 94G amino acid mutations; or the titin-T chain has 56S, 58E, 66S and 77S amino acid mutations, and / or the obscurin-O chain has 12S, 13Y, 22S, 42L, 45T, 67Q, 69S, 92E and 94G amino acid mutations. The mutation sites of the titin-T chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 35; the mutation sites of the obscurin-O chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 50.In some embodiments, the Titin-T chain has one or more amino acid mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L, and / or Obscurin- The O chain has one or more amino acid mutations selected from G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G.In some embodiments, the Titin-T chain has M66S and T77S amino acid mutations, and / or the Obscurin-O chain has L11K, A12S, F13Y, V14T, and T22S amino acid mutations; the Titin-T chain has M66K, K70R, S79T, and G81R amino acid mutations, and / or the Obscurin-O chain has G2E, V17E, N30D, T32P, Q34E, S36T, V44I, A45T, L58V, K62E, A67Q, G 69S and A97G amino acid mutations; the Titin-T chain has P3W, S11I, I13L, T22M and N82M amino acid mutations, and / or the Obscurin-O chain has D20L, T22M and A53L amino acid mutations; the Titin-T chain has S11I, M66K, S79T and G81R amino acid mutations, and / or the Obscurin-O chain has Q41K, A45T, A67Q, G69S and V89L amino acid mutations; the Titin-T chain has G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, L75V, E83D and F84L amino acid mutations, and / or the Obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations; the Titin-T chain has Q47E, Q49G, N56S, D58E and L75V amino acid mutations, and / or the Obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations. mutation; the titin-T chain has N56S, D58E and L75V amino acid mutations, and / or the obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations; or the titin-T chain has N56S, D58E, M66S and T77S amino acid mutations, and / or the obscurin-O chain has A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E and D94G amino acid mutations. The mutation sites of the titin-T chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 35; the mutation sites of the obscurin-O chain are the natural sequence numbering sites relative to the sequence SEQ ID NO: 50.

[0197] In some embodiments, the aforementioned domain-engineered antibodies, bispecific antibodies or Fab fragments of domain-engineered antibodies: the Titin-T chain is a polypeptide having one or more amino acid mutations selected from positions 3, 11, 13, 22, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84 based on SEQ ID NO: 35, and the Obscurin-O chain is a polypeptide having one or more amino acid mutations selected from positions 2, 11, 12, 13, 14, 17, 20, 22, 30, 32, 34, 36, 41, 42, 44, 45, 53, 58, 62, 67, 69, 89, 92, 94 and 97 based on SEQ ID NO: 50. The titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 35; the obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 50. In some embodiments, the titin-T chain has one or more amino acid mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the sequence of SEQ ID NO: 35, and / or the obscurin-O chain has one or more amino acid mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the sequence of SEQ ID NO: 35 sequence has one or more amino acid mutations selected from G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G. In some embodiments, the Titin-T chain has M66S and T77S amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the Obscurin-O chain has L11K, A12S, F13Y, V14T and T22S amino acid mutations based on the sequence of SEQ ID NO: 50; the Titin-T chain has M66K, K70R, S79T and G81R amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the Obscurin-O chain has G2E, V17E, N30D, T32P, Q34E, S36T, V44I, A45T, L58V, K62E, A67Q, G69S and A97G amino acid mutations based on the sequence of SEQ ID NO: 50;The titin-T chain has P3W, S11I, I13L, T22M and N82M amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the obscurin-O chain has D20L, T22M and A53L amino acid mutations based on the sequence of SEQ ID NO: 50; the titin-T chain has S11I, M66K, S79T and G81R amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the obscurin-O chain has Q41K, A45T, A67Q, G69S and V89L amino acid mutations based on the sequence of SEQ ID NO: 50; the titin-T chain has S11I, M66K, S79T and G81R amino acid mutations based on the sequence of SEQ ID NO: 35, and / or the obscurin-O chain has Q41K, A45T, A67Q, G69S and V89L amino acid mutations based on the sequence of SEQ ID NO: 50; NO: 35 sequence, and / or the Obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations based on SEQ ID NO: 50 sequence; the Titin-T chain has Q47E, Q49G, N56S, D58E and L75V amino acid mutations based on SEQ ID NO: 35 sequence, and / or the Obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations based on SEQ ID NO: 50 sequence; the Titin-T chain has Q47E, Q49G, N56S, D58E and L75V amino acid mutations based on SEQ ID NO: 35 sequence, and / or the Obscurin-O chain has Q42L, A45T, A67T, G69S, Q92E and D94G amino acid mutations based on SEQ ID NO: 50 sequence; The amino acid mutations of the titin-T chain are N56S, D58E and L75V based on the sequence of SEQ ID NO: 35, and / or the Obscurin-O chain is Q42L, A45T, A67T, G69S, Q92E and D94G based on the sequence of SEQ ID NO: 50; or the titin-T chain is N56S, D58E, M66S and T77S based on the sequence of SEQ ID NO: 35, and / or the Obscurin-O chain is A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E and D94G based on the sequence of SEQ ID NO: 50; the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence of SEQ ID NO: 35; the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence of SEQ ID NO: 50. ;

[0198] In some embodiments, in the aforementioned domain-engineered antibody, bispecific antibody or Fab fragment of the domain-engineered antibody, the N-terminus of the titin-T chain, obscurin-O chain or obscurin-like-O chain is operably connected to VH or VL via a connecting domain. In some embodiments, the connecting domain is selected from: the N-terminal fragment of the titin-T chain, the N-terminal fragment of the obscurin-O chain or the N-terminal fragment of the obscurin-like-O chain, and (G x S) y A linker, wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6. In some embodiments, the linker domain is selected from: "KAGIR", "DQPQF", (G 4 S) 1 and (G 4 S) 2 .

[0199] In some embodiments, the Titin-T chain is linked to VH or VL via a KAGIR polypeptide, and / or the Obscurin-O chain is linked to VL or VH via a DQPQF polypeptide.

[0200] In some embodiments, the aforementioned polypeptide complex, wherein:

[0201] (A) The sequence of the titin-T chain is as shown in SEQ ID NO: 32 or further comprises one or more amino acid mutations selected from 8, 20, 22, 25, 26, 39, 3, 11, 13, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84 and / or a sequence with an additional KAGIR amino acid residue at the N-terminus based on the sequence of SEQ ID NO: 32; preferably comprises a sequence selected from A8C, V20C, T22C, C25S, A2 6C, C39T, P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S or M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L, and / or a sequence in which one or more amino acid residues of KAGIR are added to the N-terminus; and / or

[0202] (B) The sequence of the Obscurin-O chain is as shown in SEQ ID NO: 33 or further comprises, based on the sequence of SEQ ID NO: 33, an amino acid mutation at one or more positions selected from 3, 9, 25, 76, 88, 7, 11, 62, 2, 12, 13, 14, 17, 20, 22, 30, 32, 34, 36, 41, 42, 44, 45, 53, 58, 67, 69, 89, 92, 94 and 97 and / or an additional DQPQF amino acid residue at the N-terminus; preferably comprises an amino acid mutation at one or more positions selected from A3C, R9C, C25S, C76S, A88C, L7K or L7R, T 62K or T62H, G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G, and / or a sequence in which the DQPQF amino acid residue is added to the N-terminus; or

[0203] The sequence of the Obscurin-like-O chain is as shown in SEQ ID NO: 34 or a sequence having one or more amino acid mutations selected from 6, 26, 74, 77, 84 and 86 based on the sequence of SEQ ID NO: 34; preferably a sequence having one or more amino acid mutations selected from C6E, C26S, C77S, V74C, G84C and A86C;

[0204] The above titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; the obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 34;

[0205] Preferably, wherein:

[0206] (A) The titin-T chain has one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39 based on the sequence of SEQ ID NO: 32, preferably one or more amino acid residue mutations selected from positions A8C, V20C, T22C, C25S, A26C and C39T, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; more preferably, the titin-T chain has one or more amino acid residue mutations selected from positions A8C, V20C, T22C, C25S, A26C and C39T based on the sequence of SEQ ID NO: 32. NO:35, has one or more amino acid mutations selected from positions 3, 11, 13, 22, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84, preferably has one or more amino acid mutations selected from positions P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L; the titin-T chain mutation sites are the natural sequence numbering sites of the sequence SEQ ID NO:35, and / or

[0207] (B) The Obscurin-O chain has one or more amino acid residue mutations selected from positions 3, 9, 25, 76 and 88 based on the sequence of SEQ ID NO: 33, preferably one or more amino acid residue mutations selected from A3C, R9C, C25S, C76S and A88C, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 33; preferably, the Obscurin-O chain has one or more amino acid residue mutations selected from positions 7, 11 and 62 based on the sequence of SEQ ID NO: 45, preferably one or more amino acid residue mutations selected from positions L7K or L7R, T62K or T62H, and K11L, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 45; more preferably, the Obscurin-O chain has one or more amino acid residue mutations selected from positions 7, 11 and 62 based on the sequence of SEQ ID NO: 45, preferably one or more amino acid residue mutations selected from positions L7K or L7R, T62K or T62H, and K11L, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 45. NO:50 has one or more amino acid mutations selected from the group consisting of the 2nd, 11th, 12th, 13th, 14th, 17th, 20th, 22nd, 30th, 32nd, 34th, 36th, 41st, 42nd, 44th, 45th, 53rd, 58th, 62nd, 67th, 69th, 89th, 92nd, 94th and 97th positions, preferably one or more amino acid mutations selected from the group consisting of G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G, wherein the Obscurin-O chain mutation site is the sequence of SEQ ID NO: natural sequence number locus 50; or

[0208] The Obscurin-like-O chain has one or more amino acid residue mutations selected from positions 6, 26, 74, 77, 84 and 86 based on the sequence of SEQ ID NO: 34, preferably one or more amino acid residue mutations selected from C6E, C26S, C77S, V74C, G84C and A86C, and the Obscurin-like-O chain mutation sites are the natural sequence numbering sites of the sequence SEQ ID NO: 34.

[0209] In some embodiments, the aforementioned domain-engineered antibody, bispecific antibody or Fab fragment of a domain-engineered antibody, the Titin-T chain comprises a polypeptide having a sequence as shown in any one of SEQ ID NOs: 32, 35-41, 65-76 or having at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76, and / or the Obscurin-O chain comprises a polypeptide having a sequence as shown in any one of SEQ ID NOs: 33, 42-58, 77-86 or having at least 80% identity with any one of SEQ ID NOs: 33, 42-58, 77-86; or the Titin-T chain comprises a polypeptide having a sequence as shown in any one of SEQ ID NOs: 32, 35-41, 65-76 or having at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76, and / or the Obscurin-like-O chain comprises a sequence as shown in any one of SEQ ID NOs: 34, 59-64 or having at least 80% identity with any one of SEQ ID NOs. NO: 34, 59-64 have at least 80% identical polypeptides. Wherein said having at least 80% identity is, for example, having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity.

[0210] In some embodiments, the titin-T chain comprises the polypeptide set forth in SEQ ID NO:68, and the obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:80; the titin-T chain comprises the polypeptide set forth in SEQ ID NO:73, and the obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:83; the titin-T chain comprises the polypeptide set forth in SEQ ID NO:76, and the obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:84; the titin-T chain comprises the polypeptide set forth in SEQ ID NO:76, and the obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:86; the titin-T chain comprises the polypeptide set forth in SEQ ID NO:76, and the obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:86; the titin-T chain comprises the polypeptide set forth in SEQ ID NO:75, and the obscurin-O chain comprises the polypeptide set forth in SEQ ID NO:86.

[0211] In some embodiments, the aforementioned bispecific antibody is a bispecific antibody selected from any one of the following AG:

[0212] A. the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO: 89, or has at least 85% sequence identity to SEQ ID NO: 89, the sequence of the first light chain is as shown in SEQ ID NO: 90, or has at least 85% sequence identity to SEQ ID NO: 90, the sequence of the second heavy chain is as shown in SEQ ID NO: 87, or has at least 85% sequence identity to SEQ ID NO: 87, and the sequence of the second light chain is as shown in SEQ ID NO: 88, or has at least 85% sequence identity to SEQ ID NO: 88;

[0213] B. the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO:93, or has at least 85% sequence identity to SEQ ID NO:93, the sequence of the first light chain is as shown in SEQ ID NO:94, or has at least 85% sequence identity to SEQ ID NO:94, the sequence of the second heavy chain is as shown in SEQ ID NO:91, or has at least 85% sequence identity to SEQ ID NO:91, and the sequence of the second light chain is as shown in SEQ ID NO:92, or has at least 85% sequence identity to SEQ ID NO:92;

[0214] C. the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO:97, or has at least 85% sequence identity to SEQ ID NO:97, the sequence of the first light chain is as shown in SEQ ID NO:98, or has at least 85% sequence identity to SEQ ID NO:98, the sequence of the second heavy chain is as shown in SEQ ID NO:95, or has at least 85% sequence identity to SEQ ID NO:95, and the sequence of the second light chain is as shown in SEQ ID NO:96, or has at least 85% sequence identity to SEQ ID NO:96;

[0215] D. the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO:99, or has at least 85% sequence identity to SEQ ID NO:99, the sequence of the first light chain is as shown in SEQ ID NO:100, or has at least 85% sequence identity to SEQ ID NO:100, the sequence of the second heavy chain is as shown in SEQ ID NO:101, or has at least 85% sequence identity to SEQ ID NO:101, and the sequence of the second light chain is as shown in SEQ ID NO:96, or has at least 85% sequence identity to SEQ ID NO:96;

[0216] E. the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO: 102, or has at least 85% sequence identity to SEQ ID NO: 102, the sequence of the first light chain is as shown in SEQ ID NO: 100, or has at least 85% sequence identity to SEQ ID NO: 100, the sequence of the second heavy chain is as shown in SEQ ID NO: 95, or has at least 85% sequence identity to SEQ ID NO: 95, and the sequence of the second light chain is as shown in SEQ ID NO: 96, or has at least 85% sequence identity to SEQ ID NO: 96;

[0217] F. the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO: 103, or has at least 85% sequence identity to SEQ ID NO: 103, the sequence of the first light chain is as shown in SEQ ID NO: 104, or has at least 85% sequence identity to SEQ ID NO: 104, the sequence of the second heavy chain is as shown in SEQ ID NO: 95, or has at least 85% sequence identity to SEQ ID NO: 95, and the sequence of the second light chain is as shown in SEQ ID NO: 96, or has at least 85% sequence identity to SEQ ID NO: 96;

[0218] G. the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO: 107, or has at least 85% sequence identity to SEQ ID NO: 107, the sequence of the first light chain is as shown in SEQ ID NO: 108, or has at least 85% sequence identity to SEQ ID NO: 108, the sequence of the second heavy chain is as shown in SEQ ID NO: 109, or has at least 85% sequence identity to SEQ ID NO: 109, and the sequence of the second light chain is as shown in SEQ ID NO: 110, or has at least 85% sequence identity to SEQ ID NO: 110;

[0219] H. the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO: 122, or has at least 85% sequence identity to SEQ ID NO: 122, the sequence of the first light chain is as shown in SEQ ID NO: 123, or has at least 85% sequence identity to SEQ ID NO: 123, the sequence of the second heavy chain is as shown in SEQ ID NO: 116, or has at least 85% sequence identity to SEQ ID NO: 116, and the sequence of the second light chain is as shown in SEQ ID NO: 117, or has at least 85% sequence identity to SEQ ID NO: 117;

[0220] I. the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO: 118, or has at least 85% sequence identity to SEQ ID NO: 118, the sequence of the first light chain is as shown in SEQ ID NO: 119, or has at least 85% sequence identity to SEQ ID NO: 119, the sequence of the second heavy chain is as shown in SEQ ID NO: 124, or has at least 85% sequence identity to SEQ ID NO: 124, and the sequence of the second light chain is as shown in SEQ ID NO: 125, or has at least 85% sequence identity to SEQ ID NO: 125;

[0221] wherein the aforementioned has at least 85% identity: for example, at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity.

[0222] In some embodiments, the present disclosure provides a method for preparing a multispecific antibody, the method comprising replacing antibody CH1 / CL with titin-T chain and obscurin-O chain, or titin-T chain and obscurin-like-O chain. In some embodiments of the method for preparing a multispecific antibody, the multispecific antibody of the present disclosure has reduced light chain and heavy chain mispairing compared to the wild type in which CH1 / CL is not replaced by titin-T chain / obscurin-O chain, or titin-T chain / obscurin-like-O chain.

[0223] In some embodiments, the disclosure also provides a multispecific antibody prepared by the aforementioned method for preparing a multispecific antibody. In some embodiments, the multispecific antibody comprises a first heavy chain variable region (VH1) and a first light chain variable region (VL1), wherein the VH1 and VL1 form an antigen binding site that specifically binds to a first antigen, and the C-terminus of the VH1 is operably connected to the N-terminus of the Titin-T chain, the C-terminus of the VL1 is operably connected to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain, or the C-terminus of the VL1 is operably connected to the N-terminus of the Titin-T chain, and the C-terminus of the VH1 is operably connected to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain.

[0224] In some embodiments, the method for preparing a multispecific antibody, the Titin-T chain comprises a polypeptide as shown in any one of SEQ ID NOs: 32, 35-41, 65-76, or having at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76, and / or the Obscurin-O chain comprises a polypeptide as shown in any one of SEQ ID NOs: 33, 42-58, 77-86, or having at least 80% identity with any one of SEQ ID NOs: 33, 42-58, 77-86; or the Titin-T chain comprises a polypeptide as shown in any one of SEQ ID NOs: 32, 35-41, 65-76, or having at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76, and / or the Obscurin-like-O chain comprises a polypeptide as shown in any one of SEQ ID NOs: 34, 59-64, or having at least 80% identity with any one of SEQ ID NOs: Any of the sequences of NO: 34, 59-64 has a polypeptide with at least 80% identity.

[0225] In some embodiments, the Titin-T chain comprises the polypeptide shown in SEQ ID NO: 68, and the Obscurin-O chain comprises the polypeptide shown in SEQ ID NO: 80; in some embodiments, the Titin-T chain comprises the polypeptide shown in SEQ ID NO: 73, and the Obscurin-O chain comprises the polypeptide shown in SEQ ID NO: 83; in some embodiments, the Titin-T chain comprises the polypeptide shown in SEQ ID NO: 76, and the Obscurin-O chain comprises the polypeptide shown in SEQ ID NO: 84; in some embodiments, the Titin-T chain comprises the polypeptide shown in SEQ ID NO: 76, and the Obscurin-O chain comprises the polypeptide shown in SEQ ID NO: 86; in some embodiments, the Titin-T chain comprises the polypeptide shown in SEQ ID NO: 75, and the Obscurin-O chain comprises the polypeptide shown in SEQ ID NO: 86.

[0226] In some embodiments, wherein:

[0227] (A) The sequence of the titin-T chain is as shown in SEQ ID NO: 32 or further comprises one or more amino acid mutations selected from 8, 20, 22, 25, 26, 39, 3, 11, 13, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84 and / or a sequence with 5 amino acid residues KAGIR added to the N-terminus based on the sequence of SEQ ID NO: 32; preferably comprises a sequence selected from A8C, V20C, T22C, C25S, A2 6C, C39T, P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S or M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L, and / or a sequence in which 5 amino acid residues KAGIR are added to the N-terminus; and / or

[0228] (B) The sequence of the Obscurin-O chain is as shown in SEQ ID NO: 33 or further comprises, based on the sequence of SEQ ID NO: 33, an amino acid mutation at one or more positions selected from 3, 9, 25, 76, 88, 7, 11, 62, 2, 12, 13, 14, 17, 20, 22, 30, 32, 34, 36, 41, 42, 44, 45, 53, 58, 67, 69, 89, 92, 94 and 97 and / or an additional DQPQF amino acid residue at the N-terminus; preferably comprises an amino acid mutation at one or more positions selected from A3C, R9C, C25S, C76S, A88C, L7K or L7R, T 62K or T62H, G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G, and / or a sequence in which the DQPQF amino acid residue is added to the N-terminus; or

[0229] The sequence of the Obscurin-like-O chain is as shown in SEQ ID NO: 34 or a sequence having one or more amino acid mutations selected from 6, 26, 74, 77, 84 and 86 based on the sequence of SEQ ID NO: 34; preferably a sequence having one or more amino acid mutations selected from C6E, C26S, C77S, V74C, G84C and A86C;

[0230] The above titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; the obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 34;

[0231] Preferably, wherein

[0232] (A) The titin-T chain has one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39 based on the sequence of SEQ ID NO: 32, preferably one or more amino acid residue mutations selected from positions A8C, V20C, T22C, C25S, A26C and C39T, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; more preferably, the titin-T chain has one or more amino acid residue mutations selected from positions A8C, V20C, T22C, C25S, A26C and C39T based on the sequence of SEQ ID NO: 32. NO:35, has one or more amino acid mutations selected from positions 3, 11, 13, 22, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84, preferably has one or more amino acid mutations selected from positions P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L; the titin-T chain mutation sites are the natural sequence numbering sites of the sequence SEQ ID NO:35, and / or

[0233] (B) The Obscurin-O chain has one or more amino acid residue mutations selected from positions 3, 9, 25, 76 and 88 based on the sequence of SEQ ID NO: 33, preferably one or more amino acid residue mutations selected from A3C, R9C, C25S, C76S and A88C, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 33; preferably, the Obscurin-O chain has one or more amino acid residue mutations selected from positions 7, 11 and 62 based on the sequence of SEQ ID NO: 45, preferably one or more amino acid residue mutations selected from positions L7K or L7R, T62K or T62H, and K11L, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 45; more preferably, the Obscurin-O chain has one or more amino acid residue mutations selected from positions 7, 11 and 62 based on the sequence of SEQ ID NO: 45, preferably one or more amino acid residue mutations selected from positions L7K or L7R, T62K or T62H, and K11L, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 45. NO:50 has one or more amino acid mutations selected from the group consisting of the 2nd, 11th, 12th, 13th, 14th, 17th, 20th, 22nd, 30th, 32nd, 34th, 36th, 41st, 42nd, 44th, 45th, 53rd, 58th, 62nd, 67th, 69th, 89th, 92nd, 94th and 97th positions, preferably one or more amino acid mutations selected from the group consisting of G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G, wherein the Obscurin-O chain mutation site is the sequence of SEQ ID NO: natural sequence number locus 50; or

[0234] The Obscurin-like-O chain has one or more amino acid residue mutations selected from positions 6, 26, 74, 77, 84 and 86 based on the sequence of SEQ ID NO: 34, preferably one or more amino acid residue mutations selected from C6E, C26S, C77S, V74C, G84C and A86C, and the Obscurin-like-O chain mutation sites are the natural sequence numbering sites of the sequence SEQ ID NO: 34.

[0235] In some embodiments, the present disclosure provides a conjugate comprising the polypeptide complex, multispecific polypeptide complex, domain-engineered antibody, Fab fragment of domain-engineered antibody or bispecific antibody, or multispecific antibody described in any of the above.

[0236] In some embodiments, the present disclosure provides a polypeptide whose sequence is as shown in any one of SEQ ID NOs: 32, 35-41, 65-76, or has at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76; or the sequence is as shown in any one of SEQ ID NOs: 33, 42-58, 77-86, or has at least 80% identity with any one of SEQ ID NOs: 33, 42-58, 77-86; or the sequence is as shown in any one of SEQ ID NOs: 34, 59-64, or has at least 80% identity with any one of SEQ ID NOs: 34, 59-64; preferably, the polypeptide can be used to replace antibody CH1 and / or CL. More preferably, the polypeptides are titin-T chain and obscurin-O chain, or titin-T chain and obscurin-like-O chain, and after the single-side CH1 and CL of the bispecific antibody are replaced by titin-T chain and obscurin-O chain, or titin-T chain and obscurin-like-O chain, mispairing is not likely to occur between the first heavy chain and the second light chain, or between the first light chain and the second heavy chain.

[0237] In some embodiments, the sequence of the titin-T chain is as shown in SEQ ID NO: 32 or the sequence of SEQ ID NO: 32 further comprises one or more amino acid mutation sequences selected from 8, 20, 22, 25, 26, 39, 3, 11, 13, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84; preferably comprises one or more amino acid mutation sequences selected from A8C, V20C, T22C, C25S, A26C, C39T, P3W, S11I, I13 L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S or M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L, and / or the sequence of 5 amino acid residues KAGIR added to the N-terminus; the sequence of the Obscurin-O chain is as shown in SEQ ID NO: 33 or is SEQ The sequence of IDNO: 33 also has an amino acid mutation selected from one or more positions of 3, 9, 25, 76, 88, 7, 11, 62, 2, 12, 13, 14, 17, 20, 22, 30, 32, 34, 36, 41, 42, 44, 45, 53, 58, 67, 69, 89, 92, 94 and 97 and / or a sequence with an additional DQPQF amino acid residue at the N-terminus; preferably has an amino acid mutation selected from A3C, R9C, C25S, C76S, A88C, L7K or L7R, T62K or T62H, G2 E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G, and / or a DQPQF amino acid residue is added to the N-terminus; the sequence of the Obscurin-like-O chain is as shown in SEQ ID NO: 34 or the SEQ ID NO: 34 sequence further has an amino acid mutation sequence selected from 6, 26, 74, 77, 84 and 86; preferably has an amino acid mutation sequence selected from C6E, C26S, C77S, V74C, G84C and A86C.

[0238] A polypeptide for replacing CH1 and / or CL of an antibody, replacing CH1 and / or CL of an antigen-binding fragment, or replacing CH1 and / or CL of a polypeptide complex, wherein the sequence of the polypeptide is as shown in any one of SEQ ID NOs: 32, 35-41, 65-76, or has at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76; or the sequence is as shown in any one of SEQ ID NOs: 33, 42-58, 77-86, or has at least 80% identity with any one of SEQ ID NOs: 33, 42-58, 77-86; or the sequence is as shown in any one of SEQ ID NOs: 34, 59-64, or has at least 80% identity with any one of SEQ ID NOs: 34, 59-64; preferably, the polypeptide is titin-T chain and obscurin-O chain, or titin-T chain and obscurin-like-O chain. More preferably, after the polypeptide replaces one side CH1 and CL of the bispecific antibody, mispairing is not likely to occur between the first heavy chain and the second light chain, and between the first light chain and the second heavy chain of the bispecific antibody.

[0239] In some embodiments, the present disclosure provides a Titin-T chain, an Obscurin-O chain and / or an Obscurin-like-O chain, wherein the sequence of the Titin-T chain is as shown in any one of SEQ ID NOs: 32, 35-41, 65-76 or has at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76, the sequence of the Obscurin-O chain is as shown in any one of SEQ ID NOs: 33, 42-58, 77-86 or has at least 80% identity with any one of SEQ ID NOs: 33, 42-58, 77-86; the sequence of the Obscurin-like-O chain is as shown in any one of SEQ ID NOs: 34, 59-64 or has at least 80% identity with any one of SEQ ID NOs: 34, 59-64. In some embodiments, the Titin-T chain / Obscurin-O chain, or Titin-T chain / Obscurin-like-O chain can be used to replace antibody CH1 and / or CL.

[0240] In some embodiments, the sequence of the titin-T chain is as shown in SEQ ID NO: 32 or as shown in SEQ ID NO: NO:32 sequence also has one or more amino acid mutation sequences selected from 8, 20, 22, 25, 26, 39, 3, 11, 13, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84; preferably has one or more amino acid mutation sequences selected from A8C, V20C, T22C, C25S, A26C, C39T, P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S or M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L; the sequence of the Obscurin-O chain is as shown in SEQ ID The sequence shown in NO:33 or SEQ ID NO:33 also has an amino acid mutation sequence selected from one or more positions of 3, 9, 25, 76, 88, 7, 11, 62, 2, 12, 13, 14, 17, 20, 22, 30, 32, 34, 36, 41, 42, 44, 45, 53, 58, 67, 69, 89, 92, 94 and 97; preferably has an amino acid mutation sequence selected from A3C, R9C, C25S, C76S, A88C, L7K or L7R, T62K or T62H, G2E , L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G; the sequence of the Obscurin-like-O chain is as shown in SEQ ID NO: 34 or the SEQ ID NO: 34 sequence further has one or more amino acid mutation sequences selected from 6, 26, 74, 77, 84 and 86; preferably has one or more amino acid mutation sequences selected from C6E, C26S, C77S, V74C, G84C and A86C.

[0241] In some embodiments, the present disclosure further discloses the use of Titin-T chain and Obscurin-O chain, or Titin-T chain and Obscurin-like-O chain in reducing light chain / heavy chain mispairing of multispecific antibodies; in some embodiments, the Titin-T chain comprises a polypeptide as shown in any one of SEQ ID NOs: 32, 35-41, 65-76 or having at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76, and / or the Obscurin-O chain comprises a polypeptide as shown in any one of SEQ ID NOs: 33, 42-58, 77-86 or having at least 80% identity with any one of SEQ ID NOs: 33, 42-58, 77-86; or the Titin-T chain comprises a polypeptide as shown in any one of SEQ ID NOs: 32, 35-41, 65-76 or having at least 80% identity with any one of SEQ ID NOs: NO:32, 35-41, 65-76, and / or the Obscurin-like-O chain comprises a polypeptide as shown in any one of SEQ ID NO:34, 59-64 or having at least 80% identity with any one of SEQ ID NO:34, 59-64.

[0242] In some embodiments, the aforementioned titin-T chain and obscurin-O chain, or titin-T chain and obscurin-like-O chain are used to reduce light chain / heavy chain mispairing of multispecific antibodies, wherein the sequence of the titin-T chain is as shown in SEQ ID NO: 32 or the sequence of SEQ ID NO: 32 further comprises amino acid mutations at one or more positions selected from 8, 20, 22, 25, 26, 39, 3, 11, 13, 40, 42, 45, 47, 49, 56, 58, 66, 70, 75, 77, 79, 81, 82, 83 and 84, and / or a sequence with 5 amino acid residues KAGIR added to the N-terminus; preferably comprises a sequence selected from A8C, V20C, T22C, C25S, A26C, C39T, P3W , S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S or M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L, and / or a sequence with 5 amino acid residues KAGIR added to the N-terminus; the sequence of the Obscurin-O chain is as shown in SEQ ID NO: 33 or is as shown in SEQ ID NO: The sequence of NO:33 also has an amino acid mutation sequence selected from one or more positions of 3, 9, 25, 76, 88, 7, 11, 62, 2, 12, 13, 14, 17, 20, 22, 30, 32, 34, 36, 41, 42, 44, 45, 53, 58, 67, 69, 89, 92, 94 and 97, and / or a sequence with an additional DQPQF amino acid residue at the N-terminus; preferably has an amino acid mutation sequence selected from A3C, R9C, C25S, C76S, A88C, L7K or L7R, T62K or T62H, G2E , L11K, A12S, F13Y, V14T, V17E, D20L, T22M or T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q or A67T, G69S, V89L, Q92E, D94G and A97G, and / or a sequence with DQPQF amino acid residues added to the N-terminus; the sequence of the Obscurin-like-O chain is as shown in SEQ The sequence shown in ID NO: 34 or SEQ ID NO: 34 also has one or more amino acid mutation sequences selected from 6, 26, 74, 77, 84 and 86; preferably has one or more amino acid mutation sequences selected from C6E, C26S, C77S, V74C, G84C and A86C.

[0243] In some embodiments, the multispecific antibody comprises a first heavy chain variable region (VH1) and a first light chain variable region (VL1), wherein the VH1 and VL1 form an antigen binding site that specifically binds to a first antigen, and the C-terminus of the VH1 is operably linked to the N-terminus of the Titin-T chain, the C-terminus of the VL1 is operably linked to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain, or the C-terminus of the VL1 is operably linked to the N-terminus of the Titin-T chain, and the C-terminus of the VH1 is operably linked to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain.

[0244] In some embodiments, the present disclosure provides a nucleic acid molecule encoding the polypeptide complex described in any of the foregoing, or the multispecific polypeptide complex, or the domain-engineered antibody, or the Fab fragment of the domain-engineered antibody, or the bispecific antibody, or the polypeptide, or the multispecific antibody.

[0245] In some embodiments, the present disclosure provides a vector comprising the aforementioned nucleic acid molecule.

[0246] In some embodiments, the present disclosure provides a host cell, which is obtained by transformation (or transduction, transfection) of the aforementioned vector; the host cell is selected from prokaryotic cells and eukaryotic cells, preferably eukaryotic cells, and more preferably mammalian cells. In some embodiments, the host cell does not include any animal or plant cells that can develop into a complete individual, such as human embryonic stem cells, fertilized eggs, and germ cells.

[0247] In some embodiments, the host cell is a eukaryotic cell, more preferably a mammalian cell, wherein the mammalian cell includes but is not limited to CHO, 293, NSO, and cells in which gene editing can change the glycosylation modification of the antibody or its antigen-binding fragment, thereby changing the ADCC function of the antibody or its antigen-binding fragment, for example, knocking out genes such as FUT8 or GnT-III. In some embodiments, the mammalian cell does not include a human cell.

[0248] In some embodiments, the present disclosure provides a method for preparing the polypeptide complex, multispecific polypeptide complex, domain-engineered antibody, Fab fragment of domain-engineered antibody, bispecific antibody, or polypeptide, or multispecific antibody described in any of the above, the method comprising the following steps:

[0249] The host cells described above are cultured, and then the polypeptide complex, multispecific polypeptide complex, domain-engineered antibody, Fab fragment of domain-engineered antibody, bispecific antibody or polypeptide, or multispecific antibody is purified and recovered.

[0250] In some embodiments, the present disclosure provides a pharmaceutical composition, which contains any of the polypeptide complexes, or multispecific polypeptide complexes, or domain-modified antibodies, or Fab fragments of domain-modified antibodies, or bispecific antibodies, or nucleic acids, or multispecific antibodies, or conjugates described above, and one or more pharmaceutically acceptable carriers, excipients, or diluents. Preferably, the pharmaceutical composition may contain 0.01 to 99% by weight of the aforementioned polypeptide complex, or multispecific polypeptide complex, or domain-modified antibodies, or Fab fragments of domain-modified antibodies, or bispecific antibodies, or multispecific antibodies, or conjugates in a unit dose, or the amount of the aforementioned polypeptide complex, or multispecific polypeptide complex, or domain-modified antibodies, or Fab fragments of domain-modified antibodies, or bispecific antibodies, or multispecific antibodies, or conjugates in a unit dose of the pharmaceutical composition is preferably 0.1-2000 mg, more preferably 1-1000 mg.

[0251] In some embodiments, the disclosure provides a polypeptide complex, a multi-specific polypeptide complex, a domain-engineered antibody, a Fab fragment of a domain-engineered antibody, a bispecific antibody, a pharmaceutical composition, or a nucleic acid molecule, or a multi-specific antibody as described in any of the foregoing, for use in the preparation of a medicament for treating or preventing a disease or condition. In some embodiments, the disease or condition is a tumor, an inflammatory disease, an autoimmune disease, or an infectious disease. In some embodiments, the disease or condition is a bone-related disease, a disease or disorder of osteoporosis, osteopenia, or osteoarthritis, rheumatoid arthritis, periodontal disease, or multiple myeloma. In some embodiments, the tumor is selected from a carcinoma, a lymphoma, a blastoma, a sarcoma, and a leukemia or lymphoid malignancy. In some embodiments, the tumor is selected from the group consisting of squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), primary mediastinal large B-cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), T-cell / histiocyte-rich large B -cell lymphoma, multiple myeloma, myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), gastrointestinal cancer, kidney cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, gastric cancer, bone cancer, Ewing's sarcoma, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon cancer, hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (RCC), head and neck cancer, pharyngeal cancer, hepatobiliary cancer In some embodiments, the inflammatory disease is selected from the group consisting of rheumatoid arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, multiple sclerosis, type I diabetes, hepatitis (e.g., hepatitis B, A, C), myocarditis, Sjogren's syndrome, autoimmune hemolytic anemia after transplant rejection, bullous pemphigoid, Grave's disease, Hashimoto's thyroiditis, systemic lupus erythematosus (SLE), myasthenia gravis, pemphigus, and pernicious anemia.In some embodiments, the immune disease can be selected from: rheumatoid arthritis, psoriasis, joint psoriasis, dermatitis, systemic scleroderma and sclerosis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, respiratory distress syndrome, meningitis, encephalitis, uveitis, glomerulonephritis, eczema, asthma, arteriosclerosis, leukocyte adhesion deficiency, multiple sclerosis, Raynaud's syndrome, Sjogren's syndrome, juvenile diabetes, Reiter's disease, Behcet's disease, immune complex nephritis, IgA nephropathy, IgM polyneuropathy, immune-mediated thrombocytopenia symptoms (such as acute Idiopathic thrombocytopenic purpura, chronic idiopathic thrombocytopenic purpura), hemolytic anemia, myasthenia gravis, lupus nephritis, systemic lupus erythematosus, rheumatoid arthritis (RA), atopic dermatitis, pemphigus, Graves' disease, Hashimoto's thyroiditis, Wegener's granulomatosis, Omenn's syndrome, chronic renal failure, acute infectious mononucleosis, HIV and herpes virus-related diseases, severe acute respiratory syndrome, chorioretinitis, and immune diseases caused by viral infections (such as diseases caused or mediated by EBV-infected B cells).

[0252] In some embodiments, the present disclosure provides a method for treating or preventing a disease or condition, the method comprising administering to a subject a preventive or therapeutically effective amount of any of the foregoing polypeptide complexes, multi-specific polypeptide complexes, domain-engineered antibodies, Fab fragments of domain-engineered antibodies, bispecific antibodies, pharmaceutical compositions, or nucleic acid molecules, or multi-specific antibodies. In some embodiments, the disease or condition is a tumor, an inflammatory disease, an autoimmune disease, or an infectious disease. In some embodiments, the disease or condition is a bone-related disease, osteoporosis, osteopenia, or osteoarthritis, rheumatoid arthritis, periodontal disease, or multiple myeloma. In some embodiments, the tumor is selected from a carcinoma, a lymphoma, a blastoma, a sarcoma, and a leukemia or lymphoid malignancy. In some embodiments, the tumor is selected from the group consisting of squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), primary mediastinal large B-cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), T-cell / histiocyte-rich large B -cell lymphoma, multiple myeloma, myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), gastrointestinal cancer, kidney cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, gastric cancer, bone cancer, Ewing's sarcoma, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon cancer, hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (RCC), head and neck cancer, pharyngeal cancer, hepatobiliary cancer In some embodiments, the inflammatory disease is selected from the group consisting of rheumatoid arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, multiple sclerosis, type I diabetes, hepatitis (e.g., hepatitis B, A, C), myocarditis, Sjogren's syndrome, autoimmune hemolytic anemia after transplant rejection, bullous pemphigoid, Grave's disease, Hashimoto's thyroiditis, systemic lupus erythematosus (SLE), myasthenia gravis, pemphigus, and pernicious anemia.In some embodiments, the immune disease can be selected from: rheumatoid arthritis, psoriasis, joint psoriasis, dermatitis, systemic scleroderma and sclerosis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, respiratory distress syndrome, meningitis, encephalitis, uveitis, glomerulonephritis, eczema, asthma, arteriosclerosis, leukocyte adhesion deficiency, multiple sclerosis, Raynaud's syndrome, Sjogren's syndrome, juvenile diabetes, Reiter's disease, Behcet's disease, immune complex nephritis, IgA nephropathy, IgM polyneuropathy, immune-mediated thrombocytopenia symptoms (such as acute Idiopathic thrombocytopenic purpura, chronic idiopathic thrombocytopenic purpura), hemolytic anemia, myasthenia gravis, lupus nephritis, systemic lupus erythematosus, rheumatoid arthritis (RA), atopic dermatitis, pemphigus, Graves' disease, Hashimoto's thyroiditis, Wegener's granulomatosis, Omenn's syndrome, chronic renal failure, acute infectious mononucleosis, HIV and herpes virus-related diseases, severe acute respiratory syndrome, chorioretinitis, and immune diseases caused by viral infections (such as diseases caused or mediated by EBV-infected B cells).

[0253] In some embodiments, the present disclosure provides a polypeptide complex, a multi-specific polypeptide complex, a domain-engineered antibody, a Fab fragment of a domain-engineered antibody, a bispecific antibody, a pharmaceutical composition, or a nucleic acid molecule, or a multi-specific antibody as described in any of the preceding items for use as a medicament. In some embodiments, the medicament is used to treat or prevent a disease or condition. In some embodiments, the disease or condition is a tumor, an inflammatory disease, an autoimmune disease, or an infectious disease. In some embodiments, the disease or condition is a bone-related disease, a disease or disorder of osteoporosis, osteopenia, or osteoarthritis, rheumatoid arthritis, periodontal disease, or multiple myeloma. In some embodiments, the tumor is selected from a carcinoma, a lymphoma, a blastoma, a sarcoma, and a leukemia or a lymphoid malignancy. In some embodiments, the tumor is selected from the group consisting of squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), primary mediastinal large B-cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), T-cell / histiocyte-rich large B -cell lymphoma, multiple myeloma, myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), gastrointestinal cancer, kidney cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, gastric cancer, bone cancer, Ewing's sarcoma, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon cancer, hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (RCC), head and neck cancer, pharyngeal cancer, hepatobiliary cancer In some embodiments, the inflammatory disease is selected from the group consisting of rheumatoid arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, multiple sclerosis, type I diabetes, hepatitis (e.g., hepatitis B, A, C), myocarditis, Sjogren's syndrome, autoimmune hemolytic anemia after transplant rejection, bullous pemphigoid, Grave's disease, Hashimoto's thyroiditis, systemic lupus erythematosus (SLE), myasthenia gravis, pemphigus, and pernicious anemia.In some embodiments, the immune disease can be selected from: rheumatoid arthritis, psoriasis, joint psoriasis, dermatitis, systemic scleroderma and sclerosis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, respiratory distress syndrome, meningitis, encephalitis, uveitis, glomerulonephritis, eczema, asthma, arteriosclerosis, leukocyte adhesion deficiency, multiple sclerosis, Raynaud's syndrome, Sjogren's syndrome, juvenile diabetes, Reiter's disease, Behcet's disease, immune complex nephritis, IgA nephropathy, IgM polyneuropathy, immune-mediated thrombocytopenia symptoms (such as acute Idiopathic thrombocytopenic purpura, chronic idiopathic thrombocytopenic purpura), hemolytic anemia, myasthenia gravis, lupus nephritis, systemic lupus erythematosus, rheumatoid arthritis (RA), atopic dermatitis, pemphigus, Graves' disease, Hashimoto's thyroiditis, Wegener's granulomatosis, Omenn's syndrome, chronic renal failure, acute infectious mononucleosis, HIV and herpes virus-related diseases, severe acute respiratory syndrome, chorioretinitis, and immune diseases caused by viral infections (such as diseases caused or mediated by EBV-infected B cells).

[0254] In some embodiments, the present disclosure provides a detection method, which comprises: a step of contacting a sample to be tested with the polypeptide complex, or multi-specific polypeptide complex, or domain-engineered antibody, or Fab fragment of a domain-engineered antibody, or bispecific antibody, or multi-specific antibody as described in any of the foregoing.

[0255] In some embodiments, the present disclosure provides a reagent for detection or measurement, wherein the reagent comprises: the polypeptide complex described in any of the preceding items, or the multispecific polypeptide complex, or the domain-engineered antibody, or the Fab fragment of the domain-engineered antibody, or the bispecific antibody, or the multispecific antibody. BRIEF DESCRIPTION OF THE DRAWINGS

[0256] Figure 1A and Figure 1B : Diagram of the interaction interface between the domains of Titin-T and Obscurin-O or Titin-T and Obscurin-like-O chains;

[0257] Figure 2 : Schematic diagram of Fab with CH1 and CL replaced;

[0258] Figure 3 : Schematic diagram of the structure of IgG monospecific antibody with CH1 and CL replaced on both sides;

[0259] Figure 4: Schematic diagram of the structure of IgG bispecific antibody with CH1 and CL replaced on one side;

[0260] Figure 5 : Schematic diagram of the structure of DI-1 bispecific antibody;

[0261] FIG. 6A to FIG. 6C : Mass spectrum analysis of DI-1. Fig. 6A is the mass spectrum of LC1 / LC2, Figure 6B is the mass spectrum of HC1 / HC2; Figure 6C : is the mass spectrum of LC1+LC2+HC1+HC2;

[0262] Figure 7 :Schematic diagram of the molecular structure of antibody light chain / heavy chain cross-mismatch;

[0263] Figure 8 : Schematic diagram of the structure of BU5 bispecific antibody;

[0264] 9A to 9C : BU5 mass spectrum analysis;

[0265] Fig.10 : Results of osteoclast differentiation experiment of DI-1 bispecific antibody;

[0266] Fig.11 : DI-1 bispecific antibody TF1 cell proliferation assay results;

[0267] Fig.12 : Schematic diagram of the structures of bispecific antibodies HJ-1, HJ-2, HJ-3 and HJ-4;

[0268] FIG. 13A to FIG. 13D : Mass spectrometry analysis of the co-expression of the four chains of bispecific antibodies HJ-1, HJ-2, HJ-3, and HJ-4;

[0269] FIG. 14A to FIG. 14B : Mass spectrometry analysis of the co-expression of the three chains of the bispecific antibody HJ-1: HJ-1-H1, HJ-1-H2, and HJ-1-L2;

[0270] FIG. 15A to FIG. 15B : Mass spectrometry analysis of the co-expression of the three chains of the bispecific antibody HJ-3: HJ-3-H1, HJ-3-H2, and HJ-3-L2;

[0271] FIG. 16A to FIG. 16B : Interactions between residues. DETAILED DESCRIPTION

[0272] In order to make the present disclosure more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise explicitly defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present disclosure belongs.

[0273] The three letter codes and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).

[0274] "Antibody (Ab)" is generally an immunoglobulin (Ig). A natural complete antibody is a tetrapeptide chain structure composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds. The amino acid composition and arrangement order of the constant region of the immunoglobulin heavy chain are different, so their antigenicity is also different. Based on this, immunoglobulins can be divided into five classes, namely IgM, IgD, IgG, IgA and IgE, and their corresponding heavy chains are μ chain, δ chain, γ chain, α chain, and ε chain. The same class of Ig can be divided into different subclasses according to the difference in the amino acid composition of its hinge region and the number and position of the disulfide bonds of the heavy chain. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. The light chain is divided into κ chain or λ chain by the difference in the constant region, and antibodies can be divided into two types based on this. Each of the five types of Ig can have κ chain or λ chain. According to the differences in individual amino acids in the constant region of the λ chain, it can be divided into four subtypes: λ1, λ2, λ3 and λ4.

[0275] The antibodies referred to in the present disclosure include antibodies or antigen-binding fragments thereof, including antibodies or antigen-binding fragments thereof that have been modified on the basis of immunoglobulins while retaining the ability to bind to antigens; including monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies); and also monovalent antibodies, or multivalent antibodies (e.g., bivalent antibodies). The antigen-binding fragment of an antibody, for example, may be an antigen-binding fragment comprising at least one VH-CH1 and at least one VL-CL structure, wherein the VH and VL structures can be close to each other based on interchain interactions and retain the ability to bind to antigens. In some embodiments, the antigen-binding fragment of the antibody is a monovalent Fab fragment (Fab1 fragment), a bivalent Fab fragment (F(ab)2), a trivalent Fab fragment (F(ab)3), a multivalent (two or more) Fab fragment, or may be other monospecific, bispecific, or multispecific antigen-binding fragments comprising at least one Fab fragment.

[0276] The "domain-modified antibody" disclosed herein refers to an antibody formed after the CH1 and / or CL of the antibody is replaced by other domains or peptide fragments. The domains or peptide fragments that can be used to replace the CH1 / CL domains of the antibody usually have intermolecular interactions; the selectable domain combinations include but are not limited to: IL13RA1 Fibronectin type-III 3 domain / IL4RFibronectin type-III domain, IL6ST Fibronectin type-III 2 domain / IL6R Fibronectin type-III 2 domain, HFE Ig-like C1-type domain / B2M Ig-like C1-type domain, CD1B Ig-like domain / B2MIg-like C1-type domain, Obscurin Ig-like 1 domain / Titin Ig-like 152 domain or Obscurin-like Ig-like 1 / Titin Ig-like 152 domain. In some embodiments, the structurally modified antibody is a monospecific antibody, a bispecific antibody, or a multispecific antibody; in some embodiments, the structurally modified antibody is a monovalent antibody, a bivalent antibody, or a multivalent antibody; in some embodiments, the structurally modified antibody is a complete antibody or an antigen-binding fragment thereof; in some embodiments, the antibody antigen-binding fragment is a Fab fragment, which can be a monovalent Fab fragment (Fab1 fragment), a bivalent Fab fragment (F(ab)2), a trivalent Fab fragment (F(ab)3), or a multivalent (two or more) Fab fragment. Exemplarily, the structural schematic diagram of the CH1 and CL of the antibody Fab fragment replaced by the Titin-T chain / Obscurin-O chain or by the Titin-T chain / Obscurin-like-O chain is shown in the attached Figure 2 ; The CH1 and CL of the antibody are replaced by titin-T chain / obscurin-O chain, or titin-T chain / obscurin-like-O chain. See the attached schematic diagram of the structure Figure 3 ; A schematic diagram of the structure in which one side CH1 and CL of the bispecific antibody are replaced by titin-T chain / obscurin-O chain, or titin-T chain / obscurin-like-O chain is shown in the attached Figure 4Other antibodies in which at least one CH1 and at least one CL are replaced by Titin-T chain / Obscurin-O chain, or by Titin-T chain / Obscurin-like-O chain: for example, one side CH1 and CL of a bivalent antibody are replaced by Titin-T chain / Obscurin-O chain or Titin-T chain / Obscurin-like-O chain; both sides CH1 and CL of a bispecific antibody are replaced by Titin-T chain / Obscurin-O chain, or Titin-T chain / Obscurin-like-O chain; two CH1 / CL of a F(ab)2 fragment are replaced by Titin-T chain / Obscurin-O chain, or Titin-T chain / Obscurin-like-O chain; one, two or three CH1 / CL of a F(ab)3 fragment are replaced by Titin-T chain / Obscurin-O chain, or Titin-T chain / Obscurin-like-O chain.

[0277] "Titin" is a giant sarcomere protein with a complex molecular folding structure. It is known to have functions such as connecting thick filaments to Z-lines and maintaining the integrity and stability of myofibrils. Titin is the third most abundant protein in skeletal muscle fibers, with a molecular weight of 2700kDa (more than 25,000 amino acids) and a length of 1μm, accounting for about half of the sarcomere.

[0278] The "Titin Ig-like 152 domain" is an Ig-like domain named Titin Ig-like 152 on the Titin protein, which can bind to the Obscurin Ig-like 1 or Obscurin-like Ig-like 1 domain through intermolecular interactions to form a dimer complex (available from the RCSB PDB database).

[0279] "Titin-T chain", "T chain" refers to a peptide segment of 78-118 amino acids in the Titin protein containing the TitinIg-like 152 domain or its functional variant, wherein the Titin-T chain can bind to the Obscurin Ig-like 1 or Obscurin-like Ig-like 1 domain through intermolecular interactions to form a complex. The T chain functional variant is a peptide segment that is mutated to some amino acids of the wild-type T chain, but still has a peptide segment that binds to Obscurin Ig-like 1 or Obscurin-like Ig-like 1 through intermolecular interactions to form a complex. In the present disclosure, the Titin-T chain can be used to replace the CH1 or CL domain of an antibody without affecting the binding of the antibody VH and VL and the binding of the antibody to the antigen epitope. Some amino acids of the Titin-T chain can be mutated as long as it can still associate with the Obscurin Ig-like 1 domain to form a complex. For example, amino acids of appropriate length are added or shortened at the C-terminus and / or N-terminus of the Titin Ig-like 152 domain; for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues can be added or shortened; for example, the five amino acids "KAGIR" in the Titin protein adjacent to the N-terminus of the Titin Ig-like 152 domain are added at the N-terminus of the Titin Ig-like 152 domain; a linker sequence of appropriate length (for example, (G x S) y Linker, wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6, such as "G 4 S", "(G 4 S)2”), so that the N-terminus of the Titin Ig-like 152 domain is connected to the VH / or VL of the antibody through a connecting sequence. Other mutations can also be made to the amino acids of the Titin Ig-like 152 domain, for example, certain amino acids are mutated to increase interchain disulfide bonds and improve the stability of the complex. In some embodiments of the present disclosure, the Titin-T chain is a polypeptide having a sequence as shown in any one of SEQ ID NOs: 32, 35-41, 65-76 or having at least 80% identity with any one of SEQ ID NOs: 32, 35-41, 65-76, and the polypeptide can associate with the Obscurin-O chain or the Obscurin-like-O chain to form a complex.

[0280] "Obscurin" is a protein encoded by the OBSCN gene and belongs to the giant sarcosine signaling protein family. Obscurin is expressed in cardiac and skeletal muscles and plays an important role in the organization of myofibrils during sarcomere assembly. Obscurin is the main cytoplasmic ligand of the sarcoplasmic reticular protein sANK1, which can prevent the degradation of sANK1 (Lange S et al. Molecular Biology of the Cell. 23 (13): 2490-504); Obscurin plays a signaling role between the sarcoplasmic reticular domain and the sarcoplasmic reticular domain (Bagnato P et al., The Journal of Cell Biology. 160 (2): 245-53.); Obscurin participates in the formation of new sarcomeres during myofibril assembly (Borisov AB, et al., Biochemical and Biophysical Research Communications. 310 (3): 910-918).

[0281] The "Obscurin Ig-like 1 domain" is an Ig-like domain named Obscurin Ig-like 1 in the Obscurin protein, which can form a complex with the Titin Ig-like 152 domain through intermolecular interaction (available from the RCSB PDB database).

[0282] "Obscurin-O chain", "O chain" refers to a peptide segment of 87-117 amino acids on the Obscurin protein containing the Obscurin Ig-like 1 domain or its functional variant, wherein the Obscurin-O chain can form a complex with the Titin Ig-like 152 domain through intermolecular interactions. The Obscurin-O chain functional variant is a mutation of some amino acids of the wild-type O chain, but it still has a peptide segment that forms a complex with the Titin Ig-like 152 domain through intermolecular interactions. In the present disclosure, the Obscurin-O chain can replace the CH1 or CL domain of the antibody without affecting the binding of the antibody VH and VL and the binding of the antibody to the antigen epitope. Some amino acids of the Obscurin-O chain can be mutated as long as it can associate with the Titin Ig-like 152 domain to form a complex. For example, amino acids of appropriate length are added or truncated at the C-terminus and / or N-terminus of the Obscurin-O domain, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids are added or truncated; for example, 5 amino acids "DQPQF" in the wild-type Obscurin protein adjacent to the N-terminus of the Obscurin Ig-like 1 domain are added to the N-terminus of the Obscurin-O domain. A linker sequence of appropriate length (e.g., (G x S) y Linker, wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6, such as "G 4 S", "(G 4 S)2”), so that the N-terminus of the Obscurin-O domain is connected to the VH / or VL of the antibody through a connecting sequence. Other mutations may also be made to some amino acids of the Obscurin Ig-like 1 domain, for example, mutations to certain amino acids are made to increase interchain disulfide bonds, further improve antibody stability, etc. In some embodiments of the present disclosure, the Obscurin-O chain is a polypeptide having a sequence as shown in any one of SEQ ID NOs: 33, 42-58, 77-86 or having at least 80% identity with any one of SEQ ID NOs: 33, 42-58, 77-86, and the polypeptide can associate with the Titin-T chain to form a complex.

[0283] "Obscurin-like 1" or "Obscurin-like 1" is a protein encoded by the OBSL1 gene located in SPEG of human chromosome 2q35, which is closely related to obscurin. Its alternative splicing produces multiple isoforms with a predicted molecular weight range of 130 kD to 230 kD (Geisler SB et al. (2007). Genomics. 89(4): 521-31).

[0284] The "Obscurin-like Ig-like 1 domain" is an Ig-like domain named Obscurin-like Ig-like 1 in the Obscurin-like 1 protein, which can form a complex with the Titin Ig-like 152 domain through natural intermolecular interactions (available from the RCSB PDB database).

[0285] "Obscurin-like-O chain" and "OL chain" refer to a peptide segment of 78-118 amino acids on the Obscurin-like 1 protein that contains the Obscurin-like Ig-like 1 domain or its functional variant. The Obscurin-like-O chain can form a complex with the Titin Ig-like 152 domain through intermolecular interactions. The Obscurin-like-O chain functional variant is a peptide that mutates some of the amino acids of the wild-type OL chain, but still has the ability to interact with the Titin Ig-like 152 domain to form a complex. In the present disclosure, the Obscurin-like-O chain can replace the CH1 or CL domain of the antibody without affecting the binding of the antibody VH and VL and the binding of the antibody to the antigen epitope. It is also possible to mutate some of the amino acids of the Obscurin-like-O chain, as long as it can associate with the Titin Ig-like 152 domain to form a complex. In some embodiments, for example, an appropriate length of amino acids is added or truncated at the C-terminus and / or N-terminus of the Obscurin-O domain, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids are added or truncated). A linker sequence of appropriate length (e.g., (G x S) y Linker, wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6, such as "G 4 S", "(G 4 S)2”), so that the N-terminus of the Obscurin-like-O domain is connected to the VH or VL of the antibody through a connecting sequence. Other mutations may also be made to some amino acids of the Obscurin-like Ig-like 1 domain, for example, mutations to certain amino acids are made to increase interchain disulfide bonds, further improve antibody stability, etc. In some embodiments of the present disclosure, the Obscurin-like-O chain is a polypeptide with a sequence as shown in any one of SEQ ID NOs: 34, 59-64 or a sequence having at least 80% identity with any one of SEQ ID NOs: 34, 59-64, and the polypeptide can associate with the Titin-T chain to form a complex.

[0286] In addition, some amino acids on the Titin Ig-like 152 domain, the Obscurin Ig-like 1 domain, or the Obscurin-like Ig-like 1 domain may be mutated as long as it still enables the Titin Ig-like 152 domain and the Obscurin Ig-like 1 domain, or the Titin Ig-like 152 domain and the Obscurin-like Ig-like 1 domain to associate with each other to form a complex. In some embodiments, an appropriate length of amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids of the wild-type protein immediately adjacent to the domain) can be added or truncated at the C-terminus and / or N-terminus of the Titin Ig-like 152 domain, the Obscurin Ig-like 1 domain or the Obscurin-like Ig-like 1 domain, as long as it still enables the Titin Ig-like 152 domain and the Obscurin Ig-like 1 domain, or the Titin Ig-like 152 domain and the Obscurin-like Ig-like 1 domain to associate with each other to form a complex. For example, five amino acids "KAGIR" in the wild-type titin protein adjacent to the N-terminus of the titin Ig-like 152 domain are added to the N-terminus of the titin Ig-like 152 domain; or five amino acids "DQPQF" in the wild-type obscurin protein adjacent to the N-terminus of the obscurin Ig-like 1 domain are added to the N-terminus of the obscurin Ig-like 1 domain. In some embodiments, a linker sequence of appropriate length (e.g., (G x S) y Linker, wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6, such as "G 4 S", "(G 4 In some embodiments, other mutations may be made to some amino acids on the Titin Ig-like 152 domain, the Obscurin Ig-like 1 domain, or the Obscurin-like Ig-like 1 domain, as long as the Titin Ig-like 152 domain and the Obscurin Ig-like 1 domain, or the Titin Ig-like 152 domain and the Obscurin-like Ig-like 1 domain can still interact with each other to form a complex, for example, mutations may be made to some amino acids to increase interchain disulfide bonds, further improve antibody stability, etc.

[0287] The term "Fab fragment" refers to an antigen-binding fragment that can be produced by enzymatic treatment of a monoclonal antibody and comprises a light chain (VL-CL) and a heavy chain VH-CH1 structure.

[0288] "Fab fragment with modified domain" refers to a polypeptide fragment formed after CL and / or CH1 in the antibody Fab fragment is replaced by other domains or peptide fragments. The Fab fragment with modified domain still retains the interaction between VH and VL, as well as the ability of the antibody to bind to the antigen. In some embodiments, the Fab fragment with modified domain can be used as part of a multivalent antibody or a multivalent polypeptide complex. In other embodiments, the Fab fragment with modified domain acts as a single protein molecule. The Fab fragment can be a monovalent Fab fragment (Fab fragment 1), a divalent Fab fragment (F(ab)2), a trivalent Fab fragment (F(ab)3) or a multivalent (two or more) Fab fragment. Exemplarily, the schematic diagram of the replacement of CH1 and CL of the Fab fragment is shown in the attached figure. Figure 2 .

[0289] The term "specific antibody" or "specific polypeptide complex" refers to an antibody or polypeptide complex that can specifically bind to a target antigen or antigenic epitope. According to the number of different target antigens or different antigenic epitopes bound by the antibody, it is divided into monospecific antibodies, bispecific antibodies, trispecific antibodies, tetraspecific antibodies..., multispecific (binding to two or more different target antigens or different antigenic epitopes) antibodies. According to the number of different target antigens or different antigenic epitopes bound by the polypeptide complex, it is divided into monospecific polypeptide complexes, multispecific polypeptide complexes, trispecific polypeptide complexes, tetraspecific polypeptide complexes..., multispecific (binding to two or more different target antigens or different antigenic epitopes) polypeptide complexes. For example, a "bispecific antibody" refers to an antibody (including an antibody or its antigen-binding fragment, such as a single-chain antibody) that can specifically bind to two different antigens or two different antigenic epitopes of the same antigen. The prior art has disclosed bispecific antibodies of various structures; according to the integrity of the IgG molecule, they can be divided into IgG-like bispecific antibodies and antibody fragment-type bispecific antibodies; according to the number and configuration of the antigen binding regions, they can be divided into bivalent, trivalent, tetravalent or more bispecific antibodies; according to whether the structure is symmetrical on the left and right, they can be divided into symmetrical bispecific antibodies and asymmetrical bispecific antibodies.Among them, bispecific antibodies based on antibody fragments, such as Fab fragments lacking Fc fragments, are formed by combining two or more Fab fragments into one molecule. They have low immunogenicity, small molecular weight, and high tumor tissue permeability. Typical antibody structures of this type include bispecific antibodies such as F(ab)2, scFv-Fab, (scFv)2-Fab, etc.; IgG-like bispecific antibodies (for example, with Fc fragments) have a relatively large molecular weight. The Fc fragment helps in the later purification of antibodies and improves their solubility and stability. The Fc part may also bind to the receptor FcRn to increase the serum half-life of the antibody. Typical bispecific antibody structural models include KiH, CrossMAb, Triomab quadroma, FcΔAdp, ART-Ig, BiMAb, Biclonics, BEAT, DuoBody, Azymetric, XmAb, 2:1 TCBs, 1Fab-IgG TDB, FynomAb, two-in-one / DAF, scFv-Fab-IgG, DART-Fc, LP-DART, CODV-Fab-TL, HLE-BiTE, F(ab)2-CrossMAb, IgG-(scFv)2, Bs4Ab, DVD-Ig, Tetravalent-DART-Fc, (scFv)4-Fc, CODV-Ig, mAb2, F(ab)4-CrossMAb and the like bispecific antibodies (see Aran F.Labriin et al., Nature Reviews Drug Discovery volume 18, pages 585-608 (2019); Chen S1 et al., J Immunol Res. 2019 Feb 11; 2019: 4516041).

[0290] The terms "monovalent", "bivalent", "trivalent" or "multivalent" refer to the presence of a specified number of antigen binding sites in an antibody or polypeptide complex. For example, a "monovalent antibody" means that there is one antigen binding site in the antibody, and a "monovalent polypeptide complex" means that there is one antigen binding site in the polypeptide complex; a "bivalent antibody" means that there are two antigen binding sites in the antibody, and a "bivalent polypeptide complex" means that there are two antigen binding sites in the polypeptide complex; a "trivalent antibody" means that there are three antigen binding sites in the antibody, and a "trivalent polypeptide complex" means that there are three antigen binding sites in the polypeptide complex; a "multivalent antibody" means that there are multiple (e.g., three or more) antigen binding sites in the antibody, and a "multivalent polypeptide complex" means that there are multiple (e.g., two or more) antigen binding sites in the polypeptide complex.

[0291] The terms "polypeptide", "peptide" or "protein" are used interchangeably in this disclosure to refer to a polymer of amino acid residues, or a collection of multiple amino acid residue polymers. These terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding naturally occurring amino acids, as well as naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. Polypeptide sequences are usually described as the left-hand end of the polypeptide sequence being the amino terminus (N-terminus, N-terminus); the right-hand end of the polypeptide sequence being the carboxyl terminus (C-terminus, C-terminus). The "polypeptide complex" disclosed herein refers to a complex comprising one or more polypeptides associated with achieving certain functions. In some embodiments, the polypeptide complex is an antibody or antigen-binding fragment thereof that can specifically bind to an antigen.

[0292] The term "binding region" or "binding site" or "binding domain" for an antigen refers to a region or portion in a specific protein molecule (such as an antibody molecule) that can specifically bind to an antigen. The antigen binding region can be a portion of a ligand binding domain that can directly bind to an antigen, or it can be a domain containing an antibody variable region that can directly bind to an antigen.

[0293] The term "operably linked" or "operably linked" or "operably connected" refers to the connection of two or more biological sequences in a manner that causes them to function in a desired manner, regardless of whether there is a spacer (also called a linker, a connector, a connecting sequence). When applied to polypeptides, the term indicates that the polypeptide sequences are connected in a manner that allows the connected product to have the desired biological function, and there may or may not be a spacer between the two sequences. For example, an antibody variable region can be operably linked to a constant region to form a stable product with antigen binding activity. The term can also be applied to polynucleotides. For example, when a polynucleotide encoding a polypeptide is operably linked to a regulatory sequence (e.g., a promoter, an enhancer, a silencer sequence, etc.), the term indicates that the polynucleotide sequence is connected in a manner that allows the expression of the polypeptide to be regulated by the polynucleotide.

[0294] The term "dimerization domain" refers to a polypeptide domain that can promote association with each other to form a dimer. In some embodiments, a first dimerization domain can associate with a second dimerization domain. The association can be combined or connected or bonded by any suitable means; for example, by a linker, a disulfide bond, a hydrogen bond, an electrostatic interaction, a salt bridge, or a hydrophobic-hydrophilic interaction, or a combination thereof. Exemplary dimerization domains include, but are not limited to, antibody hinge regions, antibody CH2 domains, antibody CH3 domains, and other suitable protein monomers or polypeptides that can dimerize and interact with each other. Hinge regions, CH2, CH3 can be derived from any antibody isotype, such as IgG1, IgG2, IgG3, and IgG4.

[0295] The term "interaction domain" refers to a domain of a polypeptide that can promote the interaction or association of two or more homologous or heterologous polypeptides. For example, the interaction domain is a dimerization domain that promotes mutual association to form a dimer. The domain of protein-protein interaction is a domain of a polypeptide that interacts or associates between two or more proteins, for example, the Obscurin-like Ig-like 1 domain in the Obscurin-like protein can form a complex with the Titin Ig-like 152 domain of the Titin protein through intermolecular interactions. In some embodiments, the domain that interacts with the Titin-T chain is the Obscurin-O chain or the Obscurin-like-O chain.

[0296] The term "dimer" refers to a structure formed by two molecules (such as polypeptides or proteins) through covalent or non-covalent interactions. Homodimers or homodimerizations are formed by two identical molecules, and heterodimers or heterodimerizations are formed by two different molecules. Two molecules can form dimers through natural interchain bonds, or they can form dimers through non-natural interchain bonds. In some embodiments of the present disclosure, the titin-T chain and the obscurin-O chain or the titin-T chain and the obscurin-like-O chain can form dimers through natural interchain bonds. It is well known to those skilled in the art that two domains that associate with each other to form a dimer, wherein the contact interface residues within 6 angstroms between the first domain and the second domain (especially the residues within 4.5 angstroms) play a key role in maintaining the association of the two domains (Yan, Changhui et al. "Characterization of protein-protein interfaces." The protein journal vol.27, 1 (2008): 59-70). The complexes formed by the association of titin-T chain with obscurin-O chain or titin-T chain with obscurin-like-O chain were analyzed by MOE (Molecular Operating Environment) system (see Appendix Figure 1A and Figure 1B), it was found that one or more residues in positions 7-15, 19-24, 26, 55, 59 and 60 on the titin-T chain interacted with one or more residues in positions 3-6, 9, 41, 73, 75 and 80-90 on the obscurin-O chain, and one or more residues in positions 1, 7-10, 13-16, 19-26, 59-60 and 96 on the titin-T chain interacted with one or more residues in positions 4-5, 10, 12-13, 74, 76, 78 and 82-91 on the obscurin-like-O chain (see Appendix Fig.16A and Fig. 16B), the distance between the contact interface residues of the above sites is within 4.5 angstroms, which plays an important role in maintaining the association of the two domains. In addition, in some other embodiments, the titin-T chain and the obscurin-O chain or the titin-T chain and the obscurin-like-O chain can form a dimer through a non-natural interchain bond, wherein the dimer contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more non-natural interchain bonds. The dimer can be stabilized by mutating some amino acids on the titin-T chain, the obscurin-O chain or the obscurin-like-O chain so that a disulfide bond is formed between the titin-T chain and the obscurin-O chain or the titin-T chain and the obscurin-like-O chain. In some embodiments, the Titin-T chain has one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39, and / or the Obscurin-O chain has one or more amino acid residue mutations selected from positions 3, 9, 25, 76 and 88; or the Titin-T chain has one or more amino acid residue mutations selected from positions 8, 20, 22, 25, 26 and 39, and / or the Obscurin-like-O chain has one or more amino acid residue mutations selected from positions 6, 26, 74, 77, 84 and 86. In some embodiments, the Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T, and / or the Obscurin-O chain has one or more amino acid residue mutations selected from A3C, R9C, C25S, C76S and A88C; or the Titin-T chain has one or more amino acid residue mutations selected from A8C, V20C, T22C, C25S, A26C and C39T, and / or the Obscurin-like-O chain has one or more amino acid residue mutations selected from C6E, C26S, C77S, V74C, G84C and A86C.In some embodiments, the titin-T chain has C25S, C39T and A8C mutations, and the obscurin-O chain has an A88C mutation; the titin-T chain has C25S, C39T and V20C mutations, and the obscurin-O chain has an A3C mutation; the titin-T chain has C25S, C39T and A26C mutations, and the obscurin-O chain has an R9C mutation; the titin-T chain has C25S, C39T and A26C mutations, and the obscurin-O chain has an R9C mutation. 39T and A8C mutations, the Obscurin-O chain has C25S, C76S and A88C mutations; the Titin-T chain has C25S, C39T and V20C mutations, the Obscurin-O chain has C25S, C76S and A3C mutations; the Titin-T chain has C25S, C39T and A26C mutations, the Obscurin-O chain has C25S, C76S and R9C mutations; the Titin-T chain has C25S , C39T, and A8C mutations, and the Obscurin-like-O chain has C6E and V74C mutations; the Titin-T chain has C25S, C39T, and V20C mutations, and the Obscurin-like-O chain has C6E and G84C mutations; the Titin-T chain has C25S, C39T, and T22C mutations, and the Obscurin-like-O chain has C6E and A86C mutations; the Titin-T chain has C25S, C39T, and A8 C mutations, Obscurin-like-O chain has C6E, C26S, C77S and V74C mutations; Titin-T chain has C25S, C39T and V20C mutations, Obscurin-like-O chain has C6E, C26S, C77S and G84C mutations; Titin-T chain has C25S, C39T and T22C mutations, Obscurin-like-O chain has C6E, C26S, C77S and A86C mutations.In some embodiments, the Obscurin-O chain further has one or more amino acid residue mutations selected from positions 7, 11, and 62; preferably, the Obscurin-O chain has one or more amino acid residue mutations selected from L7K or L7R, K11L, T62K, or T62H; most preferably, the Titin-T chain has C25S, C39T, and A8C mutations, and the Obscurin-O chain has C25S, C76S, A88C, L7K, and T62K mutations; the Titin-T chain having C25S, C39T and A8C mutations, and the Obscurin-O chain having C25S, C76S, A88C, L7K and T62H mutations; the Titin-T chain having C25S, C39T and A8C mutations, and the Obscurin-O chain having C25S, C76S, A88C, K11L and T62K mutations; or the Titin-T chain having C25S, C39T and A8C mutations, and the Obscurin-O chain having C25S, C76S, A88C, K11L and T62H. The above-mentioned Titin-T chain mutation site is the natural sequence site relative to the T.0 chain (sequence SEQ ID NO: 32); the Obscurin-O chain mutation site is the natural sequence site relative to the O.0 chain (sequence SEQ ID NO: 33); the Obscurin-like-O chain mutation site is the natural sequence site relative to the OL.0 chain (sequence SEQ ID NO: 34).

[0297] In the present disclosure, "mismatch" refers to the interaction or association of two or more homologous or heterologous polypeptides to form an undesirable dimer or multimer pairing. "Not prone to mismatch" means, for example, when polypeptides A1, B1 and B2 are co-expressed, if the expression amount of the desired A1-B1 dimer is greater than the amount of the A1-B 2 dimer, it is considered that preferential pairing occurs between A1-B 1, that is, mismatching is not likely to occur between A1-B 2. In the present disclosure, in some embodiments, in the multi-specific polypeptide complex, mismatching is not likely to occur between VH1 of the first polypeptide complex and VL2 of the second polypeptide complex, and / or mismatching is not likely to occur between VL1 of the first polypeptide complex and VH2 of the second polypeptide complex, but VH1-VL1 is preferentially paired, and VH2-VL2 is preferentially paired.

[0298] "Disulfide bond" refers to a covalent bond formed between sulfur atoms in the structure RSSR'. The amino acid cysteine ​​contains a thiol group that can form a disulfide bond with a second thiol group, for example, with a thiol group of another cysteine ​​residue. A disulfide bond can be formed between the thiol groups of two cysteine ​​residues, respectively, on two polypeptide chains, thereby forming an interchain bridge or interchain bond.

[0299] Electrostatic interactions are non-covalent interactions and play an important role in protein folding, stability, flexibility and function, and include ionic interactions, hydrogen bonding and halogen bonding. Electrostatic interactions can form in polypeptides, for example, between Lys and Asp, between Lys and Glu, between Glu and Arg, or between Glu, Trp on the first chain and Arg, Val or Thr on the second chain.

[0300] Salt bridges are close-range electrostatic interactions, which mainly come from the anionic carboxyl group of Asp or Glu and the cationic ammonium from Lys or the guanidinium of Arg, which are pairs of oppositely charged residues that are close in space in the native protein structure. Charged and polar residues in the hydrophobic interface can serve as hot spots for binding. Among them, residues with ionizable side chains such as His, Tyr and Ser can also participate in the formation of salt bridges.

[0301] Hydrophilic interaction, molecules with polar groups have a strong affinity for water, and the molecules can form short-term bonds with water through hydrogen bonds. Hydrophobic interaction is a non-covalent interaction between non-polar molecules. These non-polar molecules (such as some neutral amino acid residues, also called hydrophobic residues) have a tendency to avoid water and aggregate with each other in an aqueous environment. For example, hydrophobic interactions can be formed between one or more Val, Tyr and Ala on the first chain and one or more Val, Leu and Trp on the second chain, or His and Ala on the first chain and Thr and Phe on the second chain. (See Brinkmann et al., 2017).

[0302] The term "hydrogen bond" refers to the electrostatic attraction between two polar groups when a hydrogen atom covalently bonds to a highly electronegative atom such as nitrogen, oxygen or fluorine. Hydrogen bonds can form between backbone oxygens (e.g., chalcogen groups) and amide hydrogens (nitrogen groups) of two residues in a polypeptide, such as between the nitrogen group in Asn and the oxygen group in His, or between the oxygen group in Asn and the nitrogen group in Lys. Hydrogen bonds are stronger than van der Waals interactions, but weaker than covalent or ionic bonds, and are critical for maintaining secondary and tertiary structure. For example, an alpha helix is ​​formed when the spacing of amino acid residues occurs regularly between positions i and i+4, and a 3-10 amino acid long peptide stretch formed when two peptides are connected by at least two or three backbone hydrogen bonds forms a twisted, wrinkled sheet called a beta sheet.

[0303] As used herein, "knob-into-hole" refers to the interaction between two polypeptides, one of which has a protrusion (i.e., a "knob") due to the presence of an amino acid residue with a bulky side chain (e.g., tyrosine or tryptophan). The other polypeptide has a cavity (i.e., a "hole") in which there are small side chain amino acid residues (e.g., alanine or threonine), and the protrusion can be positioned in the cavity to promote the interaction of the two polypeptides to form a heterodimer or complex. Methods for producing polypeptides with protrusions into holes are known in the art, and can be found in patents US5731169, WO1996027011, etc.

[0304] "Non-natural interchain bonds" refer to interchain bonds that are not found in wild-type polypeptide polymers. For example, non-natural interchain bonds can be formed between a mutated amino acid residue of one polypeptide and a wild-type amino acid residue or a mutated amino acid residue of another polypeptide. In certain embodiments, at least one non-natural interchain bond is a "disulfide bond" formed after amino acid mutation. In some embodiments of the present disclosure, the non-natural interchain bonds between the Titin-T chain and the Obscurin-O chain, or the Titin-T chain and the Obscurin-like-O chain, are formed by mutating one or more amino acid residues selected from positions 8, 20, 22, 25, 26 and 39 on the Titin-T chain, and / or positions 3, 9, 25, 76 and 88 on the Obscurin-O chain; or by mutating one or more amino acid residues selected from positions 8, 20, 22, 25, 26 and 39 on the Titin-T chain, and / or positions 6, 26, 74, 77, 84 and 86 on the Obscurin-like-O chain.

[0305] The term "contact interface" refers to a specific region on a polypeptide where the polypeptides contact or interact with each other. The contact interface comprises one or more amino acid residues, and when an interaction occurs, the contact interface amino acid residues on a polypeptide can interact with the corresponding amino acid residues in contact with it. The amino acid residues in the contact interface can be a continuous or discontinuous sequence. For example, when the interface is three-dimensional, the amino acid residues in the interface can be separated at different positions on the linear sequence.

[0306] "Connection domain" or "connection domain" or "spacer" refers to the border or border region where two polypeptide sequences are fused or combined. For example, the connection domain may comprise at least a portion of the C-terminal fragment from the first fusion polypeptide, fused to at least a portion of the N-terminal fragment from the second fusion polypeptide, with or without other spacers in between. For example, the spacer may be rich in glycine and proline residues. For example, a spacer having a single or repeated sequence consisting of threonine / serine and glycine, GGGGS, TGGGG, SGGGG, or tandem repeats thereof (e.g., 2, 3, 4, 5 or more repeats). In certain embodiments, the spacer comprises GGGGS or 2 or more tandem repeats thereof.

[0307] A natural complete antibody contains two heavy chains and two light chains. Each heavy chain consists of a variable region ("HCVR", VH) and the first, second and third constant regions (CH1, CH2 and CH3). The second (CH2) and third (CH3) constant regions of the antibody constitute "Fc". The N-terminus of CH2 may or may not contain the hinge region of the antibody. The hinge region is rich in proline and includes interchain disulfide bonds; and each light chain consists of a variable region ("LCVR", VL) and a constant region (CL). The sequence of about 110 amino acids near the N-terminus of the heavy and light chains varies greatly, which is the variable region (Fv region); the remaining amino acid sequence near the C-terminus is relatively stable, which is the constant region. The variable region includes 3 hypervariable regions (HVR) and 4 relatively conservative framework regions (FR). The 3 hypervariable regions determine the specificity of the antibody, also known as the complementarity determining region (CDR). Each light chain variable region (VL) and heavy chain variable region (VH) consists of three CDR regions and four FR regions, arranged in the order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.

[0308] The antibodies disclosed herein may be, for example, antibodies derived from animals (such as antibodies derived from mice, birds, rabbits, camels, monkeys, etc.), chimeric antibodies, humanized antibodies, and fully human antibodies. In addition to full-length antibodies, the antibodies disclosed herein also include antigen-binding fragments that can bind to antigens.

[0309] The term "murine antibody" in the present disclosure refers to a monoclonal antibody against an antigen prepared according to the knowledge and skills in the art. During preparation, the test subject is injected with the antigen, and then a hybridoma expressing an antibody with the desired sequence or functional properties is isolated. In a preferred embodiment of the present disclosure, the murine antibody or antigen-binding fragment thereof may further comprise a light chain constant region of a murine κ, λ chain or a variant thereof, or further comprise a heavy chain constant region of a murine IgG1, IgG2, IgG3 or a variant thereof.

[0310] The term "chimeric antibody" refers to an antibody formed by fusing the variable region of another first species antibody with the constant region of a second species antibody. For example, to establish a human-mouse chimeric antibody, a hybridoma that secretes mouse-specific monoclonal antibodies must first be established, and then the variable region genes are cloned from the mouse hybridoma cells, and then the constant region genes of the human antibodies are cloned as needed, and the mouse variable region genes are connected to the human constant region genes into chimeric genes and inserted into the expression vector, and finally the chimeric antibody molecules are expressed in a eukaryotic system or a prokaryotic system. In a preferred embodiment of the present disclosure, the antibody light chain of the chimeric antibody further comprises a light chain constant region of a human κ, λ chain or a variant thereof. The antibody heavy chain of the antigen chimeric antibody further comprises a heavy chain constant region of human IgG1, IgG2, IgG3, IgG4 or a variant thereof, preferably comprising a human IgG1, IgG2 or IgG4 heavy chain constant region, or an IgG1, IgG2 or IgG4 variant using amino acid mutations (e.g., L234A and / or L235A mutations, and / or S228P mutations).

[0311] The term "humanized antibody", also known as CDR-grafted antibody, refers to an antibody produced by transplanting the mouse CDR sequence into the human antibody variable region framework, that is, different types of human germline antibody framework sequences. It can overcome the heterologous reaction induced by chimeric antibodies due to carrying a large amount of mouse protein components. Such framework sequences can be obtained from public DNA databases including germline antibody gene sequences or public references. For example, the germline DNA sequences of human heavy chain and light chain variable region genes can be obtained in the "VBase" human germline sequence database, and can be found in Kabat, EA et al., 1991 Sequences of Proteins of Immunological Interest, 5th edition. In order to avoid the decrease in activity caused by the decrease in immunogenicity, the human antibody variable region framework sequence can be subjected to minimal reverse mutation or back mutation to maintain activity. The humanized antibodies disclosed herein also include humanized antibodies after further affinity maturation mutation of CDR by yeast display.

[0312] In one embodiment of the present disclosure, the antibody or antigen-binding fragment thereof may further comprise a light chain constant region of a human or mouse κ, λ chain or a variant thereof, or further comprise a heavy chain constant region of a human or mouse IgG1, IgG2, IgG3, IgG4 or a variant thereof; preferably comprises a human IgG1, IgG2 or IgG4 heavy chain constant region, or an IgG1, IgG2 or IgG4 variant using amino acid mutations (e.g., L234A and / or L235A mutations, and / or S228P mutations).

[0313] The human antibody heavy chain constant region and human antibody light chain constant region disclosed herein, including their "conventional variants", refer to variants of the heavy chain constant region or light chain constant region derived from humans that have been disclosed in the prior art and do not change the structure and function of the antibody variable region. Exemplary variants include IgG1, IgG2, IgG3 or IgG4 heavy chain constant region variants with site-directed modification and amino acid replacement of the heavy chain constant region. Specific replacements include YTE mutations known in the prior art, L234A and / or L235A mutations, S228P mutations, and / or mutations to obtain knob-into-hole structures (so that the antibody heavy chain has a knob-Fc and hole-Fc combination). These mutations have been shown to give antibodies new properties but do not change the function of the antibody variable region.

[0314] "HuMAb", "humanized antibody", "fully human antibody", "fully human antibody" are used interchangeably and may be an antibody derived from a human or an antibody obtained from a transgenic organism that has been "engineered" to produce specific human antibodies in response to antigenic stimulation and may be produced by any method known in the art. Transgenic organisms can synthesize human antibodies, and the organisms can be used to produce human antibody-secreting hybridomas. A human antibody may also be an antibody in which the heavy and light chains are encoded by nucleotide sequences derived from one or more human DNA sources. Fully human antibodies may also be constructed by gene or chromosome transfection methods and phage display technology, or by in vitro activated B cells, all of which are known in the art.

[0315] The terms "full-length antibody", "intact antibody", "complete antibody" and "whole antibody" are used interchangeably herein to refer to an antibody in substantially intact form, as distinguished from an antigen-binding fragment as defined below. The term specifically refers to an antibody whose light and heavy chains include constant regions. The disclosure "antibody" encompasses "full-length antibodies" and antigen-binding fragments thereof.

[0316] In some embodiments, the full-length antibody disclosed herein includes a light chain connected to a light chain variable region and a heavy chain connected to a heavy chain constant region. A person skilled in the art can select a light chain constant region and a heavy chain constant region from different antibody sources, such as a light chain constant region and a heavy chain constant region from a human antibody, according to actual needs.

[0317] The term "antigen-binding fragment" of an antibody refers to one or more fragments of an antibody that retain the ability to bind to an antigen (e.g., an antigen). It has been shown that fragments of a full-length antibody can be used to perform the antigen-binding function of an antibody. Examples of binding fragments encompassed by the term "antigen-binding fragment" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab') 2 Fragment, a bivalent fragment comprising two Fab fragments connected by a disulfide bridge on the hinge region, (iii) an Fd fragment consisting of a VH and CH1 domain; (iv) an Fv fragment consisting of the VH and VL domains of a single arm of an antibody; (v) a dsFv, a stable antigen-binding fragment formed by a disulfide bond between VH and VL; (vi) diabodies, bispecific antibodies and multispecific antibodies comprising fragments such as scFv, dsFv, Fab, etc. In addition, although the two domains VL and VH of the Fv fragment are encoded by separate genes, they can be connected by a synthetic linker using a recombinant method, thereby enabling them to be produced as a single protein chain in which the VL and VH regions are paired to form a monovalent molecule (called a single-chain Fv (scFv); see, for example, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85: 5879-5883). Such single-chain antibodies are also included in the term "antigen-binding fragment" of an antibody. Such antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are screened for functionality in the same manner as for intact antibodies. Antigen-binding portions can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of intact immunoglobulins. The antibody can be an antibody of different types, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtypes), IgA1, IgA2, IgD, IgE or IgM antibodies.

[0318] F(ab')2 is an antibody fragment having a molecular weight of about 100,000 and antigen-binding activity, obtained by enzymatic digestion of the portion below two disulfide bonds in the hinge region of IgG and comprising two Fab regions linked at the hinge position.

[0319] Fab' is an antibody fragment having a molecular weight of about 50,000 and antigen-binding activity obtained by cleaving the disulfide bond of the hinge region of the above F(ab')2. The Fab' of the present disclosure can be produced by treating the F(ab')2 of the present disclosure that specifically recognizes an antigen with a reducing agent such as dithiothreitol.

[0320] Furthermore, the Fab' fragment of an antibody can be produced by inserting a DNA encoding the Fab' fragment into a prokaryotic expression vector or a eukaryotic expression vector and introducing the vector into a prokaryotic organism or a eukaryotic organism to express the Fab'.

[0321] The term "single-chain antibody", "single-chain Fv" or "scFv" means a molecule comprising an antibody heavy chain variable domain (or region; VH) and an antibody light chain variable domain (or region; VL) connected by a linker. Such scFv molecules may have the general structure: NH 2 -VL-Linker-VH-COOH or NH 2 -VH-linker-VL-COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof, for example variants with 1-4 repeats are used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). Other linkers useful in the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8: 725-731, Choi et al. (2001), Eur. J. Immuno 1. 31: 94-106, Hu et al. (1996), Cancer Res. 56: 3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293: 41-56 and Roovers et al. (2001), Cancer Immunol.

[0322] Diabodies are antibody fragments in which scFv or Fab is dimerized, and are antibody fragments having bivalent antigen-binding activity. In the bivalent antigen-binding activity, the two antigens may be the same or different.

[0323] The diabodies disclosed herein can be produced by the following steps: obtaining cDNA encoding VH and VL of the antibodies disclosed herein, constructing DNA encoding scFv, inserting the DNA into an expression vector, and then introducing the expression vector into a prokaryote or eukaryote to express the diabodies.

[0324] dsFv is obtained by linking a polypeptide in which one amino acid residue in each VH and VL is substituted by a cysteine ​​residue via a disulfide bond between the cysteine ​​residues. The amino acid residue substituted by the cysteine ​​residue can be selected based on the three-dimensional structure prediction of the antibody according to a known method (Protein Engineering, 7, 697 (1994)).

[0325] The full-length antibody or antigen-binding fragment or bispecific antibody or multispecific antibody, polypeptide, polypeptide complex, multispecific polypeptide complex disclosed herein can be produced by the following steps: obtaining the encoding cDNA of the antibody disclosed herein, constructing the DNA encoding dsFv, inserting the DNA into an expression vector, and then introducing the expression vector into a prokaryote or eukaryote to express the dsFv.

[0326] The term "amino acid difference" or "amino acid mutation" refers to the presence of amino acid changes or mutations in a variant protein or polypeptide compared to the original protein or polypeptide, including the insertion, deletion or substitution of 1, 2, 3 or more amino acids based on the original protein or polypeptide.

[0327] The term "antibody framework" or "FR region" refers to a portion of a variable domain VL or VH that serves as a scaffold for the antigen binding loops (CDRs) of the variable domain. Essentially, it is a variable domain without CDRs. The term "complementarity determining region", "CDR" or "hypervariable region" refers to one of the six hypervariable regions in the variable domain of an antibody that primarily contribute to antigen binding. Typically, there are three CDRs (HCDR1, HCDR2, HCDR3) in each heavy chain variable region and three CDRs (LCDR1, LCDR2, LCDR3) in each light chain variable region. The amino acid sequence boundaries of a CDR can be determined using any of a variety of well-known schemes, including the "Kabat" numbering convention (see Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD), the "Chothia" numbering convention (see Al-Lazikani et al., (1997) JMB 273:927-948), and the ImMunoGenTics (IMGT) numbering convention (Lefranc MP, Immunologist, 7, 132-136 (1999); Lefranc, MP et al., Dev. Comp. Immunol., 27, 55-77 (2003), etc.

[0328] The term "epitope" or "antigenic determinant" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds (e.g., a specific site on an antigen molecule). An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive or non-continuous amino acids in a unique spatial conformation. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996).

[0329] The terms "specific binding", "selective binding", "selectively binds" or "specific binding" refer to the binding of an antibody to a predetermined epitope on an antigen. -7 M, for example, less than about 10 -8 M, 10 - 9 M, 10 -10 M, 10 -11 M, 10 -12 Binds with an affinity (KD) of M or less.

[0330] The term "KD" refers to the dissociation equilibrium constant for a particular antibody-antigen interaction. -7 M, for example, less than about 10 -8 M or 10 -9 The dissociation equilibrium constant (KD) of M binds to the antigen. For example, in the present disclosure, the affinity of the antibody to the antigen is determined by FACS to determine the KD value.

[0331] When the term "competes" is used in the context of antigen binding proteins (e.g., neutralizing antigen binding proteins or neutralizing antibodies) that compete for the same epitope, it means competition between antigen binding proteins, which is determined by the following assay: in the assay, the antigen binding protein (e.g., antibody or immunologically functional fragment thereof) to be tested prevents or inhibits (e.g., reduces) specific binding of a reference antigen binding protein (e.g., ligand or reference antibody) to a common antigen. Numerous types of competitive binding assays can be used to determine whether one antigen binding protein competes with another, such as: solid phase direct or indirect radioimmunoassays (RIA), solid phase direct or indirect enzyme immunoassays (EIA), sandwich competition assays (see, e.g., Stahli et al., 1983, Methods in Enzymology 9:242-253); solid phase direct biotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol. 137:3614-3619), solid phase direct label assays, solid phase direct label sandwich assays (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Manual). Press); solid phase direct labeling RIA with I-125 label (see, e.g., Morel et al., 1988, Molec. Immunol. 25: 7-15); solid phase direct biotin-avidin EIA (see, e.g., Cheung et al., 1990, Virology 176: 546-552); and directly labeled RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32: 77-82). Typically the assay involves the use of purified antigen bound to a solid surface or cells bearing either an unlabeled test antigen binding protein and a labeled reference antigen binding protein. Competitive inhibition is measured by measuring the amount of label bound to the solid surface or cells in the presence of the test antigen binding protein. Typically the test antigen binding protein is present in excess. Antigen binding proteins identified by competitive assays (competing antigen binding proteins) include: antigen binding proteins that bind to the same epitope as a reference antigen binding protein; and antigen binding proteins that bind to adjacent epitopes sufficiently close to the binding epitope of the reference antigen binding protein that the two epitopes sterically interfere with each other for binding. Additional details on methods for determining competitive binding are provided in the Examples herein. Typically, when the competing antigen binding protein is present in excess, it will inhibit (e.g., reduce) at least 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, or 75% or more of the specific binding of the reference antigen binding protein to the common antigen.In some cases, binding is inhibited by at least 80-85%, 85-90%, 90-95%, 95-97% or 97% or more. The term "nucleic acid molecule" as used herein refers to DNA molecules and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded, preferably double-stranded DNA or single-stranded mRNA or modified mRNA. When a nucleic acid is placed in a functional relationship with another nucleic acid sequence, the nucleic acid is "operably linked". For example, if a promoter or enhancer affects the transcription of a coding sequence, then the promoter or enhancer is effectively connected to the coding sequence.

[0332] The term "expression vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. In one embodiment, the vector is a "plasmid", which refers to a circular double-stranded DNA loop into which other DNA segments can be connected. In another embodiment, the vector is a viral vector, in which other DNA segments can be connected to the viral genome. The vector disclosed herein can replicate autonomously in the host cell introduced therein (e.g., bacterial vectors and additional mammalian vectors with a bacterial origin of replication) or can be integrated into the genome of the host cell after being introduced into the host cell, thereby replicating with the host genome (e.g., non-additional mammalian vectors).

[0333] Methods for producing and purifying antibodies and antigen-binding fragments are well known in the prior art, such as the Cold Spring Harbor Guide to Antibody Experimental Technology, Chapters 5-8 and 15. For example, mice can be immunized with antigens, and the resulting antibodies can be renatured, purified, and amino acid sequenced using conventional methods. Antigen-binding fragments can also be prepared using conventional methods. The antibodies or antigen-binding fragments described in the invention use genetic engineering methods to add one or more human FR regions to the non-human CDR region. Human FR germline sequences can be obtained from the ImMunoGeneTics (IMGT) website by comparing the IMGT human antibody variable region germline gene database and MOE software, or from the Journal of Immunoglobulins, 2001 ISBN012441351.

[0334] The term "host cell" refers to a cell into which an expression vector has been introduced. Host cells may include bacteria, microorganisms, plants or animal cells. Easily transformed bacteria include members of the enterobacteria, such as strains of Escherichia coli or Salmonella; Bacillus such as Bacillus subtilis; Pneumococcus; Streptococcus and Haemophilus influenzae. Suitable microorganisms include Saccharomyces cerevisiae and Pichia pastoris. Suitable animal host cell lines include CHO (Chinese hamster ovary cell line), 293 cells and NS0 cells.

[0335] The engineered antibodies or antigen-binding fragments disclosed herein can be prepared and purified by conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into expression vectors. The recombinant expression vector can stably transfect CHO cells. As a more recommended prior art, mammalian expression systems lead to glycosylation of antibodies, especially at the highly conserved N-terminal site of the Fc region. Stable clones are obtained by expressing antibodies that specifically bind to antigens. Positive clones are expanded in serum-free culture medium in a bioreactor to produce antibodies. The culture fluid that secretes antibodies can be purified by conventional techniques. For example, purification is performed using A or G Sepharose FF columns. Non-specifically bound components are washed away. The bound antibodies are then eluted using a pH gradient method, and the antibody fragments are detected using SDS-PAGE and collected. The antibodies can be filtered and concentrated using conventional methods. Soluble mixtures and polymers can also be removed using conventional methods, such as molecular sieves and ion exchange. The resulting product needs to be immediately frozen, such as -70°C, or lyophilized.

[0336] "Administering," "giving," and "treating" when applied to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, human, subject, cell, tissue, organ, or biological fluid. "Administering," "giving," and "treating" can refer to, for example, treatment, pharmacokinetics, diagnosis, research, and experimental procedures. Treatment of cells includes contact of an agent with a cell, and contact of an agent with a fluid, wherein the fluid is in contact with the cell. "Administering," "giving," and "treating" also mean in vitro and ex vivo treatment of, for example, a cell, by an agent, a diagnosis, a combination composition, or by another cell. "Treatment," when applied to humans, veterinary medicine, or research subjects, refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.

[0337] "Treatment" means administering an internal or external therapeutic agent, such as a composition comprising any of the binding compounds disclosed herein, to a subject having one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of a disease in the treated subject or population to induce regression of such symptoms or inhibit the development of such symptoms to any clinically measurable extent. The amount of a therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") may vary according to a variety of factors, such as the disease state, age, and weight of the subject, and the ability of the drug to produce the desired therapeutic effect in the subject. Whether the symptoms of the disease have been alleviated can be evaluated by any clinical test method commonly used by physicians or other professional health care personnel to evaluate the severity or progression of the symptoms. Although the embodiments of the present disclosure (e.g., treatment methods or articles) may not be effective in alleviating every symptom of the target disease, they should alleviate the target disease symptoms in a statistically significant number of subjects as determined by any statistical test known in the art, such as Student's t-test, chi-square test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test.

[0338] "Conservative modification" or "conservative substitution or replacement" refers to the replacement of an amino acid in a protein with another amino acid having similar characteristics (e.g., charge, side chain size, hydrophobicity / hydrophilicity, main chain conformation and rigidity, etc.), so that changes can be made frequently without changing the biological activity of the protein. It is known to those skilled in the art that, in general, single amino acid replacements in non-essential regions of a polypeptide do not substantially change the biological activity (see, e.g., Watson et al. (1987) Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., p. 224, (4th edition)). In addition, replacement of amino acids with similar structure or function is unlikely to destroy biological activity. Exemplary conservative replacements are set forth in the following table "Exemplary amino acid conservative replacements". Exemplary amino acid conservative replacements:

[0339]

[0340]

[0341] "Effective amount" or "effective dose" refers to the amount of a drug, compound, or pharmaceutical composition necessary to obtain any one or more beneficial or desired therapeutic results. For preventive uses, beneficial or desired results include eliminating or reducing the risk, reducing the severity, or delaying the onset of a condition, including the biochemical, histological, and / or behavioral symptoms of the condition, its complications, and intermediate pathological phenotypes presented during the development of the condition. For therapeutic applications, beneficial or desired results include clinical results, such as reducing the incidence of various target antigen-related conditions of the present disclosure or improving one or more symptoms of the condition, reducing the dose of other agents required to treat the condition, enhancing the efficacy of another agent, and / or delaying the progression of the target antigen-related condition of the present disclosure in the subject.

[0342] "Exogenous" refers to substances produced outside the body of an organism, cell, or human body, as the case may be.

[0343] "Endogenous" refers to substances produced within an organism, cell, or human body, as the case may be.

[0344] "Homology" and "identity" refer to the sequence similarity between two polynucleotide sequences or between two polypeptides. When the positions in the two compared sequences are occupied by the same base or amino acid monomer subunit, for example, if every position of the two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percentage of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared × 100. For example, when the sequences are optimally aligned, if 6 out of 10 positions in the two sequences are matched or homologous, then the two sequences are 60% homologous; if 95 out of 100 positions in the two sequences are matched or homologous, then the two sequences are 95% homologous. Typically, when two sequences are aligned, a comparison is made to give the maximum percentage homology. For example, the comparison can be performed by the BLAST algorithm, in which the parameters of the algorithm are selected to give the maximum match between each sequence over the entire length of each reference sequence. The following references relate to the BLAST algorithm frequently used for sequence analysis: BLAST ALGORITHMS: Altschul, SF et al., (1990) J. Mol. Biol. 215: 403-410; Gish, W. et al., (1993) Nature Genet. 3: 266-272; Madden, TL et al., (1996) Meth. Enzymol. 266: 131-141; Altschul, SF et al., (1997) Nucleic Acids Res. 25: 3389-3402; Zhang, J. et al., (1997) Genome Res. 7: 649-656. Other conventional BLAST algorithms such as those provided by NCBI BLAST are also well known to those skilled in the art. In the present disclosure, for example, "a site numbered relative to the natural sequence of the XX sequence" includes both sites with corresponding natural sequence numbers on the XX sequence and sites in a mutant sequence of the XX sequence that are equivalent to sites in the XX sequence. Equivalent sites can be identified by aligning the mutant sequence of the XX sequence with the XX sequence to obtain the highest percentage identity. In this case, the site on the mutant sequence of the XX sequence that corresponds to the XX sequence is the equivalent site.

[0345] As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably, and all such designations include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It should also be understood that all progeny may not be exactly identical in terms of DNA content, due to intentional or unintentional mutations. Mutant progeny having the same function or biological activity as screened for in the originally transformed cell are included. Where different designations are intended, this is clear from the context.

[0346] As used herein, "polymerase chain reaction" or "PCR" refers to a procedure or technique in which a trace amount of a specific portion of a nucleic acid, RNA and / or DNA is amplified as described, for example, in U.S. Pat. No. 4,683,195. In general, sequence information from the ends of the target region or beyond is required so that oligonucleotide primers can be designed; these primers are identical or similar in sequence to the corresponding strands of the template to be amplified. The 5' terminal nucleotides of the two primers can be consistent with the ends of the material to be amplified. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, phage or plasmid sequences, etc. See generally Mullis et al. (1987) Cold Spring Harbor Symp. Ouant. Biol. 51: 263; Erlich, ed., (1989) PCR TECHNOLOGY (Stockton Press, NY). As used herein, PCR is considered to be an example, but not the only example, of a nucleic acid polymerase reaction method for amplifying a nucleic acid test sample, which method includes using a known nucleic acid and a nucleic acid polymerase as a primer to amplify or generate a specific portion of a nucleic acid.

[0347] The terms "conjugate" and "drug conjugate" refer to a new type of drug formed by connecting a ligand to a biologically active drug through a stable linking unit. For example, an "antibody drug conjugate" (ADC) is an antibody or antibody fragment connected to a biologically active drug through a linking unit. The antibody can be coupled to the drug directly or via a linker. The average number of drug modules per antibody can range from, for example, about 0 to about 20 drug modules per antibody, in some embodiments, 1 to about 10 drug modules per antibody, and in certain embodiments, 1 to about 8 drug modules per antibody. The conjugate disclosed herein, wherein the average drug load per antibody is about 2 to about 5 or about 3 to about 4.

[0348] "Isolated" refers to a purified state, and in this case means that the specified molecule is substantially free of other biomolecules, such as nucleic acids, proteins, lipids, carbohydrates, or other materials, such as cell debris and growth medium. Generally, the term "isolated" is not intended to imply the complete absence of such materials or the absence of water, buffers, or salts, unless they are present in amounts that significantly interfere with the experimental or therapeutic use of the compounds as described herein.

[0349] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and where it does not occur.

[0350] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0351] The term "pharmaceutically acceptable carrier" refers to any inactive substance suitable for use in a formulation for delivering an antibody or antigen-binding fragment. The carrier can be an antiadhesive, a binder, a coating, a disintegrant, a filler or diluent, a preservative (such as an antioxidant, an antibacterial or antifungal agent), a sweetener, an absorption delaying agent, a wetting agent, an emulsifier, a buffer, etc. Examples of suitable pharmaceutically acceptable carriers include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.) dextrose, vegetable oils (such as olive oil), saline, buffer, buffered saline, and isotonic agents such as sugars, polyols, sorbitol, and sodium chloride.

[0352] In addition, the present disclosure includes pharmaceutical preparations for treating diseases or disorders, such as agents for treating diseases associated with target antigen-positive cells, which preparations contain the polypeptide complexes, multi-specific polypeptide complexes, domain-engineered antibodies, Fab fragments of domain-engineered antibodies, bispecific antibodies, pharmaceutical compositions, or nucleic acid molecules, or multi-specific antibodies disclosed herein as active ingredients.

[0353] The diseases disclosed herein are not limited. For example, the therapeutic response induced by the molecules disclosed herein can be through binding to human antigens and then inhibiting the binding of antigens to their receptors / ligands, or killing tumor cells that overexpress antigens.

[0354] In addition, the present disclosure relates to methods for immunodetection or determination of target antigens, reagents for immunodetection or determination of target antigens, methods for immunodetection or determination of cells expressing target antigens, and diagnostic agents for diagnosing diseases associated with target antigen-positive cells, which comprise the polypeptide complex, multi-specific polypeptide complex, domain-engineered antibody, Fab fragment of domain-engineered antibody, bispecific antibody, pharmaceutical composition, or nucleic acid molecule, or multi-specific antibody of the present disclosure as an active ingredient.

[0355] In the present disclosure, the method for detecting or determining the amount of the target antigen may be any known method. For example, it includes immunodetection or determination methods.

[0356] Immunoassay or determination method is a method for detecting or determining the amount of antibody or antigen using labeled antigen or antibody. Examples of immunoassay or determination methods include radioactive material labeled immunoantibody method (RIA), enzyme immunoassay (EIA or ELISA), fluorescent immunoassay (FIA), luminescent immunoassay, protein immunoblotting, physicochemical methods, etc.

[0357] The above-mentioned diseases associated with antigen-positive cells can be diagnosed by detecting or measuring cells expressing the antigen using the antibodies disclosed herein.

[0358] In order to detect cells expressing the polypeptide, known immunodetection methods can be used, and preferably immunoprecipitation, fluorescent cell staining, immunohistostaining, etc. In addition, fluorescent antibody staining using FMAT8100 HTS system (Applied Biosystem) can be used.

[0359] In the present disclosure, there is no particular limitation on the living sample used for detecting or measuring the target antigen, as long as it has the possibility of containing cells expressing the target antigen, such as tissue cells, blood, plasma, serum, pancreatic juice, urine, feces, tissue fluid or culture fluid.

[0360] Depending on the desired diagnostic method, the diagnostic agent containing the antibody or antibody fragment thereof disclosed herein may also contain reagents for performing antigen-antibody reactions or reagents for detecting reactions. Reagents for performing antigen-antibody reactions include buffers, salts, etc. Reagents for detection include reagents commonly used in immunoassays or assays, such as a labeled second antibody that recognizes the monoclonal antibody, its antibody fragment, or its conjugate, and a substrate corresponding to the label, etc.

[0361] The details of one or more embodiments of the present disclosure are proposed in the above description. Although any method and material similar or identical to that described herein can be used to implement or test the present disclosure, the preferred method and material are described below. Through the description and claims, other features, objects and advantages of the present disclosure will be apparent. In the description and claims, unless otherwise clearly indicated in the context, the singular form includes the case of plural references. Unless otherwise defined, all technical and scientific terms used herein have the general meaning understood by ordinary technicians in the field to which the present disclosure belongs. All patents and publications cited in the description are incorporated by reference. The following examples are proposed to more fully illustrate the preferred embodiments of the present disclosure. These embodiments should not be construed in any way as limiting the scope of the present disclosure.

[0362] The following examples are used to further describe the present invention, but these examples are not intended to limit the scope of the present invention. The experimental methods in the examples of the present invention that do not specify specific conditions are usually carried out according to conventional conditions, such as the Cold Spring Harbor Antibody Technology Laboratory Manual and the Molecular Cloning Manual; or according to the conditions recommended by the raw material or product manufacturer. Reagents that do not specify specific sources are conventional reagents purchased from the market.

[0363] Although the antibodies used in the examples target specific antigens, technicians, based on the teachings of the present disclosure, will understand that the realization of the technical effects does not depend on a specific CDR sequence, nor on a specific antigen sequence, but rather benefits from the replacement of CH1 / CL by Titin T chain / Obscurin-O chain, or Titin T chain / Obscurin-like-O chain, to improve the mismatch between the heavy chain / light chain.

[0364] Example 1. Method for preparing antibody or polypeptide protein

[0365] Design primers for PCR to construct gene fragments (e.g., antibody VH / VK gene fragments), and then perform homologous recombination with expression vectors (e.g., pHr (with signal peptide and constant region gene (e.g., CH1-Fc / CL) fragments)) to construct expression vectors (e.g., VH-CH1-Fc-pHr / VK-CL-pHr), and then introduce the constructed expression vectors into prokaryotes or eukaryotes for expression, and finally purify the products to obtain the desired antibodies or polypeptide proteins. Non-limitingly, the antibody constant region can be selected from the human κ and λ chain light chain constant regions, and the heavy chain constant region selected from IgG1, IgG2, IgG3 or IgG4. Non-limiting embodiments also include optimizing the design of human antibody constant regions, such as mutations in the L234A / L235A or L234F / L235E sites of the heavy chain constant region. Exemplarily, the antibody light / heavy chain constant region sequences are as follows:

[0366] >IgG1 heavy chain constant region (hIgG1 for short)

[0367]

[0368] Note: In the sequence, the single underlined part is CH1, the dashed part is CH2, and the italic part is CH3.

[0369] >knob-IgG1 heavy chain constant region (referred to as knob-IgG1):

[0370]

[0371] Note: In the sequence, the single underlined part is CH1, the dashed part is CH2, and the italic part is CH3.

[0372] >hole-IgG1 heavy chain constant region (referred to as hole-IgG1):

[0373]

[0374]

[0375] Note: In the sequence, the single underlined part is CH1, the dashed part is CH2, and the italic part is CH3.

[0376] >kappa light chain constant region (abbreviated as kappa or hκ)

[0377]

[0378] > Lambda light chain constant region (abbreviated as lambda or hλ)

[0379]

[0380] The amino acid sequences of the light chain and heavy chain variable regions of antibodies against various antigens such as B7H3 and CD3 mentioned in the embodiments or test examples of this disclosure are as follows:

[0381] >F0 antibody VH amino acid sequence:

[0382]

[0383] >F0 antibody VL amino acid sequence

[0384]

[0385] >N0 antibody VH amino acid sequence

[0386]

[0387] >N0 antibody VL amino acid sequence

[0388]

[0389] >S0 antibody VH amino acid sequence

[0390]

[0391] >S0 Antibody VL Amino Acid Sequence

[0392]

[0393]

[0394] >V0 antibody VH amino acid sequence

[0395]

[0396] >V0 antibody VL amino acid sequence

[0397]

[0398] >J0 antibody VH amino acid sequence

[0399]

[0400] >J0 antibody VL amino acid sequence

[0401]

[0402] >H0 antibody VH amino acid sequence

[0403]

[0404] >H0 antibody VL amino acid sequence

[0405]

[0406] >R0 antibody VH amino acid sequence

[0407]

[0408] >R0 antibody VL amino acid sequence

[0409]

[0410] >Bmab (B0 for short) antibody VH amino acid sequence

[0411]

[0412] >Bmab (B0 for short) antibody VL amino acid sequence

[0413]

[0414] >Umab (abbreviated as U0) antibody VH amino acid sequence

[0415]

[0416] >Umab (abbreviated as U0) antibody VL amino acid sequence

[0417]

[0418] >Dmab (abbreviated as D0) antibody VH amino acid sequence

[0419]

[0420] >Dmab (abbreviated as D0) antibody VL amino acid sequence

[0421]

[0422] >Tmab (abbreviated as I0) antibody VH amino acid sequence

[0423]

[0424] >Tmab (abbreviated as I0) antibody VL amino acid sequence

[0425]

[0426] >C0 Antibody VH amino acid sequence

[0427]

[0428] >C0 Antibody VL amino acid sequence

[0429]

[0430] >A0 antibody VH amino acid sequence

[0431]

[0432]

[0433] >A0 antibody VL amino acid sequence

[0434]

[0435] The heavy chain constant region sequence of the above-mentioned antibodies F0, N0, S0, V0, J0, H0, R0, B0, U0, D0, I0, C0, and A0 antibodies is an IgG1 heavy chain constant region (SEQ ID NO: 1), the light chain constant region sequence of the N0, S0, H0, R0, U0, I0, and C0 antibodies is a kappa light chain constant region (SEQ ID NO: 4); the light chain constant region sequence of the F0, V0, J0, B0, D0, and A0 antibodies is a lambda light chain constant region (SEQID NO: 5).

[0436] In addition, the sequence of the hB7H3 antigen protein is as follows:

[0437]

[0438] The hCD3 antigen protein is a heterodimer composed of the δ subunit and ε subunit of the hCD3 antigen, wherein the sequence of the δ subunit of the hCD3 antigen is:

[0439]

[0440] The epsilon subunit sequence of the hCD3 antigen:

[0441]

[0442] Example 2: Replacement of antibody CH1 / CL domain

[0443] The Ig-like domains with natural intermolecular interactions in the natural Titin / Obscurin complex, the Titin / Obscurin-like O complex and the IL6Ra / IL6Rb complex were used to replace the CH1 / CL domains of the antibody to obtain antibodies with modified CH1 / CL domains.

[0444] Wherein, in the IL6Ra / IL6Rb complex, the Ig-like domain in the IL6Ra protein used to replace the antibody CH1 or CL is the IL6Ra.0 chain, and the Ig-like domain in the IL6Rb protein used to replace the antibody CL or CH1 is the IL6Rb.0 chain; in the Titin / Obscurin complex, the Ig-like domain (Titin Ig-like 152 domain) in the Titin protein used to replace the antibody CH1 or CL is the T.0 chain, and the Ig-like domain (Obscurin Ig-like-1 domain) in the Obscurin protein used to replace the antibody CL or CH1 is the O.0 chain; in the Titin / Obscurin-like O complex, the Ig-like domain (Obscurin-like-Ig-like-1 domain) in the Obscurin-like protein used to replace the antibody CH1 or CL is the OL.0 chain, and the Ig-like domain (Titin Ig-like-152 domain) in the Titin protein used to replace the antibody CL or CH1 is the O.0 chain. Ig-like 152 domain) is T.0 chain. Among them:

[0445] >IL6Ra.0 chain sequence is:

[0446]

[0447] >IL6Rb.0 chain sequence is:

[0448]

[0449] >T.0 chain sequence is:

[0450]

[0451] >O.0 chain sequence is:

[0452]

[0453] >OL.0 chain sequence is:

[0454]

[0455] A variety of antibodies with replaced CH1 / CL were constructed, and the purity and binding activity of the antibodies to be tested with the corresponding antigens were detected according to the methods of Test Examples 2 and 4. The experimental results are shown in Table 1 below, and the experimental results show that antibodies F0, V0, S0, N0, J0, H0, R0, and C0 that bind to different antigens, after their CH1 / CL is replaced by T.0 chain / O.0 chain or T.0 chain / OL.0 chain at the same time, the antibodies still maintain good binding activity and have high antibody purity.

[0456] Table 1. Purity and affinity of antibodies after CH1 / CL domain replacement

[0457]

[0458]

[0459] Note: For example, F1 indicates that the heavy chain CH1 of F0 antibody is replaced by IL6Rb.0 chain (SEQ ID NO: 31), the light chain CL is replaced by IL6Ra.0 chain (SEQ ID NO: 30), and the other parts remain the same as F0, and the antibody is obtained. The same applies to the others. "-" in the table indicates not detected, and SEC is the purity result of the antibody detected by size exclusion chromatography (NA indicates not detected due to low expression).

[0460] Example 3: Optimal design of CH1 / CL domain modified antibodies

[0461] Individual amino acids of the Titin Ig-like 152 domain (T.0 chain), Obscurin Ig-like 1 domain (O.0 chain), and Obscurin-like Ig-like 1 domain (OL.0 chain) were mutated, including insertion, deletion, or substitution of amino acids, to verify the activity of the domain-modified antibodies.

[0462] Exemplarily, first, a small number of amino acids on the T.0 chain, the O.0 chain and the OL.0 chain are mutated to increase the interchain disulfide bonds; secondly, other individual amino acids in the domain are mutated, for example, amino acid mutations are performed on positions 7, 62 and 11 of the Obscurin Ig-like 1 domain; amino acids are added or reduced at the N-terminus of the Titin Ig-like 152 domain (for example, 5 amino acids "KAGIR" adjacent to the N-terminus of the Titin Ig-like 152 domain in the wild-type Titin protein are added); amino acids are added or reduced at the N-terminus of the Obscurin Ig-like 1 domain (for example, 5 amino acids "DQPQF" adjacent to the N-terminus of the Obscurin Ig-like 1 domain in the wild-type Obscurin protein are added); in addition, a linker sequence is added to the N-terminus or C-terminus of the Titin Ig-like 152 domain, the Obscurin Ig-like 1 domain or the Obscurin-like Ig-like 1 domain (for example, "G 4 S", "(G 4 S) 2 "Connection sequence), the C-terminus of the antibody VH or VL is connected to the Titin Ig-like 152 domain, the Obscurin Ig-like 1 domain or the Obscurin-like Ig-like 1 domain through the connection sequence. The specific domain optimization design is shown in Table 2.

[0463] Table 2. Amino acid mutations of T.0 chain, O.0 chain, and OL.0 chain

[0464]

[0465]

[0466] Note: The mutation mode O.1 in the Obscurin-O chain in the table, "A88C", means that the amino acid residue at position 88 of the O.0 (SEQ ID NO: 33) sequence is mutated from A to C; the mutation mode O.11, "C25S, C76S, A88C+Obscurin_DQPQF", means that the O.0 (SEQ ID NO: 33) sequence is subjected to C25S, C76S, A88C amino acid mutations, and 5 amino acids "DQPQF" are added to the N-terminus. The same applies to the others.

[0467] The sequences of Titin-T chain, Obscurin-O chain, and Obscurin-like-O chain after partial amino acid mutations are as follows:

[0468] >T.1 (T.0 has mutations of C25S, C39T, A8C)

[0469]

[0470] >T.2 (T.0 has mutations of C25S, C39T, V20C)

[0471]

[0472] >T.3 (T.0 has mutations of C25S, C39T, A26C)

[0473]

[0474] >T.4 (T.0 has mutations of C25S, C39T, T22C)

[0475]

[0476] >T.5 (T.0 has mutations of C25S, C39T, A8C; KAGIR added to the N-terminus)

[0477]

[0478]

[0479] >T.6 (T.0 has mutations of C25S, C39T, A8C; N-terminal addition (G 4 S) 1 Linker)

[0480]

[0481] >T.7 (T.0 has mutations of C25S, C39T, A8C; N-terminal addition (G 4 S) 2 Linker)

[0482]

[0483] >O.1 (O.0 has A88C mutation)

[0484]

[0485] >O.2 (O.0 has A3C mutation)

[0486]

[0487] >O.3 (O.0 has R9C mutation)

[0488]

[0489] >O.4 (O.0 has C25S, C76S, A88C mutations)

[0490]

[0491] >O.5 (O.0 has C25S, C76S, A3C mutations)

[0492]

[0493] >O.6 (O.0 has C25S, C76S, R9C mutations)

[0494]

[0495] >O.7 (O.0 has C25S, C76S, A88C, L7K, T62K mutations)

[0496]

[0497] >O.8 (O.0 has C25S, C76S, A88C, L7K, T62H mutations)

[0498]

[0499] >O.9 (O.0 has C25S, C76S, A88C, K11L, T62K mutations)

[0500]

[0501] >O.10 (O.0 has C25S, C76S, A88C, K11L, T62H mutations)

[0502]

[0503] >O.11 (O.0 has C25S, C76S, A88C mutations; DQPQF added to the N-terminus)

[0504]

[0505] >O.12 (O.0 has C25S, C76S, A88C, L7K, T62K mutations; DQPQF added to the N-terminus)

[0506]

[0507] >O.13 (O.0 has C25S, C76S, A88C, L7K, T62H mutations; DQPQF added to the N-terminus)

[0508]

[0509] >O.14 (O.0 has C25S, C76S, A88C, L7R, T62K mutations; DQPQF added to the N-terminus)

[0510]

[0511] >O.15 (O.0 has C25S, C76S, A88C, L7R, T62H mutations; DQPQF added to the N-terminus)

[0512]

[0513] >O.16 (O.0 has C25S, C76S, A88C mutations; N-terminal addition (G 4 S) 1 Linker)

[0514]

[0515] >O.17 (O.0 has C25S, C76S, A88C mutations; N-terminal addition (G 4 S) 2 Linker)

[0516]

[0517]

[0518] >OL.1 (OL.0 has C6E, V74C mutations)

[0519]

[0520] >OL.2 (OL.0 has C6E, G84C mutations)

[0521]

[0522] >OL.3 (OL.0 has C6E, A86C mutations)

[0523]

[0524] >OL.4 (OL.0 has C6E, C26S, C77S, V74C mutations)

[0525]

[0526] >OL.5 (OL.0 has C6E, C26S, C77S, G84C mutations)

[0527]

[0528] >OL.6 (OL.0 has C6E, C26S, C77S, A86C mutations)

[0529]

[0530] The above-mentioned mutated or structurally modified Titin-T chain, Obscurin-O chain, and Obscurin-like-O chain were used to construct various antibodies with replaced CH1 / CL, and the binding activity of each optimized mutant antibody to the corresponding antigen was detected by the method of Test Example 4 disclosed herein. The experimental results are shown in Table 3. The results show that the antibody maintains good antigen binding activity after disulfide bond modification.

[0531] Table 3. Antibody affinity after CH1 / CL domain modification

[0532]

[0533]

[0534] Note: For example, the antibody "F5" in the table indicates that the heavy chain CH1 of the F0 antibody is replaced by the T.1 chain (SEQ ID NO: 35), and the light chain CL is replaced by the O.1 chain (SEQ ID NO: 42), and the other parts remain the same as F0, and the same applies to the others.

[0535] In addition, the above-mentioned mutated or structurally modified Titin-T chain and Obscurin-O chain were used to construct antibodies with CH1 / CL replaced, and the functional activities of other antibodies with CH1 / CL replaced were detected by the methods of Test Example 2 and Test Example 4 disclosed herein. The experimental results are shown in Table 4, which show that after CH1 / CL was replaced, the antibody still has good antigen binding activity and the antibody purity SEC (%) is high.

[0536] Table 4. Purity and binding activity test results of antibodies after CH1 / CL domain modification

[0537]

[0538]

[0539] Note: For example, the antibody "F16" in the table indicates that the heavy chain CH1 of the F0 antibody is replaced by the T.5 chain (SEQ ID NO: 39), the light chain CL is replaced by the O.4 chain (SEQ ID NO: 45), and the other parts remain the same as F0, and the same applies to the others.

[0540] In addition, other amino acids in the titin Ig-like 152 domain and the obscurin Ig-like 1 domain were mutated. The specific amino acid mutation designs are shown in Table 5.

[0541] Table 5. Amino acid mutation design of T.1 chain / O.9 chain

[0542]

[0543] Note: In the table, for example, T.8 represents the Titin-T chain obtained by subjecting the T.1 (SEQ ID NO: 35) sequence to amino acid mutations M66S and T77S; O.24 represents the Obscurin-O chain obtained by subjecting O.9 (SEQ ID NO: 50) to amino acid mutations A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E and D94G, then adding the "DQPQF" sequence to the N-terminus, and finally adding the "GGGGS" linker sequence to the N-terminus, and the others are similar.

[0544] The mutant sequences of the T.1 chain and the O.9 chain are as follows:

[0545] >T.8 (T.1 has M66S, T77S mutations)

[0546]

[0547] >T.9 (T.1 has M66K, K70R, S79T, G81R mutations)

[0548]

[0549] >T.10 (T.1 has P3W, S11I, I13L, T22M, N82M mutations)

[0550]

[0551] >T.11 (T.1 has S11I, M66K, S79T, G81R mutations)

[0552]

[0553] >T.12 (T.1 has G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, L75V, E83D, F84L mutations)

[0554]

[0555] >T.13 (T.1 with Q47E, Q49G, N56S, D58E, L75V mutations)

[0556]

[0557] >T.14 (T.1 with N56S, D58E, L75V mutations)

[0558]

[0559] >T.15 (T.1 has N56S, D58E, M66S, T77S mutations)

[0560]

[0561] >T.16(T.1 has S11I, M66K, S79T, G81R mutations+(G 4 S) 1 Connection sequence)

[0562]

[0563] >T.17 (T.1 with N56S, D58E, M66S, T77S mutations, +KAGIR)

[0564]

[0565]

[0566] >T.18(T.1 has N56S, D58E, M66S, T77S mutations, +KAGIR, +(G 4 S) 1 Connection sequence)

[0567]

[0568] >T.19(T.1 has N56S, D58E, M66S, T77S mutations, +(G 4 S) 1 Connection sequence)

[0569]

[0570] >O.18 (O.9 has L11K, A12S, F13Y, V14T, T22S mutations)

[0571]

[0572] >O.19 (O.9 has G2E, V17E, N30D, T32P, Q34E, S36T, V44I, A45T, L58V, K62E, A67Q, G69S, A97G mutations)

[0573]

[0574] >O.20 (O.9 has D20L, T22M, A53L mutations)

[0575]

[0576] >O.21 (O.9 has Q41K, A45T, A67Q, G69S, V89L mutations)

[0577]

[0578] >O.22 (O.9 has Q42L, A45T, A67T, G69S, Q92E, D94G mutations)

[0579]

[0580] >O.23 (O.9 has A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E, D94G mutations)

[0581]

[0582] >O.24 (O.9 with Q41K, A45T, A67Q, G69S, V89L mutations; +(G4S)1 junction sequence)

[0583]

[0584] >O.25 (O.9 has A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E, D94G mutations, +(G4S)1 junction sequence)

[0585]

[0586] >O.26 (O.9 has A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E, D94G mutations; +DQPQF)

[0587]

[0588] >O.27 (O.9 has A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E, D94G mutations; +DQPQF; and +(G4S)1 junction sequence)

[0589]

[0590] The above-mentioned mutated or structurally modified Titin-T chain and Obscurin-O chain were used to construct antibodies with CH1 / CL replaced, and the antibodies with CH1 / CL replaced were tested by the method of Test Example 4 disclosed herein, and the experimental results are shown in Table 6. The results show that after CH1 / CL was replaced by the optimized Titin-T chain and Obscurin-O chain, the antibody still maintained good antigen binding activity.

[0591] Table 6. Results of antibody binding experiments with corresponding antigens after CH1 / CL was replaced

[0592]

[0593]

[0594] Note: For example, antibody "B1" in the table indicates that the heavy chain CH1 of B0 antibody is replaced by T.1 chain (SEQ ID NO: 35), the light chain CL is replaced by O.9 chain (SEQ ID NO: 50), and the other parts are the same as B0, and the obtained antibody is similar to that of B0.

[0595] In addition, the protein expression of the antibody after CH1 / CL was replaced was detected by the method of Test Example 1 of the present disclosure, and the experimental results are shown in Table 7. The results showed that after some amino acids of the titin Ig-like 152 domain and the obscurin Ig-like 1 domain were mutated, the expression of the antibody was greatly improved.

[0596] Table 7. Antibody expression after CH1 / CL domain modification

[0597]

[0598]

[0599] Example 4. Half-life of antibodies after CH1 / CL domain modification

[0600] In order to evaluate whether the stability of the antibody in the animal body is affected after the CH1 / CL of the antibody is replaced by Titin-T chain / Obscurin-O chain or Titin-T chain / Obscurin-like-O chain, we detected the half-life of the antibody in rats before and after the replacement. For example, we detected the half-life of antibody F20 after the CH1 / CL of F0 antibody was replaced by T.1 / O.9, and the half-life of antibody C3 after the CH1 / CL of C0 antibody was replaced by T.1 / O.9 in rats. The specific method is as follows:

[0601] The 3mpk antibody was administered to rats by intravenous injection, and 0.3 ml of whole blood was collected at 5 minutes, 8 hours, 1 day, 2 days, 4 days, 7 days, 10 days, 14 days, 21 days, and 28 days after administration, respectively. No anticoagulation was added, and the blood was placed at 4°C for 30 minutes, centrifuged at 1000g for 15 minutes, and the supernatant (serum) was placed in an EP tube and stored at -80°C. The antibody drug concentration at each time point was detected by sandwich ELISA, that is, the corresponding antigen was coated on the ELISA plate, incubated at 4 degrees overnight, washed with washing solution, and then added with blocking buffer and incubated at room temperature for 1-3 hours, washed with washing solution, and then 100 μl of standard or serum sample to be tested was added and incubated at 37°C for 3 hours, washed with washing solution, and the secondary antibody Anti-Human IgG FC (HRP) mouse preadsorbed (Abcam, product number ab98624, 1:10000 dilution) was added and incubated at 37°C for 1-1.5h, washed with wash buffer, and TMB was added and incubated at room temperature in the dark for 10 minutes, then the stop solution was added and the OD450 value was read.

[0602] The experimental results are shown in Table 8, which show that after the CH1 / CL of the antibody was replaced with Titin-T chain / Obscurin-O chain, the antibody still retained the half-life of the original antibody in rats, indicating that the antibody after CH1 / CL was replaced has good stability in vivo like the original antibody.

[0603] Table 8. Half-life of antibodies with replaced CH1 / CL domains

[0604] Antibody Name Half-life in rats (3mpk) T1 / 2 (days) F0 13.3±1.0 F20 12.8±0.3 C0 17.3±2.2 C3 15.4±4.1

[0605] Example 5. Construction and detection of bispecific antibodies

[0606] The antibody that binds to the first antigen and the antibody that binds to the second antigen are bridged by PCR to construct a bispecific antibody. Exemplarily, we constructed a variety of bispecific antibodies.

[0607] 1. Construction of bispecific antibodies

[0608] First, we constructed the DI-1 bispecific antibody, which is an IgG-like bispecific antibody composed of a heavy chain (knob modified in the Fc region) and a light chain of the D0 antibody, and a heavy chain (hole modified in the Fc region) and a light chain of the modified antibody in which the CH1 / CL of the I0 antibody was replaced by the titin-T chain / obscurin-O chain. The schematic diagram of its structure is shown in the attached figure. Figure 5 , the sequence is as follows:

[0609] Amino acid sequence of DI-1 chain 1 (DI-1-H1):

[0610]

[0611] Note: In the sequence, the bold part is VH of D0, the single underline part is CH1, the dot-dash part is CH2, and the italic part is CH3.

[0612] Amino acid sequence of DI-1 chain 2 (DI-1-L1):

[0613]

[0614] Note: In the sequence, the bold part is the VL of D0, and the single underlined part is the D0 light chain constant region CL.

[0615] Amino acid sequence of DI-1 chain 3 (DI-1-H2):

[0616]

[0617] Note: In the sequence, the bold part is VH of I0, the single underlined part is T.16, the dot-dash part is CH2, and the italic part is CH3;

[0618] Amino acid sequence of DI-1 chain 4 (DI-1-L2):

[0619]

[0620] Note: In the sequence, the bold part is VL of I0, and the single underlined part is O.24.

[0621] In addition, an IgG-like bispecific antibody constructed by B0 or ​​a CH1 / CL structure-modified antibody of B0 and U0 or a CH1 / CL structure-modified antibody of U0 was constructed (exemplary, a schematic diagram of the BU5 structure is shown in the attached Figure 8 ), the sequences of the four chains of the obtained bispecific antibody are as shown in Table 9:

[0622] Table 9. IgG-like bispecific antibody sequence list

[0623]

[0624]

[0625]

[0626]

[0627] Note: In the sequence, the bold part is the variable region sequence, the single underlined part is CH1 or titin-T chain, the dot-dash part is CH2, the italic part is CH3, and the double underlined part is CL or obscurin-O chain.

[0628] In addition, the FA-1 bispecific antibody was constructed. The FA-1 bispecific antibody is an IgG-like bispecific antibody composed of a heavy chain (knob modified in the Fc region) and a light chain of the A0 antibody, and a heavy chain (hole modified in the Fc region, CH1 replaced by T.16) and a light chain (CL replaced by O.24) of the F0 antibody. The sequences of the four chains of FA-1 are shown in Table 10:

[0629] Table 10. FA-1 bispecific antibody sequence list

[0630]

[0631] Note: In the sequence, the bold part is the variable region sequence, the single underlined part is CH1 or titin-T chain, the dot-dash part is CH2, the italic part is CH3, and the double underlined part is CL or obscurin-O chain.

[0632] 2. Detection of bispecific antibodies

[0633] DI-1 was detected by the method of Test Example 3 of the present disclosure. The four chains of DI-1 were co-transfected into cells for expression, and then mass spectrometry analysis was performed. The experimental results are shown in Table 11 and Attached Figure 6A-6C , mass spectrometry analysis results did not detect homodimers and mismatched molecules, indicating that DI-1 was assembled correctly.

[0634] Table 11. DI-1 mass spectrometry data

[0635]

[0636] In addition, the expression of BU5 was detected by the methods of Test Example 3 and Test Example 2 of the present disclosure. First, the four chains of BU5 were co-transfected into cells to express the bispecific antibody, and B0 and U0 were used as controls. Then, the purity and mass spectrometry analysis of the expression product were performed. The experimental results are shown in Table 12 and Attached 9A to 9C The experimental results showed that the bispecific antibody BU5 was successfully expressed, and the four chains of BU5 were successfully assembled into the target molecule without mismatch. The bispecific molecule BU5 was highly pure, with a SEC% of 88%.

[0637] Table 12. BU5 mass spectrometry analysis results

[0638] Antibody Mass spectrometry analysis Control B0 √ Comparison with U0 √ BU5 √

[0639] Note: In the table, “√” indicates a correct pairing

[0640] In addition, the antibody purity and antigen binding activity of the constructed BU1-BU4 bispecific antibody were detected by the methods of Test Example 2 and Test Example 4 disclosed herein. The experimental results are shown in Table 13. The experimental results show that the bispecific antibody after CH1 / CL was replaced still maintains good antigen binding activity and has high antibody purity.

[0641] Table 13. Experimental results of bispecific antibody antigen binding activity and purity

[0642]

[0643] Test Case

[0644] Test Example 1: Antibody Expression Level Test Method

[0645] HEK293E cells were transfected with expression plasmids of monoclonal antibodies or bispecific antibodies, and the expression supernatant was collected after 6 days and centrifuged at high speed to remove impurities. The supernatant was purified using a Protein A column (GE Healthcare). The column was rinsed with PBS until the A280 reading dropped to the baseline, and then the column was rinsed with 100mM acetate buffer (pH3.5) and neutralized with 1M Tris-HCl, pH8.0. The expression amount of the antibody was quantified by the final purified antibody amount / expression volume.

[0646] Test Example 2: Antibody Purity Detection Method

[0647] SEC-HPLC was used to monitor the purity of the antibody. The test was performed according to the instrument operating instructions, using a Waterse2695 chromatograph, a Waters Xbridge BEH 200A SEC column, PBS (pH adjusted to 6.8 with dilute hydrochloric acid), 100 μg of protein was injected, isocratic elution, and the flow rate was 0.5 mL / min. The purity of the antibody is the percentage of the peak area of ​​the main peak to the total peak area (SEC (%)).

[0648] Test Example 3: Antibody Mass Spectrometry Detection Method

[0649] (I) Sample preparation:

[0650] 1. Determination of the intact molecular weight of desugared antibody: Take 30μg of the expressed antibody, freeze-dry it, add 10μl 8M Gua-HCl, and denature it in a 70℃ water bath for 10min. Add 90μl distilled water, take 30μl and add 0.8μL PNGase F (peptide N-glycosidase F), incubate it in a 37℃ water bath for 2h, and take 0.5μg for the determination of the intact molecular weight of desugared antibody.

[0651] 2. Desugar reduction molecular weight determination: Take 30μg of the expressed antibody, freeze-dry it, add 10μl 8M Gua-HCl, and denature it in a 70℃ water bath for 10min. Add 90μl distilled water, take 30μl and add 0.8μL PNGase F (peptide N-glycosidase F), and incubate it in a 37℃ water bath for 2hr. Then add 2μl 0.025M DTT, reduce it in a 70℃ water bath for 10min, and take 0.5μg for desugar reduction molecular weight determination.

[0652] (II) Chromatography-mass spectrometry conditions:

[0653] Chromatographic conditions:

[0654] Chromatographic column: Poroshell 300SB-C8 5um 2.1*75mm

[0655] Mobile phase: A: 0.1% HCOOH / H2O B: 0.1% HCOOH / CAN

[0656] Column temperature: 75°C

[0657] gradient:

[0658]

[0659] Mass spectrometry conditions:

[0660] Mass spectrometer: Agilent 6530 Q-TOF LC-MS

[0661] Ionization mode ESI

[0662] Acquisition mode: 1 GHz (mass range 500-5000 m / z)

[0663] Drying gas temperature: 325℃

[0664] Drying gas flow: 10L / min

[0665] Atomizer: 40psi

[0666] Sheath gas temperature: 350℃

[0667] Sheath gas flow rate: 12L / min

[0668] Spray voltage: 500V

[0669] Capillary voltage: 3,500V

[0670] Cracking voltage: 200V

[0671] Skimmer voltage: 65V

[0672] Rf voltage: 7500V

[0673] The test antibody was subjected to mass spectrometry analysis, and the experimental results showed that after CH1 / CL was replaced by Titin-T / Obscurin-O, the antibody remained correctly assembled.

[0674] Test Example 4: Antibody Binding Activity Detection Method

[0675] For antibodies targeting membrane proteins, the antigen binding activity can be detected by FACS. For example, C0, N0, F0, V0, S0, and their CH1 / CL structure modified antibodies can be detected by FACS. In a 96-well U-bottom plate (corning, 3795), cells (2×106 cells / ml, 90 μl) resuspended in FACS buffer (98% PBS, 2% FBS) were added, and 10 μl of gradient diluted antibodies were added, incubated at 4°C for 1 hour, washed twice with FACS buffer, and then Alexa Fluor488 sheep anti-human IgG (H+L) (invitrogen, Cat#2015982, 1:1000 dilution) was added to each well, incubated at 4°C for one hour, washed twice, and resuspended with FACS buffer, and finally the fluorescence signal value was read with FACS CantoII (BD). Finally, FlowJo 7.6 and Graphpad Prism 5 were used to process and analyze the data.

[0676] For antibodies whose targets are soluble proteins, the binding activity of the antibodies to soluble proteins is detected by ELISA. For example, D0, I0, B0, U0, H0, R0, J0, and CH1 / CL structure-modified antibodies can be detected by ELISA. The method is as follows: dilute the protein to 1 μg / ml with PBS (Source Bio, B320) buffer at pH 7.4, add 100 μl / well to a 96-well ELISA plate (Corning, 9018), and incubate overnight at 4°C. After discarding the liquid, add 300 μl of 5% skim milk (BD, 232100) diluted with PBS to each well for blocking, and incubate at 37°C for 2 hours. After the blocking is completed, discard the blocking solution, wash the plate 3 times with PBST buffer (pH 7.4 PBS containing 0.1% tween-20), add 100 μl of gradient diluted antibody solution to each well, and incubate at 37°C for 1 hour. After the incubation, the plate was washed 3 times with PBST, 100 μl mouse anti-human IgG (H+L) (Jackson ImmunoResearch, 209-035-088, 1:8000 dilution) was added to each well, and incubated at 37°C for 1 hour. After washing the plate 3 times with PBST, 100 μl TMB color substrate (KPL, 5120-0077) was added to each well, incubated at room temperature for 10-15 min, 50 μl 1M H2SO4 was added to each well to terminate the reaction, and the absorbance at 450 nm was read with an enzyme reader, and the binding curve of the antibody and antigen was fitted with software to calculate the EC50 value.

[0677] The corresponding antigens of the antibodies in this test example are as follows: the antigen bound by D0 and its CH1 / CL structure-modified antibody is hRANKL (purchased from Sino biological, 11682-HNCH); the antigen bound by I0 and its CH1 / CL structure-modified antibody is hNGF (purchased from Sino biological, 11050-HNAC); the antigen bound by B0 and its CH1 / CL structure-modified antibody is hBAFF (purchased from Sino biological, 10056-HNCH); the antigen bound by U0 and its CH1 / CL structure-modified antibody is hP40 (purchased from Sinobiological, 10052-H08H); the antigen bound by H0, R0, and their CH1 / CL structure-modified antibody is hIL-5 (purchased from R&D systems, 205-IL-025 / CF); the antigen bound by J0 and its CH1 / CL structure-modified antibody is hTSLP (purchased from Sinobiol ogical, 16135-H08H); C0, N0, and the antigen bound by their CH1 / CL structure-modified antibodies is CEA (MKN45 cells overexpressing CEA (purchased from Nanjing Kebai, CBP60488)); F0, V0, S0, and the antigen bound by their CH1 / CL structure-modified antibodies is B7H3 (CT26-B7H3 recombinant cell line overexpressing B7H3 (CT26 is from the cell bank of the Chinese Academy of Sciences, and the B7H3 sequence can be found in ID: XP_005254757.1).

[0678] Test Example 5: CH1 / CL structural modified antibody mismatch reduction experimental method

[0679] 1. Expression detection method of different antibody light / heavy chain cross-mismatch molecules

[0680] This experiment analyzed the expression of different light / heavy chain antibody pairs to verify that replacement of CH1 / CL with titin-T chain / obscurin-O chain or titin-T chain / obscurin-like-O chain can effectively reduce the occurrence of heavy / light chain mispairing. Specifically, when the cells were transfected to express antibodies, the heavy / light chains of D0 and I0 were exchanged (i.e., I / D-1 (D0 heavy chain + I0 light chain); I / D-2 (I0 heavy chain + D0 light chain) to detect whether wild-type CH1 and CL would form cross-mismatched molecules; at the same time, the heavy and light chains of the structurally modified antibodies D3 (D0 heavy chain CH1 replaced by T.11, light chain CL replaced by O.21) and I3 (I0 heavy chain CH1 replaced by T.11, light chain CL replaced by O.21) after CH1 / CL of D0 and I0 were replaced by Titin-T chain / Obscurin-O chain were exchanged to construct mismatched molecules: I / D-3 (D0 heavy chain + I3 light chain), I / D-4 (D3 heavy chain + I0 light chain), I / D-5 (I0 heavy chain + I3 light chain), and I / D-6 (I3 heavy chain + D0 light chain). The schematic diagram of the constructed antibody structure is shown in the attached figure. Figure 7 .

[0681] The antibody expression amount was detected by the method of Test Example 1, and the expression product was subjected to mass spectrometry analysis by the method of Test Example 3 to detect whether mismatched molecules would be formed. The experimental results are shown in Table 14. The experimental results show that when D0 heavy chain + I0 light chain, or I0 heavy chain + D0 light chain, are co-expressed, a complete IgG molecule (150 kDa) can be formed, and the expression amount is very high, reaching 74.4 mg / L and 73.8 mg / L respectively, and the LC-MS results prove that the obtained protein is a mismatched IgG molecule, which indicates that if CH1-CL is not modified or replaced, the four different heavy and light chains of the bispecific antibody are co-expressed, and a large number of light / heavy chain mismatched molecules will be formed. After replacing CH1 / CL with titin-T chain / obscurin-O chain, no target molecule (150 kDa) was produced in the four forms of cross-mismatched expression: I / D-3 (D0 heavy chain + I3 light chain), I / D-4 (D3 heavy chain + I0 light chain), I / D-5 (I0 heavy chain + I3 light chain), and I / D-6 (I3 heavy chain + D0 light chain). Except for a small number of erroneous molecules with two heavy chains formed by the combination of D3 heavy chain + I0 light chain (molecular weight of 100 kDa), no mismatched molecules were produced in the other three forms, which indicates that the modified non-homologous pairing will not form mismatched molecules in the form of IgG structure. Therefore, replacing CH1-CL with titin-T chain / obscurin-O chain will effectively avoid or reduce the formation of non-homologous cross-matched molecules between the light / heavy chains of IgG-like bispecific antibodies.

[0682] Table 14. Expression and mass spectrometry analysis of antibodies with different light / heavy chain cross-pairings

[0683]

[0684]

[0685] Note: In the table, “√” indicates that the mismatch molecule was detected, and “×” indicates that the mismatch molecule was not detected.

[0686] 2. Detection method for light / heavy chain mismatch expression of bispecific antibodies

[0687] In order to verify that there will be no mispairing or reduced mispairing after CH1 / CL is replaced by Titin-T chain / Obscurin-O chain, this test example designed three forms of light / heavy chain cross-pairing expression, namely, using two different heavy chains and one identical VL-CL light chain to express bispecific antibodies, or replacing the light chain of CL with two different heavy chains and one identical Obscurin-O chain for expression, or using normal expression of two different heavy chains and two different light chains as a control (see Table 15 for specific pairings).

[0688] The expression product was then subjected to mass spectrometry analysis (method as shown in Test Example 3 of this disclosure), and the antibody purity SEC was detected (method as shown in Test 2 of this disclosure). The experimental results are shown in Table 15, which show that the correct molecule will be formed only when the light chain replaced by the Obscurin-O chain and the light chain not replaced by CL are added together, while the correct target molecule was not found in the cross-pairing of only one light chain not replaced by CL or only one light chain replaced by the Obscurin-O chain. This shows that the light chain replaced by the Obscurin-O chain will more easily pair and bind to the heavy chain replaced by the Titin-T chain in CH1 to form a molecule, and will not cross-mispair with the heavy chain replaced by the Titin-T chain in CH1; the light chain not replaced by the Obscurin-O chain is more likely to pair and bind to the heavy chain not replaced by the Titin-T chain in CH1, and will not bind to the heavy chain replaced by the Titin-T chain in CH1.

[0689] Table 15. Detection results of bispecific antibody light / heavy chain mismatch

[0690]

[0691]

[0692] Remarks (in the table, “√” indicates that the four-chain paired molecule was detected, and “--” indicates that the four-chain paired molecule was not detected).

[0693] Test Example 6: Affinity Detection of Bispecific Antibodies and Antigens

[0694] The affinity between the antibody to be tested and the antigen protein was determined using a Biacore T200 (GE) instrument. According to the method in the instructions of the human antibody capture kit (GE, Cat#BR-1008-39), the antibody to be tested was captured by affinity using a Protein A biosensor chip (Cat.#29127556, GE), and then a series of soluble antigens with a concentration gradient flowed over the chip surface. The reaction signal was detected in real time using a Biacore T200 instrument to obtain the binding and dissociation curves. After each experimental cycle of dissociation was completed, the biosensor chip was washed and regenerated with a glycine-hydrochloric acid regeneration solution (pH 1.5 Cat.#BR-1003-54, GE). The data obtained from the experiment were fitted with the (1:1) Langmuir model using BIAevaluation version 4.1, GE software, to obtain the affinity value. The experimental results are shown in Table 16.

[0695] The experimental results show that the structurally modified bispecific antibody disclosed in the present invention fully retains the affinity of the two parent monoclonal antibodies to its antigen. In this experiment, the antigens hRANKL (purchased from Sino biological, 11682-HNCH), hNGF (purchased from Sino biological, 11050-HNAC), hBAFF (purchased from Sino biological, 10056-HNCH), hP40 (purchased from Sino biological, 10052-H08H), hB7H3 (prepared in the laboratory, see SEQ ID NO: 111 for sequence), hCD3 antigen (prepared in the laboratory, a heterodimer composed of the δ subunit (sequence see SEQ ID NO: 112) and the ε subunit (sequence see SEQ ID NO: 113) of hCD3).

[0696] Table 16. Bispecific antibody affinity test results

[0697]

[0698]

[0699] Test Example 7: Experiment of simultaneous binding of CH1-CL bispecific antibodies to two target antigens

[0700] By using the Biacore T200 (GE) instrument to measure the affinity of the test antibody and the antigen protein, it is verified that the bispecific antibody with CH1-CL structure modification disclosed in the present invention can bind to two target antigens at the same time. The specific experimental steps are: using Protein A biosensor chip (Cat.#29127556, GE) to capture antibody BU5 with affinity, then flowing the first antigen molecule hP40 (purchased from Sino biological, 10052-H08H) of the bispecific antibody to saturation on the chip surface, and then injecting a certain concentration of the second antigen molecule hBAFF (purchased from Sino biological, 10056-HNCH), and using the Biacore T200 instrument to detect the reaction signal in real time to obtain the binding and dissociation curves. After each experimental cycle of dissociation is completed, the biosensor chip is washed and regenerated with a glycine-hydrochloric acid regeneration solution (pH 1.5Cat.#BR-1003-54, GE), and the data fitting model adopts BIAevaluationversion 4.1, and the GE software is fitted with a (1:1) Langmuir model. Then, the antibody BU5 was affinity captured by Protein A biosensor chip (Cat.#29127556, GE), and then the first antigen molecule hP40 (purchased from Sino biological, 10052-H08H) of the bispecific antibody flowed over the chip surface until saturation, and then a certain concentration of the second antigen molecule hBAFF (purchased from Sino biological, 10056-HNCH) was injected, and the reaction signal was detected in real time by Biacore T200 instrument to obtain the binding and dissociation curves. After the dissociation was completed in each experimental cycle, the biosensor chip was washed and regenerated with glycine-hydrochloric acid regeneration solution (pH 1.5 Cat.#BR-1003-54, GE), and the data fitting model was based on BIAevaluation version 4.1, and the GE software was fitted with a (1:1) Langmuir model.

[0701] The experimental results are shown in Table 17, which show that after the bispecific antibody BU5 reaches saturation in binding to the antigen hP40, it can continue to bind to the antigen hBAFF, and its ability to bind to hBaFF is comparable to that of the monoclonal antibody B0. Similarly, after the bispecific antibody BU5 reaches saturation in binding to the antigen hBAFF, it can continue to bind to the antigen hP40, and its ability to bind to hP40 is comparable to that of U0. This shows that the bispecific antibody disclosed herein, in which CH1 / CL is replaced by Titin-T chain / Obscurin-O chain, has dual-target characteristics and can bind to two target antigens at the same time.

[0702] Table 17. Antibody affinity test results

[0703]

[0704]

[0705] Test Example 8: DI-1 bispecific antibody osteoclast differentiation experiment

[0706] Raw264.7 cells (Chinese Academy of Sciences Cell Bank, SCSP-5036) were digested and resuspended for counting, then plated in a 24-well cell culture plate (Corning, 3524) and cultured overnight in a 37°C cell culture incubator. The next day, the antibody solution was diluted at different concentrations and mixed evenly with RANKL (Sino biological, 11682-HNCH) and added to the cell culture plate. The final concentration of RANKL was 50 ng / ml, and the cells were cultured at 37°C. After 96 hours, the solution in the 24-well plate was removed, 100 μl of cell lysis solution (Biyuntian, P0013J) was added to each well, and the mixture was mixed by pipetting. The lysate was transferred to an EP tube, centrifuged at 12000g for 5 minutes, and the supernatant was tested with a tartrate-resistant acid phosphatase detection kit (Biyuntian, P0332) according to the instructions, and the absorbance at 405 nm was read with an enzyme reader. The detection values ​​were fitted into a curve using software, and the IC50 value was calculated. The experimental results are shown in the attached Fig.10 The experimental results showed that the bispecific antibody DI-1 maintained good activity after CH1 / CL was replaced and effectively inhibited osteoclast differentiation.

[0707] Test Example 9: DI-1 bispecific antibody TF1 cell proliferation assay

[0708] The activity of the antibody at the cellular level was evaluated by the NGF-induced TF-1 cell (ATCC, CRL-2003) proliferation experiment. The experimental method is as follows: digest and collect TF1 cells, count after resuspending, plate in a 96-well plate (Corning, 3903), and culture in a 37°C incubator overnight. The next day, the antibody solution was diluted at different concentrations and mixed evenly with NGF (Sino biological, 11050-HNAC) and added to the cell culture plate. The final concentration of NGF was 10 ng / ml, and the cells were placed in the incubator for continued culture. After 72 hours, the cell culture plate was taken out, 50 μl Cell-titer Glo (Promega, G755B) detection solution was added to each well, incubated on a shaker for 10 minutes, and allowed to stand at room temperature for 10 minutes. The luminescent signal was detected using an enzyme reader (PerkinElmer, Victor3). The detected signal value was fitted into a curve graph using software, and the IC50 value was calculated. The experimental results are attached. Fig.11 The experimental results showed that the bispecific antibody DI-1 had good activity after CH1 / CL was replaced.

[0709] Test Example 10: Detection of light and heavy chain mismatch after bispecific antibody CH1 / CL is replaced by different domains

[0710] The following experiments analyze the mismatch of the light and heavy chains of bispecific antibodies when CH1 / CL is replaced by titin-T chain / obscurin-O chain or by TCRα / TCRβ. The specific experiments are as follows:

[0711] 1. Light and heavy chain mismatch experiment when four chains of bispecific antibodies are co-expressed

[0712] The CH1 / CL of H0 or J1 was replaced by TCRα / TCRβ to construct bispecific antibodies HJ-1 and HJ-2 consisting of four chains; the CH1 / CL of H0 or J1 was replaced by Titin-T chain / Obscurin-O chain to construct bispecific antibodies HJ-3 and HJ-4 consisting of four chains. The schematic diagram of the bispecific antibody structure is shown in the attached Fig.12 , the full length sequence of the bispecific antibody is shown in Table 18:

[0713] Table 18. Bispecific antibody sequence list

[0714]

[0715]

[0716]

[0717]

[0718] Note: In the sequence, the bold part is the replaced part, the dashed part is the constant region, and the single underlined part is the variable region.

[0719] J1 heavy chain:

[0720]

[0721] J1 light chain:

[0722]

[0723] The four chains of HJ-1, HJ-2, HJ-3 and HJ-4 were co-transfected and expressed respectively, and then the expression products were subjected to mass spectrometry analysis (the method is shown in Test Example 3 of this disclosure) to detect whether there are light and heavy chain mismatch molecules. The experimental results are shown in the attached FIG. 13A to FIG. 13D And Table 19.

[0724] Table 19. Results of mass spectrometry analysis of bispecific antibody expression

[0725]

[0726]

[0727] Note: In the table, “√” indicates that the molecule was detected, “X” indicates that the molecule was not detected, “HJ(1+2+3+4)” indicates a bispecific antibody formed by the four chains numbered 1, 2, 3 and 4 on its left side, “Mismatch molecule 1(1+2+3+3)” indicates mismatch molecule 1 formed by the four chains numbered 1, 2, 3 and 3 on its left side; “Mismatch molecule 2(1+2+4+4)” indicates mismatch molecule 2 formed by the four chains numbered 1, 2, 4 and 4 on its left side.

[0728] The experimental results show that when the four chains of the bispecific antibody replacing CH1 / CL with TCRβ / TCRα are co-transfected and expressed, the light and heavy chains will mismatch. However, the bispecific antibody replacing CH1 / CL with titin-T chain / obscurin-O chain has no mismatch between the light and heavy chains. This shows that the bispecific antibody replacing CH1 / CL with titin-T chain / obscurin-O chain disclosed in the present invention has an excellent ability to reduce the mismatch between the light and heavy chains.

[0729] Two, three-chain co-expression bispecific antibody experiment

[0730] This test uses three chains (1 heavy chain with CH1 replaced by TCRβ or Titin-T chain, 1 heavy chain with CH1 not replaced, and 1 wild-type light chain (VL-CL) with CL not replaced, see Table 18 for specific sequences) for co-transfection expression, and then performs mass spectrometry analysis on the expression product (see Test Example 3 of this disclosure for the method), detects antibody purity SEC (see Test 2 of this disclosure for the method), and verifies whether the wild-type light chain (VL-CL) will combine with the heavy chain with CH1 replaced by TCRβ or Titin-T chain to form a mismatched molecule. The experimental results are shown in the attached Fig.14A , Fig. 14B , Fig.15A , Fig. 15B and Table 20.

[0731] Table 20. Experimental results of three-chain co-expression bispecific antibody

[0732]

[0733]

[0734] Note: "√" in the table indicates that the molecule was detected, "X" indicates that the molecule was not detected, "Molecule (1+2+3)" indicates a molecule formed by the three chains numbered 1, 2, and 3 on its left side, and "Mismatched molecule (1+2+3+3)" indicates a mismatched molecule formed by the four chains numbered 1, 2, 3, and 3 on its left side.

[0735] The experimental results show that VL-CL easily binds to the heavy chain whose CH1 is replaced by TCRβ, thereby expressing a mismatched molecule with two identical light chains. However, the VL-CL light chain does not bind to the heavy chain whose CH1 is replaced by the Titin-T chain to form a mismatched molecule with two identical light chains, which indirectly indicates that compared with the bispecific antibody whose heavy chain CH1 is replaced by TCRβ, the bispecific antibody whose Titin-T chain replaces the heavy chain CH1 disclosed in the present invention has a better ability to reduce light and heavy chain mismatches. Sequence Listing <110> Jiangsu Hengrui Medicine Co., Ltd. Shanghai Hengrui Medicine Co., Ltd. <120> Novel peptide complex <130> 702150CPCT <150> CN202010020878.7 <151> 2020-01-09 <160> 126 <170> SIPOSequenceListing 1.0 <210> 1 <211> 330 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> IgG1 heavy chain constant region <400> 1 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 225 230 235 240 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 2 <211> 330 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> knob-IgG1 heavy chain constant region <400> 2 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 3 <211> 330 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> hole - IgG1 heavy chain constant region <400> 3 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 4 <211> 107 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> kappa light chain constant region <400> 4 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 <210> 5 <211> 106 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> lambda light chain constant region <400> 5 Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 1 5 10 15 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 20 25 30 Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 35 40 45 Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn 50 55 60 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 65 70 75 80 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 85 90 95 Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 100 105 <210> 6 <211> 119 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <221> DOMAIN <223> F0 antibody VH amino acid sequence <400> 6 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Thr 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Ser 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Ala Arg Leu Tyr Ala Ser Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Ala Leu Val Thr Val Ser Ser 115 <210> 7 <211> 110 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> F0 antibody VL amino acid sequence <400> 7 Asp Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Ser Thr Ser 20 25 30 His Tyr Pro Ser Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Met 35 40 45 Leu Ile Tyr Asn Thr Asn Thr Arg Ser Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala 65 70 75 80 Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Ala Ile His Val Asp Arg 85 90 95 Asp Ile Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 8 <211> 116 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> N0 antibody VH amino acid sequence <400> 8 Asp Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Ser Ser Leu Ser 20 25 30 Trp Met Ser Trp Leu Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Asn Gln Asp Gly Ser Glu Lys Asn Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Gln Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Leu Trp Thr Phe Asp Ser Trp Gly Gln Gly Thr Leu Leu 100 105 110 Thr Val Ser Pro 115 <210> 9 <211> 108 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> N0 antibody VL amino acid sequence <400> 9 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Ile Asn Asn Arg 20 25 30 Phe Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Ala Ala Ser Ser Arg Ala Thr Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Ala Glu Asp Phe Ala Met Tyr His Cys Gln Gln Tyr Gly Ser Phe Pro 85 90 95 Arg Thr Phe Gly Gln Gly Thr Met Val Asp Ile Lys 100 105 <210> 10 <211> 120 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VH amino acid sequence of S0 antibody <400> 10 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly Phe Val Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Thr Pro Glu Arg Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Gly Ile Thr Tyr Ala Pro Ser Thr Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala His Tyr Phe Gly Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 11 <211> 107 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <221> DOMAIN <223> S0 antibodyVL amino acid sequence <400> 11 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Phe Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Val 35 40 45 Tyr Asn Thr Arg Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 12 <211> 121 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VH amino acid sequence of V0 antibody <400> 12 Gln Val Gln Leu Gln Gln Ser Ala Ala Glu Leu Ala Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Thr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Asn Ser Arg Asn Thr Asp Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Glu Thr Thr Leu Thr Ala Asp Arg Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ile Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Tyr Ser Gly Ser Thr Pro Tyr Trp Tyr Phe Asp Val Trp Gly 100 105 110 Ala Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 13 <211> 106 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> V0 antibody VL amino acid sequence <400> 13 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 Asn Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr 35 40 45 Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Val Ser 50 55 60 Val Ser Gly Thr Ser His Ser Leu Thr Ile Ser Arg Val Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr 85 90 95 Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 14 <211> 120 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VH Amino Acid Sequence of J0 Antibody <400> 14 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly His Ile Lys Ser Lys Thr Asp Ala Gly Thr Thr Asp Tyr Ala Ala 50 55 60 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Ile Tyr Tyr Tyr Ala Phe Asp Ser Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 15 <211> 107 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VL Amino Acid Sequence of J0 Antibody <400> 15 Ser Tyr Glu Leu Thr Gln Pro Leu Ser Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Ala Arg Ile Thr Cys Ser Gly Asp Asn Ile Gly Ser Lys Tyr Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Asp Asn Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Ala Gln Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Ala Asp Trp Val Asp Phe Tyr 85 90 95 Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 16 <211> 118 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VH Amino Acid Sequence of H0 Antibody <400> 16 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Tyr 20 25 30 Tyr Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Thr Ser Ile Ser Tyr Glu Gly Asp Ile Thr Tyr Tyr Gly Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Ser Gln Thr Leu Arg Glu Ser Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 17 <211> 107 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VL Amino Acid Sequence of H0 Antibody <400> 17 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ala Asn Tyr 20 25 30 Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Thr Ser Asn Leu Glu Val Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Lys Glu Phe Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 18 <211> 116 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VH Amino Acid Sequence of R0 Antibody <400> 18 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Leu Ser Leu Thr Ser Asn 20 25 30 Ser Val Asn Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Leu Ile Trp Ser Asn Gly Asp Thr Asp Tyr Asn Ser Ala Ile Lys 50 55 60 Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Ser Thr Val Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Tyr Tyr Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 19 <211> 107 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <221> DOMAIN <223> R0 antibody VL amino acid sequence <400> 19 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Leu Ala Ser Glu Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala Asn Ser Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Ala Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Lys Phe Pro Asn 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Val Lys 100 105 <210> 20 <211> 123 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VH Amino Acid Sequence of B0 Antibody <400> 20 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Arg Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Asn Asn 20 25 30 Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Met Phe Gly Thr Ala Lys Tyr Ser Gln Asn Phe 50 55 60 Gln Gly Arg Val Ala Ile Thr Ala Asp Glu Ser Thr Gly Thr Ala Ser 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Arg Asp Leu Leu Leu Phe Pro His His Ala Leu Ser Pro 100 105 110 Trp Gly Arg Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 21 <211> 108 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VL amino acid sequence of B0 antibody <400> 21 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Val Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 <210> 22 <211> 119 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VH Amino Acid Sequence of U0 Antibody <400> 22 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Tyr 20 25 30 Trp Leu Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Asp Trp Ile 35 40 45 Gly Ile Met Ser Pro Val Asp Ser Asp Ile Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Met Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr 65 70 75 80 Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Arg Arg Pro Gly Gln Gly Tyr Phe Asp Phe Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 23 <211> 107 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> U0 antibody VL amino acid sequence <400> twenty three Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ile Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> twenty four <211> 122 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> D0 antibody VH amino acid sequence <400> twenty four Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Thr Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Pro Gly Thr Thr Val Ile Met Ser Trp Phe Asp Pro Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 25 <211> 108 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> D0 antibody VL amino acid sequence <400> 25 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Gly Arg 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Phe Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 26 <211> 121 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VH amino acid sequence of I0 antibody <400> 26 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ile Gly Tyr 20 25 30 Asp Leu Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Ile Ile Trp Gly Asp Gly Thr Thr Asp Tyr Asn Ser Ala Val Lys 50 55 60 Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Gly Tyr Trp Tyr Ala Thr Ser Tyr Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 27 <211> 107 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VL amino acid sequence of I0 antibody <400> 27 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asn 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Phe His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Glu His Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 28 <211> 117 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> VH Amino Acid Sequence of C0 Antibody <400> 28 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 His Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35 40 45 Gly Asp Ile Asn Pro Asp Ile Gly Gly Thr Ser Tyr Asn Gln Asn Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Asp Phe Asp Ser Phe Ala Asn Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 29 <211> 111 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> C0 antibody VL amino acid sequence <400> 29 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Glu Ser Val Ser Ile Ile 20 25 30 Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Glu Thr Gly Val Pro Asp 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Leu Gln Ser Arg 85 90 95 Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 30 <211> 104 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> IL6Ra.0 chain sequence <400> 30 Gly Ile Leu Gln Pro Asp Pro Pro Ala Asn Ile Thr Val Thr Ala Val 1 5 10 15 Ala Arg Asn Pro Arg Trp Leu Ser Val Thr Trp Gln Asp Pro His Ser 20 25 30 Trp Asn Ser Ser Phe Tyr Arg Leu Arg Phe Glu Leu Arg Tyr Arg Ala 35 40 45 Glu Arg Ser Lys Thr Phe Thr Thr Trp Met Val Lys Asp Leu Gln His 50 55 60 His Cys Val Ile His Asp Ala Trp Ser Gly Leu Arg His Val Val Gln 65 70 75 80 Leu Arg Ala Gln Glu Glu Phe Gly Gln Gly Glu Trp Ser Glu Trp Ser 85 90 95 Pro Glu Ala Met Gly Thr Pro Trp 100 <210> 31 <211> 108 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> IL6Rb.0 chain sequence <400> 31 Phe Asp Pro Val Tyr Lys Val Lys Pro Asn Pro Pro His Asn Leu Ser 1 5 10 15 Val Ile Asn Ser Glu Glu Leu Ser Ser Ile Leu Lys Leu Thr Trp Thr 20 25 30 Asn Pro Ser Ile Lys Ser Val Ile Ile Leu Lys Tyr Asn Ile Gln Tyr 35 40 45 Arg Thr Lys Asp Ala Ser Thr Trp Ser Gln Ile Pro Pro Glu Asp Thr 50 55 60 Ala Ser Thr Arg Ser Ser Phe Thr Val Gln Asp Leu Lys Pro Phe Thr 65 70 75 80 Glu Tyr Val Phe Arg Ile Arg Cys Met Lys Glu Asp Gly Lys Gly Tyr 85 90 95 Trp Ser Asp Trp Ser Glu Glu Ala Ser Gly Ile Thr 100 105 <210> 32 <211> 98 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> T.0 chain sequence <400> 32 Gly Ile Pro Pro Lys Ile Glu Ala Leu Pro Ser Asp Ile Ser Ile Asp 1 5 10 15 Glu Gly Lys Val Leu Thr Val Ala Cys Ala Phe Thr Gly Glu Pro Thr 20 25 30 Pro Glu Val Thr Trp Ser Cys Gly Gly Arg Lys Ile His Ser Gln Glu 35 40 45 Gln Gly Arg Phe His Ile Glu Asn Thr Asp Asp Leu Thr Thr Leu Ile 50 55 60 Ile Met Asp Val Gln Lys Gln Asp Gly Gly Leu Tyr Thr Leu Ser Leu 65 70 75 80 Gly Asn Glu Phe Gly Ser Asp Ser Ala Thr Val Asn Ile His Ile Arg 85 90 95 Ser Ile <210> 33 <211> 97 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> O.0 Chain Sequence <400> 33 Ser Gly Ala Pro Arg Phe Leu Thr Arg Pro Lys Ala Phe Val Val Ser 1 5 10 15 Val Gly Lys Asp Ala Thr Leu Ser Cys Gln Ile Val Gly Asn Pro Thr 20 25 30 Pro Gln Val Ser Trp Glu Lys Asp Gln Gln Pro Val Ala Ala Gly Ala 35 40 45 Arg Phe Arg Leu Ala Gln Asp Gly Asp Leu Tyr Arg Leu Thr Ile Leu 50 55 60 Asp Leu Ala Leu Gly Asp Ser Gly Gln Tyr Val Cys Arg Ala Arg Asn 65 70 75 80 Ala Ile Gly Glu Ala Phe Ala Ala Val Gly Leu Gln Val Asp Ala Glu 85 90 95 Ala <210> 34 <211> 98 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> OL.0 chain sequence <400> 34 Gln Gly Ser Pro Pro Cys Phe Leu Arg Phe Pro Arg Pro Val Arg Val 1 5 10 15 Val Ser Gly Ala Glu Ala Glu Leu Lys Cys Val Val Leu Gly Glu Pro 20 25 30 Pro Pro Val Val Val Trp Glu Lys Gly Gly Gln Gln Leu Ala Ala Ser 35 40 45 Glu Arg Leu Ser Phe Pro Ala Asp Gly Ala Glu His Gly Leu Leu Leu 50 55 60 Thr Ala Ala Leu Pro Thr Asp Ala Gly Val Tyr Val Cys Arg Ala Arg 65 70 75 80 Asn Ala Ala Gly Glu Ala Tyr Ala Ala Ala Ala Val Thr Val Leu Glu 85 90 95 Pro Pro <210> 35 <211> 98 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> T.1 chain sequence <400> 35 Gly Ile Pro Pro Lys Ile Glu Cys Leu Pro Ser Asp Ile Ser Ile Asp 1 5 10 15 Glu Gly Lys Val Leu Thr Val Ala Ser Ala Phe Thr Gly Glu Pro Thr 20 25 30 Pro Glu Val Thr Trp Ser Thr Gly Gly Arg Lys Ile His Ser Gln Glu 35 40 45 Gln Gly Arg Phe His Ile Glu Asn Thr Asp Asp Leu Thr Thr Leu Ile 50 55 60 Ile Met Asp Val Gln Lys Gln Asp Gly Gly Leu Tyr Thr Leu Ser Leu 65 70 75 80 Gly Asn Glu Phe Gly Ser Asp Ser Ala Thr Val Asn Ile His Ile Arg 85 90 95 Ser Ile <210> 36 <211> 98 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> T.2 chain sequence <400> 36 Gly Ile Pro Pro Lys Ile Glu Ala Leu Pro Ser Asp Ile Ser Ile Asp 1 5 10 15 Glu Gly Lys Cys Leu Thr Val Ala Ser Ala Phe Thr Gly Glu Pro Thr 20 25 30 Pro Glu Val Thr Trp Ser Thr Gly Gly Arg Lys Ile His Ser Gln Glu 35 40 45 Gln Gly Arg Phe His Ile Glu Asn Thr Asp Asp Leu Thr Thr Leu Ile 50 55 60 Ile Met Asp Val Gln Lys Gln Asp Gly Gly Leu Tyr Thr Leu Ser Leu 65 70 75 80 Gly Asn Glu Phe Gly Ser Asp Ser Ala Thr Val Asn Ile His Ile Arg 85 90 95 Ser Ile <210> 37 <211> 98 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> T.3 chain sequence <400> 37 Gly Ile Pro Pro Lys Ile Glu Ala Leu Pro Ser Asp Ile Ser Ile Asp 1 5 10 15 Glu Gly Lys Val Leu Thr Val Ala Ser Cys Phe Thr Gly Glu Pro Thr 20 25 30 Pro Glu Val Thr Trp Ser Thr Gly Gly Arg Lys Ile His Ser Gln Glu 35 40 45 Gln Gly Arg Phe His Ile Glu Asn Thr Asp Asp Leu Thr Thr Leu Ile 50 55 60 Ile Met Asp Val Gln Lys Gln Asp Gly Gly Leu Tyr Thr Leu Ser Leu 65 70 75 80 Gly Asn Glu Phe Gly Ser Asp Ser Ala Thr Val Asn Ile His Ile Arg 85 90 95 Ser Ile <210> 38 <211> 98 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> T.4 Chain Sequence <400> 38 Gly Ile Pro Pro Lys Ile Glu Ala Leu Pro Ser Asp Ile Ser Ile Asp 1 5 10 15 Glu Gly Lys Val Leu Cys Val Ala Ser Ala Phe Thr Gly Glu Pro Thr 20 25 30 Pro Glu Val Thr Trp Ser Thr Gly Gly Arg Lys Ile His Ser Gln Glu 35 40 45 Gln Gly Arg Phe His Ile Glu Asn Thr Asp Asp Leu Thr Thr Leu Ile 50 55 60 Ile Met Asp Val Gln Lys Gln Asp Gly Gly Leu Tyr Thr Leu Ser Leu 65 70 75 80 Gly Asn Glu Phe Gly Ser Asp Ser Ala Thr Val Asn Ile His Ile Arg 85 90 95 Ser Ile <210> 39 <211> 103 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> T.5 Chain Sequence <400> 39 Lys Ala Gly Ile Arg Gly Ile Pro Pro Lys Ile Glu Cys Leu Pro Ser 1 5 10 15 Asp Ile Ser Ile Asp Glu Gly Lys Val Leu Thr Val Ala Ser Ala Phe 20 25 30 Thr Gly Glu Pro Thr Pro Glu Val Thr Trp Ser Thr Gly Gly Arg Lys 35 40 45 Ile His Ser Gln Glu Gln Gly Arg Phe His Ile Glu Asn Thr Asp Asp 50 55 60 Leu Thr Thr Leu Ile Ile Met Asp Val Gln Lys Gln Asp Gly Gly Leu 65 70 75 80 Tyr Thr Leu Ser Leu Gly Asn Glu Phe Gly Ser Asp Ser Ala Thr Val 85 90 95 Asn Ile His Ile Arg Ser Ile 100 <210> 40 <211> 103 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> T.6 chain sequence <400> 40 Gly Gly Gly Gly Ser Gly Ile Pro Pro Lys Ile Glu Cys Leu Pro Ser 1 5 10 15 Asp Ile Ser Ile Asp Glu Gly Lys Val Leu Thr Val Ala Ser Ala Phe 20 25 30 Thr Gly Glu Pro Thr Pro Glu Val Thr Trp Ser Thr Gly Gly Arg Lys 35 40 45 Ile His Ser Gln Glu Gln Gly Arg Phe His Ile Glu Asn Thr Asp Asp 50 55 60 Leu Thr Thr Leu Ile Ile Met Asp Val Gln Lys Gln Asp Gly Gly Leu 65 70 75 80 Tyr Thr Leu Ser Leu Gly Asn Glu Phe Gly Ser Asp Ser Ala Thr Val 85 90 95 Asn Ile His Ile Arg Ser Ile 100 <210> 41 <211> 108 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> T.7 chain sequence <400> 41 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Pro Pro Lys Ile 1 5 10 15 Glu Cys Leu Pro Ser Asp Ile Ser Ile Asp Glu Gly Lys Val Leu Thr 20 25 30 Val Ala Ser Ala Phe Thr Gly Glu Pro Thr Pro Glu Val Thr Trp Ser 35 40 45 Thr Gly Gly Arg Lys Ile His Ser Gln Glu Gln Gly Arg Phe His Ile 50 55 60 Glu Asn Thr Asp Asp Leu Thr Thr Leu Ile Ile Met Asp Val Gln Lys 65 70 75 80 Gln Asp Gly Gly Leu Tyr Thr Leu Ser Leu Gly Asn Glu Phe Gly Ser 85 90 95 Asp Ser Ala Thr Val Asn Ile His Ile Arg Ser Ile 100 105 <210> 42 <211> 97 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> O.1 chain sequence <400> 42 Ser Gly Ala Pro Arg Phe Leu Thr Arg Pro Lys Ala Phe Val Val Ser 1 5 10 15 Val Gly Lys Asp Ala Thr Leu Ser Cys Gln Ile Val Gly Asn Pro Thr 20 25 30 Pro Gln Val Ser Trp Glu Lys Asp Gln Gln Pro Val Ala Ala Gly Ala 35 40 45 Arg Phe Arg Leu Ala Gln Asp Gly Asp Leu Tyr Arg Leu Thr Ile Leu 50 55 60 Asp Leu Ala Leu Gly Asp Ser Gly Gln Tyr Val Cys Arg Ala Arg Asn 65 70 75 80 Ala Ile Gly Glu Ala Phe Ala Cys Val Gly Leu Gln Val Asp Ala Glu 85 90 95 Ala <210> 43 <211> 97 <212> PRT <213> Artificial Sequence <220> <221> DOMAIN <223> O.2 chain sequence <400> 43 Ser Gly Cys Pro Arg Phe Leu Thr Arg Pro Lys Ala Phe Val Val Ser 1 5 10 15 Val Gly Lys Asp Ala Thr Leu Ser Cys Gln Ile Val Gly Asn Pro Thr 20 25 30 Pro Gln Val Ser Trp Glu Lys Asp Gln Gln Pro Val Ala Ala Gly Ala 35 40 45 Arg Phe Arg Leu Ala Gln Asp Gly Asp Leu Tyr Arg Leu Thr Ile Leu 50 55 60 Asp Leu Ala Leu Gly Asp Ser Gly Gln Tyr Val Cys Arg Ala Arg Asn 65 70 75 80 Ala Ile Gly Glu Ala Phe Ala Ala Val Gly Leu Gln Val Asp Ala Glu 85 9...

Claims

1. A polypeptide complex comprising a first antigen binding portion, wherein the first antigen binding portion comprises: A) a first polypeptide, the first polypeptide comprising a first heavy chain variable domain (VH1) from N-terminus to C-terminus, the VH1 being operably linked to a first domain, the first domain being a titin-T chain, and A second polypeptide comprising a first light chain variable domain (VL1) from N-terminus to C-terminus, wherein VL1 is operably linked to a second domain, wherein the second domain is an Obscurin-O chain or an Obscurin-like-O chain; or B) a first polypeptide, the first polypeptide comprising VH1 from N-terminus to C-terminus, the VH1 being operably linked to a first domain, the first domain being an Obscurin-O chain or an Obscurin-like-O chain, and a second polypeptide, the second polypeptide comprising VL1 from N-terminus to C-terminus, the VL1 being operably linked to a second domain, the second domain being a titin-T chain; wherein the first antigen binding portion specifically binds to the first antigen, the first domain and the second domain are capable of forming a dimer; the C-terminus of the VH1 is operably connected to the N-terminus of the first domain, and the C-terminus of the VL1 is operably connected to the N-terminus of the second domain; The titin-T chain and the obscurin-O chain, or the titin-T chain and the obscurin-like-O chain, form a dimer through a natural interchain bond; Alternatively, the titin-T chain and the obscurin-O chain, or the titin-T chain and the obscurin-like-O chain form a dimer through 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 non-natural interchain bonds; the non-natural interchain bonds are formed between the mutant residues of the titin-T chain and the obscurin-O chain, or the titin-T chain and the obscurin-like-O chain, at least one pair of the mutant residues is a cysteine ​​residue, and the non-natural interchain bonds are disulfide bonds; the sequence of the titin-T chain is as shown in SEQ ID NO: 32, or a sequence of SEQ ID NO:

33. NO:32 is mutated, wherein the mutation is selected from one or more mutations of A8C, V20C, T22C, A26C, P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on mutations C25S and C39T; and The sequence of the Obscurin-O chain is as shown in SEQ ID NO:33, or the mutation in the sequence of SEQ ID NO:33 is selected from one or more of A3C, R9C, C25S, C76S, A88C, L7K, T62K, T62H, G2E, K11L, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q, A67T, G69S, V89L, Q92E, D94G and A97G; or, the sequence of the Obscurin-like-O chain is as shown in SEQ ID NO:34, or the mutation in the sequence of SEQ ID NO:35 is selected from one or more of SEQ ID NO:

36. The mutation in the NO:34 sequence is selected from one or more of C6E, C26S, C77S, V74C, G84C and A86C; The above-mentioned Titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the Obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; and the Obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO:

34.

2. The polypeptide complex according to claim 1, wherein the mutated residues of the first domain and the mutated residues of the second domain are selected from the following mutations: The mutation of the Titin-T chain is selected from one or more of A8C, V20C, T22C, C25S, A26C and C39T, and the mutation of the Obscurin-O chain is selected from one or more of A3C, R9C, C25S, C76S and A88C; or The mutation of the Titin-T chain is selected from one or more of A8C, V20C, T22C, C25S, A26C and C39T, and the mutation of the Obscurin-like-O chain is selected from one or more of C6E, C26S, C77S, V74C, G84C and A86C.

3. The polypeptide complex according to claim 2, wherein the mutated residues of the first domain and the mutated residues of the second domain are selected from the following mutations: The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutation in the Obscurin-O chain is A88C; The mutations in the titin-T chain are C25S, C39T, and V20C, and the mutation in the obscurin-O chain is A3C; The mutations in the Titin-T chain are C25S, C39T, and A26C, and the mutation in the Obscurin-O chain is R9C; The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-O chain are C25S, C76S, and A88C; The mutations in the Titin-T chain are C25S, C39T, and V20C, and the mutations in the Obscurin-O chain are C25S, C76S, and A3C; The mutations in the Titin-T chain are C25S, C39T, and A26C, and the mutations in the Obscurin-O chain are C25S, C76S, and R9C; The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-like-O chain are C6E and V74C; The mutations in the Titin-T chain are C25S, C39T, and V20C, and the mutations in the Obscurin-like-O chain are C6E and G84C; The mutations in the Titin-T chain are C25S, C39T, and T22C, and the mutations in the Obscurin-like-O chain are C6E and A86C; The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-like-O chain are C6E, C26S, C77S, and V74C; The mutations of the Titin-T chain are C25S, C39T and V20C, and the mutations of the Obscurin-like-O chain are C6E, C26S, C77S and G84C; or The mutations in the Titin-T chain are C25S, C39T, and T22C, and the mutations in the Obscurin-like-O chain are C6E, C26S, C77S, and A86C; The mutation sites of Titin-T chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO: 32; the mutation sites of Obscurin-O chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO: 33; and the mutation sites of Obscurin-like-O chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO:

34.

4. The polypeptide complex according to claim 2, wherein the mutation of the Obscurin-O chain is further selected from one or more of L7R, L7K, T62K, T62H and K11L; The Obscurin-O chain mutation site is a site numbered in the natural order relative to the sequence SEQ ID NO:

33.

5. The polypeptide complex according to claim 4, wherein the mutations of the Titin-T chain are C25S, C39T and A8C, and the mutations of the Obscurin-O chain are C25S, C76S, A88C, L7K and T62K; The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-O chain are C25S, C76S, A88C, L7K, and T62H; The mutations in the titin-T chain are C25S, C39T and A8C, and the mutations in the obscurin-O chain are C25S, C76S, A88C, K11L and T62K; or The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-O chain are C25S, C76S, A88C, K11L, and T62H; The mutation sites of Titin-T chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO: 32; the mutation sites of Obscurin-O chain are the sites with natural sequence numbering relative to the sequence SEQ ID NO:

33.

6. The polypeptide complex according to claim 4, The mutation of the Titin-T chain is further selected from one or more of P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L, and the mutation of the Obscurin-O chain further selected from one or more of G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q, A67T, G69S, V89L, Q92E, D94G, and A97G; The above-mentioned Titin-T chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO: 35; the Obscurin-O chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO:

50.

7. The polypeptide complex according to claim 6, wherein the mutations of the Titin-T chain are M66S and T77S, and the mutations of the Obscurin-O chain are L11K, A12S, F13Y, V14T and T22S; The mutations of the Titin-T chain are M66K, K70R, S79T and G81R, and the mutations of the Obscurin-O chain are G2E, V17E, N30D, T32P, Q34E, S36T, V44I, A45T, L58V, K62E, A67Q, G69S and A97G; The mutations of the Titin-T chain are P3W, S11I, I13L, T22M and N82M, and the mutations of the Obscurin-O chain are D20L, T22M and A53L; The mutations of the Titin-T chain are S11I, M66K, S79T and G81R, and the mutations of the Obscurin-O chain are Q41K, A45T, A67Q, G69S and V89L; The mutations of the Titin-T chain are G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, L75V, E83D and F84L, and the mutations of the Obscurin-O chain are Q42L, A45T, A67T, G69S, Q92E and D94G; The mutations of the Titin-T chain are Q47E, Q49G, N56S, D58E and L75V, and the mutations of the Obscurin-O chain are Q42L, A45T, A67T, G69S, Q92E and D94G; The mutations of the Titin-T chain are N56S, D58E and L75V, and the mutations of the Obscurin-O chain are Q42L, A45T, A67T, G69S, Q92E and D94G; or The mutations of the Titin-T chain are N56S, D58E, M66S and T77S, and the mutations of the Obscurin-O chain are A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E and D94G; The above-mentioned Titin-T chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO: 35; the Obscurin-O chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO:

50.

8. The polypeptide complex of claim 1, wherein the VH1 is operably connected to the first domain via a first connecting domain, and the VL1 is operably connected to the second domain via a second connecting domain; The first connecting domain and / or the second connecting domain are selected from the group consisting of: an N-terminal fragment of a titin-T chain, an N-terminal fragment of an obscurin-O chain, an N-terminal fragment of an obscurin-like-O chain, and (G x S) y A linker, wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6.

9. The polypeptide complex of claim 8, wherein the VH1 is operably connected to the first domain via a first connecting domain, and the first connecting domain and / or the second connecting domain are selected from the following polypeptide fragments: "KAGIR", "DQPQF", (G4S)1 and (G4S)2.

10. The polypeptide complex according to claim 8, wherein the VH1 is operably connected to the first domain via a first connecting domain, the first domain is a Titin-T chain, the first connecting domain is a KAGIR polypeptide, the second domain is an Obscurin-O chain, and the second connecting domain is a DQPQF polypeptide; or The second domain is the Titin-T chain, the second connecting domain is the KAGIR polypeptide, the first domain is the Obscurin-O chain, and the first connecting domain is the DQPQF polypeptide.

11. The polypeptide complex according to claim 1, wherein (A) the sequence of the titin-T chain is as shown in SEQ ID NO:32, or SEQ ID NO:32 is mutated, wherein the mutation is selected from one or more mutations of A8C, V20C, T22C, A26C, P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the mutations C25S and C39T, and a sequence with a KAGIR amino acid residue added to the N-terminus; and (B) the sequence of the Obscurin-O chain is as shown in SEQ ID NO:33, or a mutation in the sequence of SEQ ID NO:33 is selected from one or more of A3C, R9C, C25S, C76S, A88C, L7K, T62K, T62H, G2E, K11L, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q, A67T, G69S, V89L, Q92E, D94G and A97G, and a sequence with DQPQF amino acid residues added at the N-terminus; or The sequence of the Obscurin-like-O chain is as shown in SEQ ID NO:34, or the mutation in the sequence of SEQ ID NO:34 is selected from one or more of C6E, C26S, C77S, V74C, G84C and A86C; The above-mentioned Titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the Obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; and the Obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO:

34.

12. The polypeptide complex according to claim 1, wherein the titin-T chain and the obscurin-O chain, or the combination of the titin-T chain and the obscurin-like-O chain is selected from: I. A) The titin-T chain has one or more mutations selected from A8C, V20C, T22C, C25S, A26C and C39T in the sequence of SEQ ID NO: 32, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; B) the Obscurin-O chain has one or more mutations selected from A3C, R9C, C25S, C76S and A88C in the sequence of SEQ ID NO: 33, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 33; II. A) The titin-T chain has one or more mutations selected from A8C, V20C, T22C, C25S, A26C and C39T in the sequence of SEQ ID NO: 32, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; B) the Obscurin-O chain has one or more mutations selected from L7K, L7R, T62K, T62H and K11L in the sequence of SEQ ID NO: 45, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 45; III. A) The titin-T chain has one or more mutations selected from A8C, V20C, T22C, C25S, A26C and C39T on the sequence of SEQ ID NO: 32, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; B) the Obscurin-O chain has one or more mutations selected from the group consisting of G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q, A67T, G69S, V89L, Q92E, D94G and A97G based on the sequence of SEQ ID NO: 50, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 50; IV. A) The titin-T chain has one or more mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the sequence of SEQ ID NO: 35; the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 35, B) the Obscurin-O chain has one or more mutations selected from A3C, R9C, C25S, C76S and A88C in the sequence of SEQ ID NO: 33, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 33; V. A) The titin-T chain has one or more mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the sequence of SEQ ID NO: 35; the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 35, B) the Obscurin-O chain is a sequence of SEQ ID NO: 45 in which one or more mutations selected from L7K, L7R, T62K, T62H and K11L occur, and the mutation sites of the Obscurin-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 45; VI. A) The titin-T chain has one or more mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the sequence of SEQ ID NO: 35; the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 35, B) the Obscurin-O chain has one or more mutations selected from the group consisting of G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q, A67T, G69S, V89L, Q92E, D94G and A97G based on the sequence of SEQ ID NO: 50, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 50; VII. A) The titin-T chain has one or more mutations selected from A8C, V20C, T22C, C25S, A26C and C39T in the sequence of SEQ ID NO: 32, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; B) the Obscurin-like-O chain has one or more mutations selected from C6E, C26S, C77S, V74C, G84C and A86C in the sequence of SEQ ID NO: 34, and the mutation sites of the Obscurin-like-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 34; and VIII. A) The titin-T chain has one or more mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L in the sequence of SEQ ID NO: 35; the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 35; B) The Obscurin-like-O chain has one or more mutations selected from C6E, C26S, C77S, V74C, G84C and A86C in the sequence of SEQ ID NO: 34, and the Obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO:

34.

13. The polypeptide complex according to claim 1, wherein the Titin-T chain has a sequence as shown in any one of SEQ ID NOs: 32, 35-41, 65-76, and the Obscurin-O chain has a sequence as shown in any one of SEQ ID NOs: 33, 42-58, 77-86; or The Titin-T chain is a sequence shown in any one of SEQ ID NOs: 32, 35-41, 65-76, and the Obscurin-like-O chain is a sequence shown in any one of SEQ ID NOs: 34, 59-64.

14. The polypeptide complex according to claim 13, wherein the Titin-T chain has a sequence as shown in SEQ ID NO: 68, and the Obscurin-O chain has a sequence as shown in SEQ ID NO: 80; The Titin-T chain has the sequence shown in SEQ ID NO: 73, and the Obscurin-O chain has the sequence shown in SEQ ID NO: 83; The Titin-T chain has the sequence shown in SEQ ID NO: 76, and the Obscurin-O chain has the sequence shown in SEQ ID NO: 84; The Titin-T chain is as shown in SEQ ID NO: 76, and the Obscurin-O chain is as shown in SEQ ID NO: 86; or The Titin-T chain is shown in SEQ ID NO: 75, and the Obscurin-O chain is shown in SEQ ID NO:

86.

15. The polypeptide complex of claim 1, wherein the first antigen is selected from the group consisting of: exogenous antigens, endogenous antigens, self-antigens, neo-antigens, viral antigens and tumor antigens.

16. The polypeptide complex according to claim 1, wherein the polypeptide complex is a multi-specific polypeptide complex, comprising: a first polypeptide complex, which is the first antigen binding portion of claim 1, which specifically binds to the first antigen, and a second polypeptide complex comprising a second antigen binding portion that specifically binds to a second antigen, The first polypeptide complex and the second polypeptide complex bind to two different antigens, or bind to two different epitopes on the same antigen; The second polypeptide complex comprises a second heavy chain variable domain (VH2) and a second light chain variable domain (VL2), and mismatching is not likely to occur between VH1 of the first polypeptide complex and VL2 of the second polypeptide complex, and / or between VH2 of the second polypeptide complex and VL1 of the first polypeptide complex.

17. The polypeptide complex of claim 16, wherein the second antigen-binding portion of the second polypeptide complex comprises: a third polypeptide comprising, from N-terminus to C-terminus, VH2 operably linked to a third domain comprising CH1, and a fourth polypeptide comprising, from N-terminus to C-terminus, VL2 operably linked to a fourth domain comprising CL; The C-terminus of VH2 is operably connected to the N-terminus of CH1, and the C-terminus of VL2 is operably connected to the N-terminus of CL.

18. The polypeptide complex according to claim 1, wherein the polypeptide complex is a Fab fragment or a domain-engineered antibody comprising a Fab fragment, comprising the first antigen-binding portion according to claim 1, a constant region domain CH1 and a constant region domain CL; the first antigen-binding portion comprises a heavy chain variable region VH1 and a light chain variable region VL1; The constant region domain CH1 and the constant region domain CL are replaced by titin T chain and obscurin-O chain, or by titin T chain and obscurin-like-O chain, as follows: A) The CH1 domain is replaced by the Titin-T chain, and the CL domain is replaced by the Obscurin-O chain; B) The CL domain is replaced by the Titin-T chain, and the CH1 domain is replaced by the Obscurin-O chain; E) the CH1 domain is replaced by an Obscurin-like-O chain, and the CL domain is replaced by a Titin-T chain; or F) The CL domain is replaced by the Obscurin-like-O chain, and the CH1 domain is replaced by the Titin-T chain; The C-terminus of the VH1 is operably linked to the N-terminus of the Titin-T chain, and the C-terminus of the VL1 is operably linked to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain, or the C-terminus of the VL1 is operably linked to the N-terminus of the Titin-T chain, and the C-terminus of the VH1 is operably linked to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain; The titin-T chain and the obscurin-O chain, or the titin-T chain and the obscurin-like-O chain, form a dimer through a natural interchain bond; Alternatively, the titin-T chain and the obscurin-O chain, or the titin-T chain and the obscurin-like-O chain form a dimer through 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 non-natural interchain bonds; the non-natural interchain bonds are formed between the mutant residues of the titin T chain and the obscurin-O chain or the obscurin-like-O chain, at least one pair of the mutant residues is a cysteine ​​residue, and the non-natural interchain bonds are disulfide bonds; the sequence of the titin-T chain is as shown in SEQ ID NO: 32, or a sequence of SEQ ID NO:

33. NO:32 is mutated, wherein the mutation is selected from one or more mutations of A8C, V20C, T22C, A26C, P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on mutations C25S and C39T; and The sequence of the Obscurin-O chain is as shown in SEQ ID NO:33, or the mutation in the sequence of SEQ ID NO:33 is selected from one or more of A3C, R9C, C25S, C76S, A88C, L7K, T62K, T62H, G2E, K11L, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q, A67T, G69S, V89L, Q92E, D94G and A97G; or, the sequence of the Obscurin-like-O chain is as shown in SEQ ID NO:34, or the mutation in the sequence of SEQ ID NO:35 is selected from one or more of SEQ ID NO:

36. The mutation in the NO:34 sequence is selected from one or more of C6E, C26S, C77S, V74C, G84C and A86C; The above-mentioned Titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the Obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; and the Obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO:

34.

19. The polypeptide complex according to claim 1, wherein the polypeptide complex is a bispecific antibody, which comprises the first antigen-binding portion according to claim 1, wherein the first antigen-binding portion comprises a first heavy chain and a first light chain that specifically bind to a first antigen, and further comprises a second heavy chain and a second light chain that specifically bind to a second antigen, wherein: The CH1 domain of the first heavy chain is replaced by the Obscurin-O chain, and the CL domain of the first light chain is replaced by the Titin-T chain; The CL domain of the first light chain is replaced by the Obscurin-O chain, and the CH1 domain of the first heavy chain is replaced by the Titin-T chain; The CH1 domain of the first heavy chain is replaced by an Obscurin-like-O chain, and the CL domain of the first light chain is replaced by a Titin-T chain; or The CL domain of the first light chain is replaced by the Obscurin-like-O chain, and the CH1 domain of the first heavy chain is replaced by the Titin-T chain; The first antigen and the second antigen are not the same, or the first antigen and the second antigen are two different epitopes on the same antigen; wherein the first heavy chain comprises a first heavy chain variable region (VH1), the first light chain comprises a first light chain variable region (VL1), and the VH1 and VL1 form an antigen binding site that specifically binds to a first antigen, and The C-terminus of the VH1 is operably linked to the N-terminus of the Titin-T chain, and the C-terminus of the VL1 is operably linked to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain, or The C-terminus of the VL1 is operably linked to the N-terminus of the Titin-T chain, and the C-terminus of the VH1 is operably linked to the N-terminus of the Obscurin-O chain or the Obscurin-like-O chain; The titin-T chain and the obscurin-O chain, or the titin-T chain and the obscurin-like-O chain, are bonded via natural interchain bonds and / or non-natural interchain bonds to form a dimer; Alternatively, the titin-T chain and the obscurin-O chain, or the titin-T chain and the obscurin-like-O chain, form a dimer through 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 non-native interchain bonds; The non-natural interchain bonds are formed between the mutated residues of the titin-T chain and the obscurin-O chain, or between the titin-T chain and the obscurin-like-O chain, at least one pair of the mutated residues is a cysteine ​​residue, and the non-natural interchain bonds are disulfide bonds; The sequence of the titin-T chain is as shown in SEQ ID NO:32, or SEQ ID NO:32 is mutated, wherein the mutation is selected from one or more mutations of A8C, V20C, T22C, A26C, P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on mutations C25S and C39T; The sequence of the Obscurin-O chain is as shown in SEQ ID NO:33, or one or more mutations selected from the group consisting of A3C, R9C, C25S, C76S, A88C, L7K, T62K, T62H, G2E, K11L, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q, A67T, G69S, V89L, Q92E, D94G and A97G occur in the sequence of SEQ ID NO:33; or The sequence of the Obscurin-like-O chain is as shown in SEQ ID NO:34, or one or more mutations selected from C6E, C26S, C77S, V74C, G84C and A86C occur in the sequence of SEQ ID NO:34; The above-mentioned Titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the Obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; and the Obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO:

34.

20. The polypeptide complex of claim 19, wherein the second heavy chain comprises a second heavy chain variable region (VH2) from N-terminus to C-terminus, which is operably linked to CH1; the second light chain comprises a second light chain variable region (VL2) from N-terminus to C-terminus, which is operably linked to CL; The VH2 and VL2 form an antigen binding site that specifically binds to a second antigen, and the C-terminus of the VH2 is operably connected to the N-terminus of the CH1; the C-terminus of the VL2 is operably connected to the N-terminus of the CL.

21. The polypeptide complex of claim 19, wherein the C-termini of the first heavy chain and the second heavy chain comprise a CH2 and / or CH3 domain; The CH1, CH2 and CH3 domains are derived from IgG1, IgG2, IgG3 or IgG4; The first heavy chain and the second heavy chain are combined by a means selected from the group consisting of an antibody hinge region or a portion thereof, a linker, a disulfide bond, a hydrogen bond, an electrostatic interaction, a salt bridge, a hydrophobic-hydrophilic interaction, or a combination thereof.

22. The polypeptide complex according to claim 21, wherein: The first heavy chain is sequentially: VH1-L1-Titin-T chain-L2-CH2-CH3 from N-terminus to C-terminus, The first light chain is, from N-terminus to C-terminus, VL1-L3-Obscurin-O chain or VL1-L4-Obscurin-like-O chain; The second heavy chain is VH2-CH1-CH2-CH3 from N-terminus to C-terminus. The second light chain is as follows from N-terminus to C-terminus: VL2-CL; or, The first light chain is arranged from the N-terminus to the C-terminus in the order: VL1-L1-Titin-T chain, The first heavy chain is VH1-L2-Obscurin-O chain-L3-CH2-CH3 from N-terminus to C-terminus, or VH1-L4-Obscurin-like-O chain-L5-CH2-CH3; The second heavy chain is VH2-CH1-CH2-CH3 from N-terminus to C-terminus. The second light chain is as follows from N-terminus to C-terminus: VL2-CL; The L1 to L5 are spacers, which may or may not exist; The spacer is selected from the group consisting of: the N-terminal fragment of the titin-T chain, the N-terminal fragment of the obscurin-O chain, the N-terminal fragment of the obscurin-like-O chain, or (G x S) y Linker; wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6.

23. The polypeptide complex according to claim 22, wherein: The spacer region is selected from the group consisting of: "KAGIR", "DQPQF", (G4S)1 and (G4S)2.

24. The polypeptide complex of claim 22, wherein the CH2 and CH3 of the first heavy chain are different from the CH2 and CH3 of the second heavy chain, and are bound in a manner that prevents homodimerization and / or favors heterodimerization; the binding manner is selected from: knob-into-hole, hydrophobic interaction, electrostatic interaction, hydrophilic interaction, or increased flexibility.

25. The polypeptide complex of claim 24, wherein the first heavy chain and the second heavy chain are bound by a knob-into-hole mechanism.

26. The polypeptide complex according to claim 25, wherein the first heavy chain CH2-CH3 domain is amino acid residues 104 to 330 in the sequence shown in SEQ ID NO: 2, and the second heavy chain CH2-CH3 domain is amino acid residues 104 to 330 in the sequence shown in SEQ ID NO: 3; or The first heavy chain CH2-CH3 domain is the amino acid residues 104 to 330 in the sequence shown in SEQ ID NO:3, and the second heavy chain CH2-CH3 domain is the amino acid residues 104 to 330 in the sequence shown in SEQ ID NO:

2.

27. The polypeptide complex according to claim 19, wherein the operably linked two polypeptide sequences are linked via a linker domain or two polypeptides are directly linked.

28. The polypeptide complex according to claim 19, wherein the mutation of the titin-T chain is selected from one or more of A8C, V20C, T22C, C25S, A26C and C39T, and The mutation of the Obscurin-O chain is selected from one or more of A3C, R9C, C25S, C76S and A88C; or The mutation of the titin-T chain is selected from one or more of A8C, V20C, T22C, C25S, A26C and C39T, and The mutation of the Obscurin-like-O chain is selected from one or more of C6E, C26S, C77S, V74C, G84C and A86C.

29. The polypeptide complex of claim 28, wherein the mutations of the Titin-T chain are C25S, C39T and A8C, and the mutation of the Obscurin-O chain is A88C; The mutations in the titin-T chain are C25S, C39T, and V20C, and the mutation in the obscurin-O chain is A3C; The mutations in the Titin-T chain are C25S, C39T, and A26C, and the mutation in the Obscurin-O chain is R9C; The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-O chain are C25S, C76S, and A88C; The mutations in the Titin-T chain are C25S, C39T, and V20C, and the mutations in the Obscurin-O chain are C25S, C76S, and A3C; The mutations in the Titin-T chain are C25S, C39T, and A26C, and the mutations in the Obscurin-O chain are C25S, C76S, and R9C; The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-like-O chain are C6E and V74C; The mutations in the Titin-T chain are C25S, C39T, and V20C, and the mutations in the Obscurin-like-O chain are C6E and G84C; The mutations in the Titin-T chain are C25S, C39T, and T22C, and the mutations in the Obscurin-like-O chain are C6E and A86C; The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-like-O chain are C6E, C26S, C77S, and V74C; The mutations of the Titin-T chain are C25S, C39T and V20C, and the mutations of the Obscurin-like-O chain are C6E, C26S, C77S and G84C; or The mutations in the Titin-T chain are C25S, C39T, and T22C, and the mutations in the Obscurin-like-O chain are C6E, C26S, C77S, and A86C; The above-mentioned Titin-T chain mutation site is the natural sequence site relative to the sequence SEQ ID NO: 32; the Obscurin-O chain mutation site is the natural sequence site relative to the sequence SEQ ID NO: 33; and the Obscurin-like-O chain mutation site is the natural sequence site relative to the sequence SEQ ID NO:

34.

30. The polypeptide complex of claim 28, wherein the mutation of the Obscurin-O chain is further selected from one or more of L7K, L7R, K11L, T62K and T62H.

31. The polypeptide complex of claim 30, wherein the mutations of the Titin-T chain are C25S, C39T and A8C, and the mutations of the Obscurin-O chain are C25S, C76S, A88C, L7K and T62K; The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-O chain are C25S, C76S, A88C, L7K, and T62H; The mutations in the titin-T chain are C25S, C39T and A8C, and the mutations in the obscurin-O chain are C25S, C76S, A88C, K11L and T62K; or The mutations in the Titin-T chain are C25S, C39T, and A8C, and the mutations in the Obscurin-O chain are C25S, C76S, A88C, K11L, and T62H; The above-mentioned Titin-T chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO: 32; the Obscurin-O chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO:

33.

32. The polypeptide complex of claim 30, wherein the mutation of the titin-T chain is further selected from one or more of P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L, and / or Obscurin-O chain mutations selected from one or more of G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q, A67T, G69S, V89L, Q92E, D94G, and A97G; The above-mentioned Titin-T chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO: 35; the Obscurin-O chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO:

50.

33. The polypeptide complex of claim 32, wherein the mutations of the Titin-T chain are M66S and T77S, and the mutations of the Obscurin-O chain are L11K, A12S, F13Y, V14T and T22S; The mutations of the Titin-T chain are M66K, K70R, S79T and G81R, and the mutations of the Obscurin-O chain are G2E, V17E, N30D, T32P, Q34E, S36T, V44I, A45T, L58V, K62E, A67Q, G69S and A97G; The mutations of the Titin-T chain are P3W, S11I, I13L, T22M and N82M, and the mutations of the Obscurin-O chain are D20L, T22M and A53L; The mutations of the Titin-T chain are S11I, M66K, S79T and G81R, and the mutations of the Obscurin-O chain are Q41K, A45T, A67Q, G69S and V89L; The mutations of the Titin-T chain are G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, L75V, E83D and F84L, and the mutations of the Obscurin-O chain are Q42L, A45T, A67T, G69S, Q92E and D94G; The mutations of the Titin-T chain are Q47E, Q49G, N56S, D58E and L75V, and the mutations of the Obscurin-O chain are Q42L, A45T, A67T, G69S, Q92E and D94G; The mutations of the Titin-T chain are N56S, D58E and L75V, and the mutations of the Obscurin-O chain are Q42L, A45T, A67T, G69S, Q92E and D94G; or The mutations of the Titin-T chain are N56S, D58E, M66S and T77S, and the mutations of the Obscurin-O chain are A12S, F13Y, T22S, Q42L, A45T, A67Q, G69S, Q92E and D94G; The above-mentioned Titin-T chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO: 35; the Obscurin-O chain mutation site is the site with natural sequence numbering relative to the sequence SEQ ID NO:

50.

34. The polypeptide complex of claim 19, wherein the N-terminus of the Titin-T chain, Obscurin-O chain or Obscurin-like-O chain is operably linked to VH1 or VL1 via a linker domain; The connecting domain is selected from the group consisting of: an N-terminal fragment of a titin-T chain, an N-terminal fragment of an obscurin-O chain, an N-terminal fragment of an obscurin-like-O chain, and (G x S) y A linker, wherein X is selected from an integer of 1-5, and Y is selected from an integer of 1-6.

35. The polypeptide complex of claim 34, wherein the connecting domain is selected from the group consisting of: "KAGIR", "DQPQF", (G4S)1 and (G4S)2.

36. The polypeptide complex according to claim 34, wherein the Titin-T chain is connected to VH1 or VL1 via a KAGIR polypeptide, and / or the Obscurin-O chain is connected to VL1 or VH1 via a DQPQF polypeptide.

37. The polypeptide complex according to claim 19, wherein: A) the sequence of the titin-T chain is as shown in SEQ ID NO:32, or SEQ ID NO:32 is mutated, wherein the mutation is selected from one or more mutations of A8C, V20C, T22C, A26C, P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S / M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the mutations C25S and C39T, and a sequence with a KAGIR amino acid residue added to the N-terminus; and B) the sequence of the Obscurin-O chain is as shown in SEQ ID NO:33, or one or more mutations selected from the group consisting of A3C, R9C, C25S, C76S, A88C, L7K, L7R, T62K, T62H, G2E, K11L, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, T62E, A67Q, A67T, G69S, V89L, Q92E, D94G and A97G are present in the sequence of SEQ ID NO:33, and a sequence in which the DQPQF amino acid residues are added at the N-terminus; or The sequence of the Obscurin-like-O chain is as shown in SEQ ID NO:34, or a sequence in which one or more mutations selected from C6E, C26S, C77S, V74C, G84C and A86C occur in the sequence of SEQ ID NO:34; The above-mentioned Titin-T chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 32; the Obscurin-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO: 33; and the Obscurin-like-O chain mutation site is the natural sequence numbering site of the sequence SEQ ID NO:

34.

38. The polypeptide complex of claim 19, wherein the titin-T chain and the obscurin-O chain, or the combination of the titin-T chain and the obscurin-like-O chain is selected from: I. A) The titin-T chain has one or more mutations selected from A8C, V20C, T22C, C25S, A26C and C39T in the sequence of SEQ ID NO: 32, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; B) the Obscurin-O chain has one or more mutations selected from A3C, R9C, C25S, C76S and A88C in the sequence of SEQ ID NO: 33, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 33; II. A) The titin-T chain has one or more mutations selected from A8C, V20C, T22C, C25S, A26C and C39T in the sequence of SEQ ID NO: 32, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; B) the Obscurin-O chain has one or more mutations selected from L7K, L7R, T62K, T62H and K11L in the sequence of SEQ ID NO: 45, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 45; III. A) The titin-T chain has one or more mutations selected from A8C, V20C, T22C, C25S, A26C and C39T on the sequence of SEQ ID NO: 32, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; B) the Obscurin-O chain has one or more mutations selected from the group consisting of G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q, A67T, G69S, V89L, Q92E, D94G and A97G based on the sequence of SEQ ID NO: 50, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 50; IV. A) The titin-T chain has one or more mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the sequence of SEQ ID NO: 35; the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 35, B) the Obscurin-O chain has one or more mutations selected from A3C, R9C, C25S, C76S and A88C in the sequence of SEQ ID NO: 33, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 33; V. A) The titin-T chain has one or more mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L in the sequence of SEQ ID NO: 35; the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 35; B) the Obscurin-O chain has one or more mutations selected from L7K, L7R, T62K, T62H and K11L in the sequence of SEQ ID NO: 45, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 45; VI. A) The titin-T chain has one or more mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the sequence of SEQ ID NO: 35; the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 35; B) the Obscurin-O chain has one or more mutations selected from the group consisting of G2E, L11K, A12S, F13Y, V14T, V17E, D20L, T22M, T22S, N30D, T32P, Q34E, S36T, Q41K, Q42L, V44I, A45T, A53L, L58V, K62E, A67Q, A67T, G69S, V89L, Q92E, D94G and A97G in the sequence of SEQ ID NO: 50, and the mutation sites of the Obscurin-O chain are the sites with natural sequence numbering of the sequence of SEQ ID NO: 50; VII. A) The titin-T chain has one or more mutations selected from A8C, V20C, T22C, C25S, A26C and C39T based on the sequence of SEQ ID NO: 32, and the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 32; B) the Obscurin-like-O chain has one or more mutations selected from C6E, C26S, C77S, V74C, G84C and A86C based on the sequence of SEQ ID NO: 34, and the mutation sites of the Obscurin-like-O chain are the natural sequence numbering sites of the sequence SEQ ID NO: 34; and VIII. A) The titin-T chain has one or more mutations selected from P3W, S11I, I13L, T22M, G40S, R42K, H45S, Q47E, Q49G, N56S, D58E, M66S, M66K, K70R, L75V, T77S, S79T, G81R, N82M, E83D and F84L based on the sequence of SEQ ID NO: 35; the mutation sites of the titin-T chain are the natural sequence numbering sites of the sequence SEQ ID NO: 35; B) The Obscurin-like-O chain has one or more mutations selected from C6E, C26S, C77S, V74C, G84C and A86C based on the sequence of SEQ ID NO: 34, and the Obscurin-like-O chain mutation sites are the natural sequence numbering sites of the sequence SEQ ID NO:

34.

39. The polypeptide complex according to claim 19, wherein: The titin-T chain is a sequence as shown in any one of SEQ ID NOs: 32, 35-41, 65-76, and The Obscurin-O chain is a sequence as shown in any one of SEQ ID NOs: 33, 42-58, 77-86 or; or The titin-T chain is a sequence as shown in any one of SEQ ID NOs: 32, 35-41, 65-76, and The Obscurin-like-O chain is a sequence as shown in any one of SEQ ID NOs: 34, 59-64.

40. The polypeptide complex according to claim 39, wherein the Titin-T chain comprises the polypeptide shown in SEQ ID NO: 68, and the Obscurin-O chain comprises the polypeptide shown in SEQ ID NO: 80; The Titin-T chain is a polypeptide as shown in SEQ ID NO: 73, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO: 83; The Titin-T chain is a polypeptide as shown in SEQ ID NO: 76, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO: 84; The Titin-T chain is a polypeptide as shown in SEQ ID NO: 76, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO: 86; The Titin-T chain is a polypeptide as shown in SEQ ID NO: 75, and the Obscurin-O chain is a polypeptide as shown in SEQ ID NO:

86.

41. The polypeptide complex according to claim 19: wherein A) the sequence of the first heavy chain of the bispecific antibody is shown in SEQ ID NO: 89, the sequence of the first light chain is shown in SEQ ID NO: 90, the sequence of the second heavy chain is shown in SEQ ID NO: 87, and the sequence of the second light chain is shown in SEQ ID NO: 88; B) the sequence of the first heavy chain of the bispecific antibody is shown in SEQ ID NO: 93, the sequence of the first light chain is shown in SEQ ID NO: 94, the sequence of the second heavy chain is shown in SEQ ID NO: 91, and the sequence of the second light chain is shown in SEQ ID NO: 92; C) the sequence of the first heavy chain of the bispecific antibody is shown in SEQ ID NO: 97, the sequence of the first light chain is shown in SEQ ID NO: 98, the sequence of the second heavy chain is shown in SEQ ID NO: 95, and the sequence of the second light chain is shown in SEQ ID NO: 96; D) the sequence of the first heavy chain of the bispecific antibody is shown in SEQ ID NO: 99, the sequence of the first light chain is shown in SEQ ID NO: 100, the sequence of the second heavy chain is shown in SEQ ID NO: 101, and the sequence of the second light chain is shown in SEQ ID NO: 96; E) the sequence of the first heavy chain of the bispecific antibody is as shown in SEQ ID NO: 102 or, the sequence of the first light chain is as shown in SEQ ID NO: 100, the sequence of the second heavy chain is as shown in SEQ ID NO: 95, and the sequence of the second light chain is as shown in SEQ ID NO: 96; F) the sequence of the first heavy chain of the bispecific antibody is shown in SEQ ID NO: 103, the sequence of the first light chain is shown in SEQ ID NO: 104, the sequence of the second heavy chain is shown in SEQ ID NO: 95, and the sequence of the second light chain is shown in SEQ ID NO: 96; and G) the sequence of the first heavy chain of the bispecific antibody is shown in SEQ ID NO: 107, the sequence of the first light chain is shown in SEQ ID NO: 108, the sequence of the second heavy chain is shown in SEQ ID NO: 109, and the sequence of the second light chain is shown in SEQ ID NO: 110; H) the sequence of the first heavy chain of the bispecific antibody is shown in SEQ ID NO: 122, the sequence of the first light chain is shown in SEQ ID NO: 123, the sequence of the second heavy chain is shown in SEQ ID NO: 116, and the sequence of the second light chain is shown in SEQ ID NO: 117; I) The sequence of the first heavy chain of the bispecific antibody is shown in SEQ ID NO: 118, the sequence of the first light chain is shown in SEQ ID NO: 119, the sequence of the second heavy chain is shown in SEQ ID NO: 124, and the sequence of the second light chain is shown in SEQ ID NO:

125.

42. A nucleic acid molecule encoding the polypeptide complex according to any one of claims 1 to 41.

43. A vector comprising the nucleic acid molecule of claim 42.

44. A host cell obtained by transformation with the vector according to claim 43; the host cell is selected from the group consisting of prokaryotic cells and eukaryotic cells.

45. The host cell of claim 44, wherein the host cell is a eukaryotic cell.

46. ​​The host cell of claim 44, wherein the host cell is a mammalian cell.

47. A preparation method for preparing the polypeptide complex according to any one of claims 1 to 41, The method comprises the following steps: Cultivate the host cell according to any one of claims 44 to 46, and then purify and recover the polypeptide complex.

48. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers, excipients or diluents, and the polypeptide complex according to any one of claims 1 to 41.